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ABSTRACT
Cell migration is an important mediator of cancer metastasis and invasion, which
is responsible for 90% of cancer-related premature deaths in Canada. Synthetic
triterpenoids are a class of promising anti-cancer compounds that have shown
considerable efficacy in targeting various cellular functions including apoptosis, growth,
inflammation and cytoprotection in both cell culture and animal tumor models. However,
their effect on cell migration, an important event in metastasis, remains poorly
understood. This thesis focuses on deciphering the molecular mechanisms whereby the
synthetic triterpenoids affect cell migration. I observed that the imidazolide and methyl
ester derivatives of the synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic
aic acid (CDDO-Im and CDDO-Me), inhibit cell migration by disrupting microtubule
dynamics. In addition, I found that these triterpenoids disrupt cell polarity by displacing
proteins at the leading edge of migrating cells.

Furthermore, using a two-pronged

proteomic approach involving protein arrays and mass spectrometry, I identified
numerous triterpenoid-binding targets involved in actin polymerization and focal
adhesion maintenance. My data further revealed that triterpenoids inhibit branched actin
polymerization by targeting Arp3 in the Arp2/3 complex and target GSK3β activity to
alter focal adhesion sizes.

Collectively, my studies provided novel insights on the

underlying molecular mechanisms by which triterpenoids act to affect cell migration.
This knowledge will be important for developing a more efficacious and specific
therapeutic triterpenoid compound that targets cancer metastasis.
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CHAPTER 1

INTRODUCTION

2

1

INTRODUCTION

1.1

CELL MIGRATION
Cell migration is a process in which cells move in response to stimuli in the

cellular environment. This process plays an essential role in many different physiological
processes such as growth and development, immune responses, and wound healing.

1.2

CELL MIGRATION IN PHYSIOLOGICAL PROCESSES

1.2.1

Cell migration in growth and development
Cell migration is crucial in gastrulation, a process during early embryonic

development in which germ cell layers are formed and the basic blueprint of the organism
is established. Gastrulation arises from the reorganization of a single-layered blastula
into a three-germline-layered gastrula. These three layers are composed of the endoderm,
mesoderm and the ectoderm and they eventually give rise to different organs and tissues.
In order for these cells to form specific tissues and organs and perform their functions,
they must move to specific locations in a timely manner. The distance over which the
cells migrate and the number and type of cells that do so vary widely and are regulated by
different guidance signals.
Cells have been shown to migrate as either epithelial sheets or individual cells. In
the first case, sheet-like epithelial cell movement is evident during massive tissue
deformation where epithelial cells ingress and eventually surrounds the entire embryo. In

3

the latter case, cell movement requires the cells to undergo either a partial or nearcomplete process called epithelial to mesenchymal transition (EMT). EMT is a program
of development where cells characterized to have a non-migratory phenotype with cell
adhesions acquire changes that allow them to become more elongated in morphology and
adopt a highly migratory phenotype. As a result, these cells detach from the epithelial
sheet layer, form extensive protrusions and establish polarity in order to move towards a
chemical gradient or stimulus. An example of this process is found in the adult animal in
the form of wound healing.

1.2.2

Cell migration and wound healing
In response to tissue injury, cells initiate the wound healing process in order to

protect the body from infection and undergo tissue repair. There are three phases in
wound healing: inflammation, new tissue formation, and tissue remodeling, all of which
are heavily regulated by cell migration.

In response to an injury, tissues undergo an

inflammatory phase where neutrophils, monocytes and lymphocytes arrive at the site of
injury and release growth factors, cytokines, and hormones as part of the immune
response. The factors attract endothelial cells and fibroblasts in order for the formation
of new blood vessels and the deposition of extracellular matrix needed for blood clot
formation to occur.
During the formation of new tissue, keratinocytes from the edge of the wound
dedifferentiate, move towards the site of injury and proliferate to aid with the wound
healing process. After re-epithelialization, these cells re-differentiate to restore the barrier
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function of the skin, which protects the skin from water loss, bacteria or infection.
Simultaneously, the connective tissue layer of the skin is repaired by the migration and
proliferation of fibroblasts, which differentiate into myfibroblasts and promote wound
contraction. Vascular, lymphatic and nerve networks are also restored by the migration
and proliferation of respective cells into the wound. Overall, cell migration is a process
that requires the highly orchestrated efforts of different components of the cell.

1.3

CELL MIGRATION: A MULTISTEP PROCESS
The process of cell migration is a complex multi-step phenomenon, which may

differ between different organisms or even between cell types within an organism. For
instance, cells can migrate as single cells where their morphologies are dependent on the
expression of adhesion receptors and the surrounding microenvironment. Cells can also
migrate via a chain-linked manner where a leading edge directs the migration of cells that
are physically linked to one another. Cell migration has also been shown to occur with the
assistance of heterotypic cell-cell contacts where they migrate in a manner that is guided
by specific proteins (Figure 1.1).
Regardless of the mode of migration, most migrating cells form lamellipodia and
filopodia (1). Lamellipodia consist of a meshwork of branched actin beneath the plasma
membrane that forms a persistent protrusion over a surface, resulting in a 'leading edge'.
Filopodia are fingerlike protrusions made up of actin bundles that extend beyond the
lamellipodia and play an important sensory and exploratory role in steering the cell
towards a stimulus (1). In turn, the cell starts establishing polarity where it undergoes
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Figure 1.1 Cell migration is regulated by numerous signaling molecules and the
cytoskeletal network.
In response to a stimulus, polarity proteins, including Rac1, CDC42, CLIP170, Par6,
aPKCζ/ι, GSK3β, IQGAP1, Arp2/3 complex and n-WASp redistribute within the cell
body and localize to the leading edge. Furthermore, the cytoskeletal network including
actin filaments and microtubules rearranges to prepare for movement. Focal adhesions
serve as traction points for cells to move forward on the ECM. The TGFβ receptor
complex is located at the leading edge and plays an important role in Par6-dependent cell
motility.
Rac1: Rho-related C3 botulinum toxin substrate; CDC42: cell division cycle 42;
CLIP170: cytoplasmic linker protein of 170 kda; Par6: Partitioning defective 6;
GSK3β: glycogen synthase kinase 3 beta; IQGAP1: IQ-motif containing GAP1; Arp2/3:
actin-related protein 2/3; n-WASp: neural Wiskott Aldrich Syndrome protein; TGFβ:
transforming growth factor beta; TGFβRI/II: transforming growth factor beta receptor
I/II; ECM: extracellular matrix.
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asymmetrical distribution of proteins and the rearrangement of cytoskeleton in order to
prepare for directional movement. Simultaneously, the cell also begins to anchor itself to
a new area via focal adhesion formation and the lagging end of the cell then experiences
contraction and cell adhesion turnover in order for the cell to detach itself and move
forward. There are many proteins that initiate and sustain directional cell movement and
are described in further detail below.

1.4

CELLULAR COMPONENTS IMPORTANT FOR CELL MIGRATION

1.4.1

The microtubule cytoskeleton
Microtubules are an integral part of the cytoskeletal network, which are involved

in physiological processes such as cell division, vesicle trafficking, cell polarization and
migration. Microtubules are made up of thirteen laterally associated protofilaments, which
form stiff but dynamic tubular structures. The protofilaments are made up of stable
alpha/beta (α/β) tubulin heterodimers. Tubulin heterodimers are oriented in the same
direction, generating a polarity with distinctive minus and plus ends (2).
The minus end of the microtubule is often anchored to the microtubule-organizing
center (MTOC) while the alpha/beta (α/β) heterodimers are added to the plus end of the
protofilament, generating a guanosine triphosphate (GTP) cap, which stabilizes the
growing microtubule. Eventually, steady state is reached when the rate of microtubule
disassembly is balanced by the rate of microtubule assembly. However, as the tubulin
heterodimer binds, the GTP bound by the β−tubulin monomer undergoes hydrolysis,
causing the loss of the GTP cap. Hence, depending on the rate of addition of subunits to
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the growing microtubule and the rate of hydrolysis of GTP, the protofilament can undergo
either growth or shrinkage, a process known as dynamic instability (3).
Dynamic instability helps microtubules distribute throughout the cell during
cytoskeletal reorganization as microtubules undergo the ‘search and capture’ process
where the plus end of the microtubule grows and explores the intracellular space before it
is captured by organelles or microtubule-associated proteins that stabilize its structure.
For instance, microtubules are stabilized by different binding proteins such as the Tau
family of proteins, microtubule-associated protein (MAP)2 and MAP4 and microtubule
plus-end tracking proteins (+TIPs) such as cytoplasmic linker protein of 170 kDa
(CLIP170), cytoplasmic linker-associated proteins (CLASPs), and end-binding protein
(EB) 1.

Similarly, microtubules can be destabilized by different end binding or

microtubule severing proteins such as kinesin 13, stathmin/Op18 and katanin. These
positive end proteins are also involved in interaction of microtubules with other
cytoskeletal structures such as actin filaments.

1.4.2

The actin cytoskeleton
Actin is a protein of abundance in the cytosol with concentration that can range as

high as 5 mM in the eukaryotic cell. It is often observed to extend across the interior of
the cell and is crucial in regulating polarity and migration. Actin exists in a monomeric
(globular or G-actin) form or in a polymeric (filamentous or F-actin) form.
The actin cyotskeleton is dynamic and cycles between G-actin and F-actin. The
hydrolysis of adenosine triphosphate (ATP) to adenosine diphosphate (ADP) is an
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important regulatory step in actin polymerization. F-actin is initially formed by the
spontaneous and unstable nucleation of G-actin monomers.

When three monomers

associate, they form a stable seed or nucleus for effective actin elongation. In vitro, the
subunits in an actin filament point towards one direction, creating a polarity in the
filament. The steady state mechanism whereby actin undergoes polymerization and
depolymerization at the same rate is known as actin filament treadmilling. As a result of
treadmilling, rigid actin filaments move forward and help form the lamellipodia in the
leading edge of migrating cells (4).
Actin filaments adopt different morphologies depending on their function and
localization within a cell. The four main types of actin structures that are found within
the cell are filopodia, lamellipodia, stress fibers, and actin arcs. Actin structures in
filopodia and lamellipodia are regulated by the Ras homolog gene family (Rho) of small
GTPases (Figure 1.2). Stress fibers are bundles of anti-parallel actin filaments, which
interact with myosin II, a member of the ATP-dependent motor protein family that
possesses contractile properties; hence, giving the cell the flexibility to move. These
stress fibers are often found in the basal portion of the cell and are tethered to the ECM
by adhesive structures. In addition, to provide transverse structural support for the cell,
actin arcs, which are large actin filament bundles, are localized to the dorsal and side
portions of cells (4).
All actin structures are the result of one of two modes of actin nucleation
assembly: branched or unbranched. These two modes of actin assembly are similar in
that the fundamental building block is G-actin and the formation of both types of F-actin
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Figure 1.2 The formation of different actin cytoskeletal structures is regulated by
the Rho small GTPase superfamily.
CDC42, Rac1 and RhoA are Rho small GTPases that play an important role in the
formation of filopodia, lamellipodia and stress fibers. Lamellipodia are formed by the
Arp2/3 complex through branched actin nucleation, whereas filopodia and stress fibers
are formed by formin through progressive unbranched actin nucleation. Specifically,
CDC42 activates n-WASp, which in turn promotes nucleation and branched actin
polymerization. Alternatively, the activation of RhoA leads to the activation of myosin II
and ROCK and induces formin-dependent unbranched actin polymerization.
Interestingly, Rac1 has been shown to be involved both indirectly and directly in
branched and unbranched actin polymerization through n-WASp, WAVE and formin.
Rho small GTPase: Ras homolog gene family small guanine triphosphatase; CDC42: cell
dividing cycle 42; Rac1: Rho-related C3 botulinum toxin substrate; Arp2/3: actin-related
protein 2/3; n-WASp: neural Wiskott Aldrich Syndrome protein; RhoA: Ras homolog
gene family member A; ROCK: Rho-associated kinase; WAVE: WASP-family verprolin
homologous protein.
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requires the activation of a nucleation promoting factor (NPF) and the protein that
activates the NPF.

1.4.2.1

Branched Actin Polymerization
Nucleation of branched actin results in a dense meshwork of actin filaments that

forms the lamellipodia. This initiation of branched actin is via the activation of the Actinrelated protein (Arp) 2/3 complex. The Arp2/3 complex is a stable complex of seven
conserved subunits that is composed of two actin-related proteins, Arp2 and Arp3, and
five Arp-related protein subunits (ARPC): ARPC1, ARPC2, ARCPC3, ARPC4, and
ARPC5 (4). Several studies have characterized the Arp2/3 complex and have found that
Arp3 is involved in the nucleation process of actin, while ARPC2 and ARPC4 form the
structural core of the complex. In addition, ARPC1, ARPC3 and ARPC5 have been
shown to play a role in the activation of the complex by signaling proteins (5).

The

activation of Arp2/3 is regulated by the Wiskott-Aldrich Syndrome proteins (WASp)
family of proteins which includes the hematopoietic WASp, the ubiquitous nWASp
(neural WASp) and SCAR (suppressor of camp receptor) / WAVE (WASP-family
verprolin homology protein) isoform 1, 2, and 3. These proteins are involved in the
regulation of actin dynamics in different cellular processes including endocytosis,
phagocytosis, cell migration, intracellular trafficking and internalization as well as the
propulsion of pathogens. Thus far, two models have been proposed for the mechanism
whereby branched actin is assembled via Arp2/3 and nWASP. In the first model, studies
have shown that Arp2/3 serves as the nucleator. In fact, when activated by the verprolin-
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cofilin-acidic (VCA) domain of WASP, the Arp2/3 complex has been shown to bind to
the side of an existing actin filament and form a new branching actin filament (6-8).
In the second model, studies have indicated that the Arp2/3, WASP and G-actin
complex bind to the barbed end of the mother filament and the hydrolysis of the GTP on
the GTP-bound-actin dissociates the filament from the membrane bound activator, WASP.
As a result, Arp2/3 then nucleates a lateral branch, that is now the daughter filament, and
both the growth of the mother and daughter filaments drive membrane protrusion (9-11).

1.4.2.2

Processive actin polymerization
The second mode of actin assembly is known as the processive or unbranched

actin assembly, which makes up the actin structures found in filopodia, stress fibers and
actin arcs. This type of actin structure is formed by the activation of formin, which is a
family of proteins that is involved in many physiological processes such as cytokinesis,
endocytosis, filopodia formation, cell polarity, cell-cell adhesions and cell matrix
adhesion (12). Specifically, the diaphanous-related formin, mDia, has been shown to
induce the formation of processive actin assembly as a dimer with the actin-binding
protein, profilin.
The rate of actin polymerization is regulated by different proteins that bind to Gactin monomers and/or the actin filament. These proteins can either enhance the rate of
actin assembly or slow down actin polymerization. For instance, profilin and cofilin are
actin-binding proteins that have been shown to stimulate the rate of treadmilling in vivo
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by increasing the pool of ATP-bound actin, while gelsolin acts to sever actin filaments
and stimulate depolymerization.

1.4.3

Polarity complex proteins and other proteins at the leading edge of migrating
cells
Cell polarization is the process in which the cell undergoes cytoskeletal

reorganization and directs its intracellular components and specific signaling proteins to
form an internal axis of asymmetry. This process is evident in many physiological
processes such as morphogenesis and cell migration.
The molecular machineries that are responsible for creating and maintaining cell
polarity are the Scribble, Crumbs and the Par (Partitioning defective) complexes. These
complexes define the basolateral domain, apical domain and the apical-lateral border
respectively, by interacting with a wide array of signaling proteins in the cell (13).
Specifically, the Par complex was the first polarity complex to be discovered (14) with
the broadest functions (15) and is composed of the two par proteins, Par6 and Par3 and
members of the atypical protein kinase C (aPKC) family.
Three Par6 proteins, Par6A/C, Par6B and Par6D/G, have been identified in
mammals. Despite the fact that different genes encode these proteins, they are all of
similar molecular weights and have three important conserved domains. These three
domains include: the Phox/Bem1 (PB1) domain, which binds to other PB1 domaincontaining proteins, the Cdc42/Rac1 interacting binding (CRIB) motif, which binds to
activated Rho small GTPases (16,17), and the PSD95/Dlg1/ZO-1 (PDZ) domain
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(18,19), which binds to other PDZ domain-containing proteins. Although Par6 lacks
enzymatic function, it is able to scaffold several signaling proteins. In the context of cell
migration, Par6 forms a complex with both aPKC (via its PB1 domain) and Par3 (via its
PDZ domain) at the leading edge.
Two aPKC proteins, aPKCλ/ι and aPKCζ, are encoded by two different genes in
mammals. These atypical PKCs are part of a much larger PKC family, which also
includes classical PKCs and conventional PKCs. Although all PKCs possess a kinase
domain at the C-terminus, atypical PKCs are different from the conventional PKCs and
classical PKCs in that they have a PB1 domain that interacts with proteins such as Par6
but they lack a complete C1 domain which is necessary for calcium, diacylglyercol and
phorbol ester-dependent activation (14). Studies have shown that in epithelial cells,
aPKCs localize with the other members of the Par complex to tight junctions or the
leading edge of migrating cells (20). In addition, aPKCs have an important role as
activators of the downstream signaling cascades leading to the establishment of cell
polarity. This was evident in a study where the overexpression of kinase-deficient aPKC
mutants resulted in the blockage of tight junction formation as well as the disruption of
cell polarity (21).
Studies in C. elegans and D. melanogaster have shown that Par3-Par6-PKC
complex plays a critical role in anterior-posterior polarity (22).

Subsequent studies in

mammalian cells have confirmed that complex formation is important in regulating cell
polarity (17,23). However, it is important to note that in some cases, aPKC-Par6 complex
but not Par3 plays an indispensable role in polarized migration (24). Hence, although
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Par3 is undoubtedly important in ensuring the function of the Par complex as a unit in
some cell types, its interaction with Par6-aPKC may be transient and dynamic (24).

1.4.4

The Rho superfamily
Regulation of the Par complex is dependent on its interactions with a family of

important proteins known as the Rho small GTPases. The mammalian Rho small GTPase
superfamily is composed of about 20 intracellular signaling molecules. These Rho small
GTPases are essential molecular switches that regulate different signaling networks by
cycling between a guanosine diphosphate (GDP)-bound inactive form and a guanosine
triphosphate (GTP)-bound active form (3).
The states of Rho small GTPases are controlled by three different types of
regulators. In resting cells, Rho small GTPase often exists in the GDP-bound form in a
complex with Rho GDP-dissociation inhibitor (GDI). GDI, when bound to GDP-Rho
GTPase, inhibits the exchange of GDP for GTP.

In response to extracellular signals,

GDP-Rho GTPase dissociates from GDI to allow the guanine-nucleotide-exchange factor
(GEF) to promote the exchange of GDP for GTP. In its active GTP-Rho GTPase form, it
can then bind to downstream effectors and elicit various signaling responses. To revert
back to its inactive form, GTPase activating proteins (GAPs) act to enhance the intrinsic
activity of Rho GTPase by hydrolysis and as a result, GDP-Rho GTPase associates with
GDI.
Rho-related C3 botulinum toxin substrate 1 (Rac1) and cell divison cycle 42
(CDC42) are two Rho GTPases that localize to the leading edge of migrating cells and
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have been shown to play important roles in cell polarization. Indeed, work by EtienneManneville and colleagues has shown that CDC42 localizes and binds to Par6, which in
turn, activates the Par6-PKCζ complex by phosphorylating PKCζ in migrating astrocytes.
As a result of this activation, PKCζ can then phosphorylate downstream substrates such
as Glycogen Synthase Kinase 3 β (GSK3β) (25).
GSK3β is a constitutively active serine/threonine kinase that is known to have an
inhibitory effect on the tumor suppressor protein, adenomatous polyposis coli (APC) by
preventing it from binding to the microtubules. Thus, the phosphorylation and
inactivation of GSK3β by activated PKCζ dissociates APC from GSK3β so that it can
bind to and stabilize microtubules. The association of APC with microtubules and another
protein, Dislarge1 (Dlg1), allows for reorientation of the centrosome, Golgi apparatus and
nuclei and induces targeted vesicle transport to the leading edge, all of which are
important for cell polarization (15,25). Interestingly, studies have shown that aPKCmediated inactivation of GSK3β can also suppress Ras homolog gene family member A
(RhoA) activity at the front of the cell by inhibiting p190ARhoGAP (26). Consistent
with this study, RhoA has been shown to mostly localize at the lagging edge of migrating
cells and is largely involved in the degradation of the Par complex and the induction of
EMT through the Transforming Growth Factor Beta (TGFβ)-dependent pathway.
The TGFβ pathway is an extensively studied pathway that is known for its role in
numerous physiological processes such as tissue morphogenesis, wound healing and
migration as well as its roles as both a tumor suppressor and promoter in carcinogenesis.
It signals through the canonical Mothers against decapentaplegic drosophilia, homolog
(Smad) pathway in which the TGFβ ligand binds to the constitutively active transforming
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growth factor beta receptor (TGFβR) II, which in turn, comes into close proximity with
TGFβRI and transphosphorylates TGFβRI (27,28). The activated receptor complex is
then internalized via clathrin-coated pits where it phosphorylates Smad2/3 and together
with Smad4, the Smad2/4 complex translocates to the nucleus to propagate signal
transduction (Figure 1.3). Alternatively, the activated receptor complex can enter the
caveolae and bind to inhibitory-Smad7 and E3 ubiquitin ligases, Smad ubiquitination
regulatory factor (SMURF) 1 and 2, which targets the complex for degradation and signal
termination (29). In the context of cell polarity, the Par-aPKC complex associates with
the TGFβ receptors (Figure 1.3).

As a result of TGFβ binding, ligand-activated

TGFβRII phosphorylates Par6, which in turn, activates the E3 ubiquitin ligase SMURF1
and induces the proteasomal degradation of RhoA (30,31). The degradation of RhoA
contributes to the loss of apico-basal polarity and allows the cells to become more
migratory. In addition, the activation of the Par-aPKC complex by CDC42 has been
shown to be coupled to Rac1 activation through the Rac-specific GAP, T-cell lymphoma
invasion and metastasis-1 (TIAM1). This results in actin polymerization, microtubule
stabilization, and front-rear polarity (32). Therefore, studies have provided important
insights on not only how Rho small GTPases work cooperatively but antagonistically to
establish and regulate cell polarity in a migrating cell.
Beside Rho small GTPases, other leading edge proteins have also been shown to
have essential roles in modulating the actin and microtubule cytoskeletons, which in turn,
contribute to the establishment and maintenance of cell polarity. For instance, IQGAP1 is
a 190-kDA protein found ubiquitously expressed in most, if not all organisms ranging
from yeast to mammals. It has two other isoforms, IQGAP2 and IQGAP3, which exhibit
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Figure 1.3 TGFβ signaling plays an important role in numerous physiological
processes.
TGFβ signaling is initiated when TGFβ binds to TGFβRII at the cell surface, which in
turns, transphosphorylates TGFβRI and induces receptor internalization. Activated
receptor complexes on the early endosome associate and phosphorylate Smad2/3
proteins. Phosphorylated Smad2/3 then binds to Smad4, and together, these proteins
translocate into the nucleus and affect gene transcription. Alternatively, TGFβ can also
induce EMT and stimulate cell migration. Specifically, TGFβRII is redistributed to tight
junctions where it activates TGFβRI and phosphorylates Par6. Phosphorylation of Par6
leads to the recruitment of SMURF1, which directs the ubiquitination of RhoA.
Degradation of RhoA promotes EMT and cell migration.

TGFβ: transforming growth factor beta; TGFβR I/II: transforming growth factor beta
receptor I/II; Smad: mammalian homolog of mothers against decapentaplegic; EMT:
epithelial-to-mesenchymcal transition; Par6: Partitioning defective 6; SMURF1: Smad
ubiquitination regulatory factor 1; Rho A: Ras homolog gene family, member A.
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some common characteristics including considerable sequence overlap; however, they
differ vastly in their functions, tissue distribution and subcellular localization. Of the
three known isoforms, IQGAP1 is the most extensively studied. It was first identified as
a Rac/Cdc42 binding protein that localized at the leading edge of migrating cells (33).
Since then, over 90 proteins have been identified as IQGAP1 binding partners (34).
These binding partners include adaptor/scaffold proteins, calcium-binding proteins,
cytoskeleton-associated proteins, Rho small GTPases and their regulators, kinases,
members of the mitogen-activated protein kinase (MAPK) family, microbial proteins,
neuronal proteins, nuclear proteins, members of the phosphatidylinositol 3-kinase/protein
kinase B (PI3K/Akt) survival pathway, receptors, and trafficking proteins (34). As a
result, the ability to interact with these proteins makes IQGAP1 a protein with
remarkably diverse biological functions.
The role of IQGAP1 in regulating the cytoskeleton and cell polarity is of
particular interest and has been extensively studied. IQGAP1 was first found to bind
directly to actin and induce the cross-linking of actin filaments in the cell (33). Further
studies then showed that IQGAP1 can also bind to n-WASP, and stimulate Arp2/3dependent branched actin assembly and is a barbed end actin capper for actin filaments
(35,36), both of which are important in the formation of leading edge and cell polarity. In
addition, activated Rac1 and CDC42 can form a complex with numerous microtubule
plus end binding proteins such as CLIP170, CLASP2, EB1 and APC through IQGAP1
(37-39).

These complexes all contribute to the underlying mechanism whereby

microtubule dynamics and stability are modulated during cell polarization and cell
migration. Specifically, IQGAP1 and CLIP170 have first been shown to mediate the
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transient capturing of microtubules to the leading edge (37). Later studies then indicated
that APC was part of this complex and helped with stabilizing the interaction of IQGAP1
and CLIP170 at the plus ends of microtubules (39). Recently, CLASP2 has also been
identified as a novel binding partner of IQGAP1 and GSK3β is found to modulate the
phosphorylation of CLASP2, which can then affect its binding ability to IQGAP1, EB1
and microtubules, and ultimately, cell polarization and cell migration (38).

Since

IQGAP1 can bind to both F-actin and microtubules, it is often observed to be a critical
linker protein that bridges and organizes the cytoskeleton during cell migration.
Collectively, the proteins discussed above make up a small but important subset
of proteins at the leading edge that, with their complementary and antagonistic regulatory
roles, help establish and maintain cell polarity in order to form a focal point for
directional cell movement.

1.4.5

Focal adhesions
As a cell initiates migration by polarizing and extending protrusions towards a

stimulus, the protrusions are stabilized by cell adhesions in order to anchor the cell onto
the extracellular matrix (ECM) (40) (Figure 1.4).
Structurally, adhesions can be characterized into morphologically distinct
adhesion complexes, focal adhesions, or fibrillar adhesions, depending on their
subcellular localization, size, shape, molecular composition or dynamics (40). Focal
complexes are made up of small nascent adhesions that rapidly assemble and disassemble
at the leading edge or at the periphery of migrating cells. They often consist of areas rich
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Figure 1.4 The role of focal adhesions in cell migration.
At the leading edge of a migrating cell, focal adhesion proteins form a complex at the cell
membrane. In response to stimuli, integrins are induced to form clusters, which in turn
recruit different proteins including FAK, paxillin, tensin, vinculin, actinin and talin.
These proteins play a key role as traction points in order for the cell to move forward.
FAK: focal adhesion kinase.
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in β3-integrin, talin, paxillin and appear as dot-like structures of 1 µm2. Focal adhesions
or focal contacts grow to about 2-5 µm oblongs and are observed in slower moving cells.
These structures are more stable and are localized to the periphery and in the central area
of the cell where there is less motility. In contrast to focal complexes, focal adhesions
contain a much larger range of proteins including vinculin, talin, paxillin, zyxin, αactinin, VASP, FAK, phosphotyrosine proteins and αvβ3 integrin. Fibrillar adhesions are
elongated structures associated with fibronectin fibrils. These structures do not adhere to
stress fibers and consist of high levels of tensin and α5β1 integrin. It is important to note
that different types of adhesive structures can co-exist in a single cell at any one time
(41). In fact, fibrillar adhesion structures often evolve from focal adhesions, which
originate from nascent adhesion structures that have matured. However, although the
molecular compositions of these adhesions share similarities, there are also subtle
differences that distinguish them. For instance, zyxin is not found in focal complexes. In
addition, a small amount of paxillin and no β3 integrin nor vinculin are found in fibrillar
adhesions (4,40). Finally, besides the classical adhesion structures mentioned above, two
other classes of cell-ECM adhesion structures known.

They are podosomes and

invadopodia which are adhesion structures that can recruit matrix metalloproteinases
(MMPs) and facilitate matrix degradation (1).
The formation of focal adhesions are thought to be first initiated in response to the
microclustering of more than ten integrin molecules at the ECM, which in turn, leads to
the activation of integrin signaling. Activated integrins then recruit the adaptor protein,
paxillin, to promote nascent adhesion formation and further integrin clustering.

In

addition, nascent focal adhesion growth also induces the recruitment of α-actinin, which
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together with the actin-binding protein talin, helps stabilize the link between ECM-bound
integrin and the actin cytoskeleton. These nascent adhesions normally undergo rapid
turnover within minutes.

Tension has been shown to cause the recruitment,

phosphorylation and activation of FAK.

In addition, tension can also induce the

phosphorylation of other focal adhesion proteins such as paxillin and p130Cas and
establish scaffolding platforms for numerous phosphotyrosine-binding, Src homology
(SH)2 domain-containing proteins in order to promote adhesion growth.

Similar to

nascent focal complexes, focal adhesions often undergo adhesion turnover within 10-20
minutes; however, a subset of these mature further into fibrillar adhesions by the
dephosphorylation of paxillin at tyrosine 31 or 118.

Interestingly, these fibrillar

adhesions do not promote cell migration but are involved in ECM remodeling (42).
The assembly and disassembly of focal adhesions depends on the conformation,
the exposed binding motifs, and the signaling domains that are contained within each of
the proteins that are recruited (40). More importantly, the turnover of focal adhesions is
largely associated with the signal transduction that occurs as a result of the binding of
these proteins. Focal adhesion-associated proteins often initiate downstream signaling
cascades that ultimately determine the maturation and the lifespan of focal adhesions.
Thus far, at least 150 different proteins have been shown to be involved in regulating the
formation, maintenance and disassembly of adhesion structures (43). Of interest, FAK is
one of the many proteins that play a critical role in focal adhesion dynamics and is known
to be a master regulator of focal adhesion turnover. In fact, fibroblasts from Fak-/- mice
have reduced cell spreading and migration as well as an increase in the number and size
of cell adhesions on the periphery of the cells (44).
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FAK is a cytoplasmic non-receptor protein-tyrosine kinase, which was first
identified as a substrate of the viral Src oncogene product and was found to localize to
integrin-enriched cell adhesion sites in normal cells (45). FAK itself is a multi-domain
protein which is maintained in an autoinhibitory position; however, when it is stimulated
by integrin clustering, actin cytoskeleton-induced tension or by the binding of proteins
and phospholipids, it can unfold and expose the tyrosine 397 site for phosphorylation
(46). Specifically, the phosphorylation of tyrosine 397 creates a binding site for various
SH2-containing proteins, which leads to downstream signaling cascades that regulate
different cellular processes. In the context of cell migration, the phosphorylation of PI3K
and Growth factor receptor-bound protein (GRB) 7 by FAK have been shown to promote
cell motility in a cooperative manner (47). In addition, the phosphorylation and binding
of these proteins to tyrosine 397 can lead to the phosphorylation of other tyrosine
residues in the kinase domain, which are necessary for maximal FAK catalytic activity.
Finally, the proline-rich repeats (PRRs) in FAK associate with SH3 domain-containing
proteins such as p130Cas, GTPase regulator associated with FAK (GRAF) or the ArfGTPase-activating proteins (ASAP), all of which regulate the activities of Rho small
GTPases.
Interestingly, FAK possesses many more phosphorylation sites other than those
mentioned above, most of which are not within the kinase region. To date, at least four
serine phosphoryaltion sites (serine 722, 840, 843, 910) and a few other tyrosine
phosphorylation sites (tyrosine 407, 861 and 925) were found (48). In particular, studies
have shown that tyrosine 925 and serine 722 are important regulators of cell adhesions.
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Indeed, FAK phosphorylation at serine 722 by GSK3β has been shown by Bianchi and
colleagues to regulate cell spreading and cell migration (51).
GSK3 is a serine/threonine kinase family that was originally identified as an
important mediator of glycogen metabolism and insulin signaling. The two isoforms,
GSK3α and GSK3β, which are encoded by two different genes, share approximately
85% identity, with up to 98% homology between their kinase domains. The major
differences between the two isoforms are the last 76 amino acids in the C-terminus and a
glycine-rich extension on the N-terminus of GSK3α (52).

However, despite their

similarities, they are not functionally identical nor redundant. In fact, even though there
are many overlapping properties between GSK3α and GSK3β, they play quite distinct
roles in different cell types and in different physiological processes (53-64).
instance, Gsk3β-/-

mice

For

undergo hepatocyte apoptosis that leads to embryonic

lethality (54) while Gsk3α-/- mice survive and only display enhanced glucose and insulin
sensitivity as well as reduced fat mass (65).
Unlike many protein kinases, GSK3β is constitutively active in resting cells and it
undergoes rapid and transient inhibition in response to different external signals. It is
unique both in its regulation and its preference for substrates. Studies using the crystal
structure of GSK3β have shown that there are two phosphorylation sites that can affect
the catalytic activity of the protein (66,67). Specifically, the phosphorylation of tyrosine
216 in its activation loop is a pre-requisite for maximal catalytic activity. In addition, in
its unphosphorylated form, it serves to block access of substrate from the binding groove
(67). The other phosphorylation site, serine 9, is a site that, when phosphorylated, can
lead to the inhibition of GSK3β activity. Interestingly, GSK3β has the unique preference
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of targeting proteins that are pre-phosphorylated at a ‘priming’ residue located on the Cterminal three amino acids from the site of GSK3β phosphorylation. Although not
absolutely required, priming phosphorylation increases the efficiency of phosphorylation
by GSK3β by 100-1000 fold (68).
To date, GSK3β has been shown to be a multi-functional kinase that not only
regulates glycogen metabolism but also affects signaling pathways involved in the
regulation of cell fate, protein synthesis, proliferation, and survival. Thus, GSK3β has
become an appealing protein target for treatment in diabetes, inflammation, neurological
disorders, as well as cardiovascular diseases. Recently, the role of GSK3s has been
extended to the field of cell migration, a precursor event of cancer metastasis. Studies
have shown that GSK3β is an important player in cytoskeletal and adhesion dynamics.
For instance, evidence suggests that GSK3β phosphorylates microtubule-associated
proteins and interacts with microtubule motor proteins to regulate microtubule dynamics
and microtubule-dependent vesicle transport (69). Moreover, inactive GSK3β is found to
localize at the leading edge of migrating cells, which enables APC to localize at the plus
end of microtubules and stimulate microtubule growth and stability during migration. In
addition, GSK3β has also been shown to regulate several small Rho GTPases including
Rac1, RhoA and Arf6, which in turn, control membrane ruffling, cell spreading and
lamellipodia formation. GSK3β also plays an important role in regulating cell adhesions
molecules such as FAK and paxillin.

As mentioned above, GSK3β stimulates the

maturation of nascent adhesions and inhibits adhesion disassembly (51). However,
Kobayashi and colleagues showed that when GSK3β formed a complex with the cyclic
adenosine monophosphate (cAMP) phosphodiesterase, h-prune, it facilitated focal
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adhesion disassembly (70). In addition, paxillin, which has been previously shown to be
an important target for FAK and c-Src is also a GSK3β substrate. Finally, it has been
proposed that the phosphorylation of paxillin at serine 126 and 130 by GSK3β and
extracellular signal-regulated kinase (ERK)2 respectively is required for cell spreading
(71).

1.5

CELL MIGRATION IN PATHOLOGICAL PROCESSES
As previously shown, cell migration is a process that requires the efforts of

numerous proteins. The dysregulation of any one of these molecules and hence, cell
migration often leads to pathological diseases such as birth defects, auto-immune
diseases, chronic inflammation and cancer. Tumor cell migration plays a critical role in
the progression of cancer and tumor invasion as it is intricately connected to the ability of
a tumor to metastasize. Studies have shown that 90% of cancer-related death is due to
metastasis. The cause of dysfunction in tumor cell migration can be attributed to many
different factors, which together, amplify the power of the process itself. Therefore, the
development of chemotherapeutic compounds that can effectively target tumor cell
migration, or at least aspects of it, could play a critical role in cancer therapy and improve
the survival of cancer patients.
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1.6

SYNTHETIC OLEANANE TRITERPENOIDS AND THEIR DEVELOPMENT
Triterpenoids are the largest group of natural plant products, composed of more

than 20 000 known members. They are synthesized by the cyclization of squalene. The
resulting carbon framework from the cyclization process is one or more cyclic triterpene
alcohols with up to six carbocyclic rings (72). Oleanolic acid (3/3-hydrox-olea-12-en2oic acid) (Figure 1.5A) is a pentacyclic triterpenoid compound that has been traditionally
used in folk medicine for its anti-inflammatory and hepatoprotective activities. Later
studies on oleanolic acid confirmed that this triterpenoid compound indeed has a positive
effect in numerous diseases such as chemical-induced liver injuries and cancer (73,74).
However, since the water solubility of oleanolic acid is limited and its biological activity
is relatively weak (75), modification of the oleanolic acid into synthetic oleanane
triterpenoids was initiated in an attempt to make the compound more bioavailable.
The work on synthetic oleanane triterpenoids started in the early 1990s in the
Gribble laboratory where more than 80 synthetic triterpenoids derived from oleanolic
acid were generated and screened for their ability to protect against inducible nitric oxide
synthase (iNOS) production induced by interferon gamma (IFN-γ) in mouse macrophages
(76). The rationale behind using this type of screening stems from the fact that
inflammation is intricately linked with carcinogenesis; hence, designing unique agents
that target inflammation represents a potential means for chemoprevention and
chemotherapy. Of all the triterpenoid candidates, TP46 was identified as an active
suppressor of nitric oxide production. The combined modification on both ring A and
ring C on the original triterpenoid resulted in 2-cyano-3, 12-dioxooleana-1,9-dien-28-oic
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acid (CDDO) (Figure 1.5B), a triterpenoid compound that is about 10 000 times more
potent than the original lead compound and 400 000 times more potent than oleanolic
acid (77). Furthermore, by modifying the C-28 site on 2-cyano-3, 12-dioxooleana-1,9dien-28-oic acid (CDDO) and replacing it with different functional groups, (i.e. nitrile,
ester, glycosides, and amides), more potent triterpenoid derivatives were developed, two
of which are CDDO-Imidazolide (CDDO-Im) and CDDO-Methyl ester (CDDO-Me)
(Figure 1.5C) (78).

Recently, other C-28 amide derivatives including CDDO-ethyl

amide, CDDO-diethyl amide, CDDO-trifluoroethyl amide and CDDO-methyl amide
were also synthesized (79).

1.7

THE BIOLOGICAL ACTIVITY AND MECHANISM OF ACTION OF THE

TRITERPENOIDS
Numerous studies have shown that this class of compounds has anti-inflammatory
and cytoprotective properties. In addition, triterpenoids can induce the differentiation and
apoptosis of cancer cells. The triterpenoids are such effective agents in targeting cancer
cells because they are able to target regulatory proteins and/or transcriptional factors,
which in turn modulate the activities of different regulatory networks and signaling
pathways. This differs from many conventional chemotherapeutic agents, which target
only individual proteins or kinases. However, cancer is a complex disease composed of
different mutations that originated from different environmental causes and genetic
mutations. As a result, gain-of-function, amplifications, and/or overexpression of
oncogenes and loss-of-function mutations, and deletions and/or epigenetic silencing of
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Figure 1.5 The molecular structure of oleanolic acid and synthetic triterpenoids.
A) The structure of oleanolic acid shows three areas of modification, which include the
hydroxyl group at carbon 3, the double bond between carbon 12 and carbon 13, and the
carbon 28 carboxyl group (red).
B) The structure of CDDO (TP151), a synthetic triterpenoid that is 400 000 times more
potent than oleanolic acid when tested for iNOS production induced by IFN-γ in mouse
macrophages . To make the synthetic triterpenoids more potent, further modifications are
made (red).
C) The structure of two derivatives of synthetic triterpenoids, CDDO-Im (TP235) and
CDDO-Me (TP155) are formed by replacing the reaction group (R; red dotted circle)
with an imdiazolide group or a methyl ester group at carbon 28 respectively. These
derivatives have been shown to have greater potencies compared to its parental
compound, CDDO.
CDDO: 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid; Im, imidazolide; Me, methyl
ester; iNOS, inducible nitric oxide; IFN-γ : interferon gamma.
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Figure 1-5
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tumor suppressor genes can all lead to changes in the programming of a cell that affects
the overall homeostasis of the body at multiple regulatory levels. Therefore, by targeting
the regulatory network and the genes that regulate cellular activities, triterpenoids have
the potential to effectively control a much larger range of dysfunctional pathways, which
are common features of pre-malignant or malignant cells and tissues, compared to monofunctional targeted drugs (80).
The molecular mechanism of action of the triterpenoids is believed to involve the
nucleophilic attack (thio-or aza-Michael addition) of a thiol or other nucleophile to the
C1 and C9 position. Triterpenoids form reversible adducts with reagents containing thiol
residues and directly interact with protein targets that contain specific reactive cysteine
residues. So far, the known triterpenoid-binding targets include peroxisome proliferatoractivated receptor-γ (PPARγ) (81), kelch-like ECH-associated protein 1 (KEAP1) (82),
tubulin (83), I-kappaB kinase beta (IKKβ) (84,85), Arp3 (86), and mammalian target of
rapamycin (mTOR) (87). It is interesting to note that although in most cases, more than
one cysteine exists in these proteins, triterpenoids do not bind to all of these cysteine
residues at random. Rather, the binding of the triterpenoids to a specific cysteine depends
largely on the reduction oxidation (REDOX) potential of the cell and the accessibility of
the cysteine residues as a folded protein structure. Although most of the targets identified
so far contain reactive cysteines, the possibility that triterpenoids could also interact with
other nucleophilic groups such as lysine, arginine, or histidine on target proteins should
not be eliminated (79).
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1.8

TRITERPENOIDS AND DISEASES
Since the triterpenoids target multiple pathways by modulating the activity of

regulators and transcription factors, it is expected that this class of compounds will also
affect neurodegenerative diseases including Parkinson’s (88,89), Huntington’s (88,90)
and Alzheimer’s diseases (89,91), inflammatory lung conditions from chronic
granulomatous disease (92) or diseases such as cystic fibrosis (93), pulmonary fibrosis
(94-96), acute lung injuries (97), retina-related injuries (98,99), emphysema (100),
inflammatory cardiovascular diseases (100,101), acute liver injury (102-104), kidney
diseases (105,106), diabetes (107) and obesogenesis (107,108). For the scope of the
thesis, the effects of triterpenoids on cancer will be reviewed in detail.

1.9

SYNTHETIC TRITERPENOIDS AND THEIR ANTI-CANCER PROPERTIES

1.9.1

Triterpenoids and tumor cell differentiation
Cell differentiation is an important process that occurs in embryonic development

or during normal cell turnover or tissue repair. All cells originate from stem cells where
they mature and fully differentiate into specialized cell types to form different organs and
parts of the organism. When a cell is fully differentiated, it loses its ability to divide. In
the case of cancer, tumor cells are thought to have bypassed or arrested at a less mature or
less differentiated state where they can rapidly divide. As a result, one of the hallmarks of
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cancer cells is uncontrolled cell division. Therefore, much effort have been put towards
differentiation therapy, which is based on the concept that treatment will force cells to
undergo differentiation where they can mature and no longer divide.
Triterpenoids play a critical role in stimulating cell differentiation in numerous
cancer cell cultures studies. For instance, one of the earliest studies on CDDO indicated
that the compound could induce monocytic differentiation of human myeloid leukemia
and adipogenic differentiation of mouse 3T3-L1 adipocyte-derived fibroblasts (109,110).
In addition, it has been shown to enhance neuronal differentiation of rat
pheochromocytoma cells (109).

Further studies then proved that the induction of

differentiation in human myeloid leukemia cells and osteosarcoma by CDDO and its
derivatives CDDO-Im and CDDO-Me was via a caspase 8-dependent mechanism
(111,112).

The induction of monocytic differentiation of leukemia cell has been

associated with the activation of the ERK and the TGFβ/Smad signaling pathways, as
well as the upregulation of the CCAAT/enhancer-binding protein (CEBP) Beta ((113).

1.9.2

Triterpenoids and growth inhibition
Cell division is highly regulated by many cell cycle checkpoints including p53,

p21, p27, and cyclin D. In the case of tumor cells, many of these cell cycle regulators are
altered, hence allowing tumor cells to bypass these checkpoints and undergo uncontrolled
cell division.

38

Nanomolar concentrations of CDDO and its derivatives have been shown to
inhibit cell proliferation in tumor cells and the anti-proliferative effect of the triterpenoids
has since been tested on numerous solid tumor cells from almost every organ as well as
leukemia (79). Although most human cancers are biologically and pathologically
different, the alteration of the p53 pathway occurs in many human cancers (115).
Interestingly, the mechanism whereby triterpenoids inhibit tumor cell growth is
independent of the status of p53 while the recruitment and expression of key cell cycle
proteins such as cyclin D1, p21, p27, proliferating cell nuclear antigen (PCNA), caveolin
and myc seem be affected in triterepenoid-treated cells (116,117,118).

In addition,

triterpenoids have been shown to associate and transactivate PPARγ, an important
transcription factor that controls key differentiation genes, to inhibit cell proliferation
(116,117). However, later studies have shown that the triterpenoids can actually affect
growth inhibition via both PPARγ-dependent and independent mechanisms (119).

1.9.3

Triterpenoids and anti-inflammation
Inflammation is a biological response that is triggered by the body as a defense

mechanism when faced with foreign and/or harmful stimuli, the stimulation of cytokine
release, an increase in oxidative stress, or tissue injury. In response to these stimuli, the
nuclear factor kappa B (NF-κB) signaling pathway is activated. In resting cells, NF-κB, a
transcription factor that is important in regulating cell survival and immune responses, is
sequestered by the IkappaB alpha (IκΒα) inhibitory protein, which prevents NF-κB from
translocating to the nucleus. However, when the signaling pathway is activated by
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upstream enzymes, IκΒα is phosphorylated by Ikappa Kinase (IκΚα/β) and is targeted
for ubiquitination, leading to its release from NF-κB, thereby rendering the transcription
factor active. The free NF-κB dimer can then be phosphorylated and be translocated into
the nucleus to induce the transcription of pro-inflammatory genes such as iNOS,
cyclooxygenase (COX2) and tumor necrosis factor alpha (TNFα), in order to trigger the
immune response and initiate tissue repair (121). Although inflammation is a critical
process in wound healing and infection, chronic inflammation can be associated with
numerous diseases including cancer. In fact, it is estimated that underlying infections and
inflammatory reactions are linked to 15-20% of all cancer deaths. It is also evident in
numerous studies that inflammation helps with the initiation and progression of cancers
and is an important facilitator of the tumor microenvironment (122).
Synthetic triterpenoids have been shown to effectively suppress the induction of
iNOS and COX2 in primary macrophages when stimulated with different proinflammatory

molecules

including

IFNγ,

TNFα,

interleukin

(IL)-1β

and

lipopolysaccharides (LPS), block the de novo synthesis of COX2 in colon myofibroblasts
stimulated with IL-1β and inhibit the inflammatory and anti-apoptotic cytokine, IL6.
(109). In addition, triterpenoids have also been shown to suppress the production of these
pro-inflammatory molecules, which are often expressed in excess in tumor cells (89).
The anti-inflammatory properties of the triterpenoids are evident in both in vivo models
and in clinical trials (120,123). For instance, CDDO-Me elicits its anti-inflammatory
properties in response to lipopolysaccharides (LPS) challenge in vivo (123) and
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suppresses the expression of vascular endothelial growth factor (VEGF), matrix
metalloproteinase (MMP)9, tumor necrosis factor (TNF), IL-8 and IL-10 (124).

1.9.4

Triterpenoids and cytoprotection
In the event of oxidative stress and/or exposure to stress-related stimuli, cells can

also activate the Nuclear factor erythrocyte 2-related factor 2 (Nrf2) signaling pathway as
a cytoprotective mechanism. The Nrf2 signaling pathway functions very similarly to the
NF-κβ signaling pathway in that Nrf2 is also held in its inhibitory position by KEAP1, a
protein that have been shown to be an oxidative stress sensor and, when bound to Nrf2,
targets it for ubiquitination and proteasomal degradation. However, under oxidative
stress, KEAP1 releases Nrf2, enabling it to translocate into the nucleus and form
heterodimers with small musculoaponeurotic fibosarcoma (Maf) proteins. The formation
of this complex then recognizes and binds to the anti-oxidant responsive element (ARE)
sequences and induce the transcription of phase-2 detoxifying enzymes or anti-oxidant
genes (132). Since the triterpenoids have a profound effect on inflammation in tumor
cells by affecting the NF-κβ pathway (which is linked to the Nrf2) (133), it is expected
that the triterpenoids may also elicit some positive effect on tumor cells by modulating
Nrf2 activity. Consistent with this hypothesis, numerous research studies have shown
that the triterpenoids induce the Nrf2 pathway. Specifically, Liby and colleagues have
shown that CDDO-Im is a potent inducer of heme-oxygenase-1 (HO-1) Nrf2/ARE
signaling by increasing Nrf2 expression in monocytic U937 leukemia cells (134).
Subsequent studies went on to show that CDDO-Im could increase nuclear accumulation
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of Nrf2 proteins in peripheral blood mononuclear cells and in neutrophils (135). The
potent cytoprotective activities mediated by the triterpenoids are shown in different cells
originated from different tissues including liver, lung, small intestine mucosa, and
cerebral cortex (137).

1.9.5

Triterpenoids and apoptosis
Apoptosis is the process in which cells undergo programmed cell death in

response to different stimuli in order to control for cellular damage or allow for overall
cellular homeostasis. The extrinsic apoptotic pathway involves the binding of death
receptor (DR) ligands to death receptors at the membrane surface while the intrinsic
pathway involves targeting the mitochrondria and inducing the release of pro-apopototic
factors to the cytosol in response to intracellular stress signals (138).

Despite the

different means of activation, the downstream effects of these two pathways eventually
converge into the activation of caspases, which are cysteinyl aspartate-specific proteases
that play a key role in executing the apoptosis process.
In the intrinsic pathway, apoptosis is commonly triggered within the cells by
different stimuli ranging from UV radiation, DNA damage, hypoxia, cytoskeleton
disruption, loss of adhesion or growth factor withdrawal, loss of survival signals, or
endoplasmic reticulum stress (138,139).

As a result of these stress stimuli, the

permeability of the outer mitochondrial membrane is increased, leading to the release of
pro-apoptotic factors such as cytochrome C into the cytoplasm. The release of these pro-
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apoptotic factors leads to the formation of an apoptosome, which works similarly to the
death-inducing signaling complex (DISC) in the extrinsic pathway to recruit and facilitate
the activation of pro-caspase 9. It is interesting to note that crosstalk does exist between
the intrinsic and extrinsic pathway. For example, caspase 8 from the extrinsic pathway
can cleave BH3 interacting-domain agonist (Bid), a pro-apoptotic Bcl-2 family protein
and activate the intrinsic mitochrondrial apoptosis pathway (138).
At concentrations of 1-5 µM, CDDO and its derivatives have been shown to
induce apoptosis in numerous cancer cells including human acute myeloid leukemia
(112,142), multiple myeloma (143), chronic lymphocytic leukemia (144), lung cancer
(145,146), breast cancer (147), prostate cancer (148), ovarian cancer (149), and
osteosarcoma (112). Specifically, studies have shown that triterpenoids are effective in
inducing apoptosis via both the intrinsic and extrinsic apoptotic pathways. Triterpenoids
have been shown to induce TRAIL-dependent apoptosis by upregulating DRs, TRAIL
receptor 1 and TRAIL receptor 2 (142,145-150), inhibiting cFLIP, (144-147,149) and
activating caspase 3, caspase 8, and caspase 9 (148,151,152,153). Although caspases are
critical players in apoptosis, it is important to note that the triterpenoids do not only act
on caspases to induce apoptosis.
In addition, other studies have shown that the triterpenoids can play an important
role on different pro-apoptotic factors to trigger apoptosis. For example, the cleavage of
Bid and the translocation of Bcl-2-associated X protein (Bax) to the mitochrondria
(148,151) as well as the release of cytochrome-c and apoptosis-inducing factor (AIF)
from the mitochrondria (148,149,152,153) are induced by triterpenoids.
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CDDO has also been shown to reduce glutathione (GSH) and in some cases,
increase ROS levels (156). GSH is an important peptide that, in its reduced state, can
neutralize ROS by donating an electron to other unstable molecules in the system.
Therefore, it may seem counter-intuitive that triterpenoids reduce the amount of
glutathione, a protective antioxidant in the body. However, studies have shown that
synthetic triterpenoids are not toxic to normal cells such as lymphocytes harvested from
the same patient or from healthy volunteers (143,144,157,158). This selective apoptosis
in cancer cells may result from higher endogenous levels of oxidative stress that exists in
transformed cells. In these tumor cells that are already under oxidative stress,
triterpenoids provide the additional production of ROS required to destroy the tumor cells
by apoptosis (79).
Since the triterpenoids are multi-functional compounds, CDDO and its derivatives
are inevitably also going to induce the apoptosis cascade by targeting other signaling
pathways, which also ultimately result in programmed cell death. For instance, CDDOMe have been shown to activate the c-Jun-NH2-terminal kinase (JNK) via coupling with
endoplasmic reticulum (ER) stress and depleting intracellular GSH as well as increasing
ROS levels. As a result, activated JNK causes the upregulation of DR expression, which
triggers apoptosis in leukemia cells (153,156,159). Konopleva and colleagues have also
indicated that CDDO-Me can induce the phosphorylation of p38 in U-937 leukemia cells
to induce apoptosis (143,160). Therefore, both JNK and p38 play a crucial role in
apoptosis in response to stress stimuli. Interestingly, CDDO has also been shown to
increase [Ca2+]cytosol in the ER in a time and dose-dependent manner in numerous

44

carcinoma cells including colon, breast and lung (161). The ER and mitochrondria play
essential roles in intracellular calcium homeostasis, and the disruption and/or sustained
elevation in [Ca2+]cytosol can lead to apoptotic cell death by activating calcium-dependent
enzymes and caspase 12, which can in turn activate other caspases in both the intrinsic
and extrinsic apoptotic pathways (162,163). Therefore, Hail and his colleagues have
provided yet another role for CDDO in inducing apoptosis by targeting the intracellular
calcium levels. Furthermore, the triterpenoids have been shown to play a role in cell
death by targeting GSK. Specifically, CDDO-Me has been shown to induce the
phosphorylation of GSK3β at serine 9; thereby, inhibiting its activity.

The data

suggested that the inactivation of GSK3 induced by the synthetic triterpenoid could help
trigger tumor cell death by reducing the apoptotic threshold and increasing the apoptotic
potential of prostate cancer cells that were previously resistant to cell death (165).
In addition, synthetic triterpenoids target proteins that can modulate the
transcription of target genes that are important for apoptosis. For instance, CDDO can
directly inhibit IKΚβ, an upstream enzyme that regulates NF-κΒ.

NF-κB is a

transcription factor that is involved in the regulation of many physiological processes
including apoptosis. Yore and colleagues have shown that, CDDO-Im directly interacts
with IKΚβ and prevents its phosphorylation and degradation in response to TNFα.

As a result, NF-κB remains inhibited, which consequently leads to decreased expression
of numerous anti-apoptotic proteins including Bcl2, Bcl-Xl and XIAP (85,152).

In

addition, numerous studies have provided convincing evidence that CDDO-Im and
CDDO-Me can target signal transducer and activator of transcription3 (STAT3) to induce
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apoptosis in numerous cancer cells. STAT3 is a DNA binding protein that is also
involved in modulating the transcription of genes that are involved in cell differentiation,
proliferation, apoptosis, angiogenesis, immune response, and tumor metastasis. The
constitutive activation of STAT3 has been associated with numerous cancers including
leukemia, myeloma, osteosarcoma, and cancer of the ovaries, lungs, breast, prostate and
head and neck (166). More importantly, it leads to poor prognosis as it can activate genes
that block apoptosis, increase proliferation and survival, as well as promote angiogenesis
and metastasis while inhibiting anti-tumor immune responses (166). In numerous cancer
cell culture studies, CDDO-Im and CDDO-Me have been shown to significantly reduce
the level of nuclear translocation and phosphorylation of STAT3. As a result, the
inhibition of STAT3 signaling pathway leads to the suppression of several anti-apoptotic
STAT3 responsive genes such as Bcl-Xl, survivin and Myeloid cell leukemia 1 (MCL-1)
in both normal cancer and multi-drug resistance cancer models. As such, CDDO-Me can
also block the activation of Janus kinase (JAK), Src and Akt, all of which are upstream
targets of STAT3 activation, indicating that synthetic triterpenoids can inactivate STAT3
via affecting multiple signaling pathways (167-171).
Finally, the synthetic triterpenoids have also been shown to induce autophagy,
which is known as programmed cell death II. Programmed cell death II is a pathway
whereby the endolysosomal system is recruited to digest intracellular components as a
survival mechanism in the case of nutrient deprivation. However, it has also been
implicated as another means by which cancer cells undergo cell death after a series of
chemotherapeutic insults. CDDO-Me has been shown to induce autophagic cell death in
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chronic myeloid leukemia cells by affecting the metabolism and function of the
mitochrondria. As a result, cells undergo rapid autophagocytosis or externalization of
phosphatidylserine (172).

1.9.6

Triterpenoids and tumor angiogenesis
Angiogenesis is the process whereby networks of new blood vessels are

developed in order for organ growth and repair and development to occur. However, in
the case of carcinogenesis, a pre-vascularized tumor can rely on simple diffusion to
obtain the nutrients required to sustain its growth. However, as the tumor gets larger, the
proliferation of blood vessels is crucial for supplying oxygen and nutrients in order to
facilitate its further development. This growth acts as a precursor for tumor metastasis as
cancer cells now have the means to travel from the original site of the tumor and
disseminate to other parts in the body.
Since angiogenesis is a crucial player in tumorigenesis, studies have focused on
the role of triterpenoids on angiogenesis. Recent work has shown that CDDO and its
derivatives are potent and effective agents for the suppression of angiogenesis in in vivo
models and in cell cultures studies. For instance, CDDO-Me effectively blocks
angiogenesis that was induced when liquid Matrigel composed of angiogenic factors such
as VEGF and TNFα was mixed with Kaposi’s sarcoma cells and injected into immunocompromised mice followed by triterpenoid treatment (173). In studies examining the
role of synthetic triterpenoids on liver metastasis, Deeb and colleagues found that CDDO
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effectively reduces the number of blood vessels, and hence the density of blood vessel
network in prostatic cancer tissue (174). Moreover, CDDO-Me has been shown to inhibit
the growth of human umbilical vein endothelial cells (hUVEC) in monolayer cultures and
to suppress endothelial cell tubulogenesis in three-dimensional Matrigel cultures but at a
higher concentration compared to the in vivo studies. Specifically in cell culture studies
using hUVECs, the triterpenoids can inhibit VEGF-induced activation of the extracellular
signal-regulated kinase ERK1/2 pathway (175). As mentioned previously, CDDO was
also found to prevent NF-κΒ translocation into the nucleus by inhibiting the
phosphorylation of its binding partner, IΚΚα; this inhibition could in turn prevent the
transcription of numerous downstream angiogenesis-related genes such as COX2, VEGF,
and MMP-9 (176).

1.10

TRITERPENOID INTERACTIONS WITH OTHER PROTEINS
Since cancer is composed of diseases driven by different mutations,

chemotherapeutic agents are often most effective when given in combination.

The

rationale for combination chemotherapy stems from the fact that different signaling
pathways may be altered in cancer, and a combination of drugs that target these pathways
may prevent cells from developing chemo-resistance.
Triterpenoids have been shown to work synergistically with proteins or ligands
present in the cell to enhance their anti-cancer effects. For example, CDDO can synergize
with TGFβ and enhance TGFβ/Smad-mediated signaling by increasing TGFβ−dependent
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gene expression, prolonging the activation of Smad2 and reversing the inhibitory role of
Smad7, suggesting a potential role of CDDO in the treatment or prevention of diseases
with aberrant TGFβ function (177).

Moreover, CDDO has been shown to induce

apoptosis partially via a PPARγ-dependent mechanism. In addition, when used in
combination with TRAIL, CDDO-Me has been shown to be able to overcome the
resistance to TRAIL-induced apoptosis that lung cancer cells had previously developed.
Since triterpenoids inhibit many cancer-promoting activities, research has been
conducted to examine the use of these compounds in combination with other therapeutic
compounds. As expected, triterpenoids have shown to have synergistic effects when used
in combination with different inhibitors. For instance, FLT3-receptor tyrosine kinase
mutations consisting of internal tandem duplications (ITD) can lead to the constitutive
autophosphorylation of the receptor in leukemia cell lines (178). This mutation occurs
frequently in patients with acute myeloid leukemia and has been associated with higher
incidence of early relapse and shorter survival time compared to those without this
mutation (179). Studies have shown that PKC412, a FLT3-tyrosine kinase inhibitor, can
inhibit the autophosphorylation of the receptor while CDDO-Me can block the
translocation of NF-κΒ into the nucleus, inhibit STAT3 signaling and induce caspase-3dependent apoptosis in these cell lines (178). However, when the PKC412 inhibitor was
used simultaneously with CDDO-Me, the synergistic anti-proliferative effects on cells
with FLT3/ITD3 mutation were apparent (178). Therefore, even though PKC412 and
CDDO-Me target different signaling pathways, they work well together to target
leukemia. Similarly, CDDO-Im also produces synergistic effects in liposarcoma, a rare
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class of mesenchymal tumor that is characterized by an overexpression of fatty acid
synthase (FAS) and is often unresponsive to chemotherapy (180). Specifically, CDDOIm can inhibit FAS mRNA expression, affect gene promoter activity, block FAS protein
production and induce apoptosis while Cerulenin, a FAS inhibitor, works to inhibit FAS
activity in liposarcoma tissues and cell lines. Interestingly, when cells were treated with
both CDDO-Im and Cerulenin, a synergistic cytotoxic effect was observed whereby
CDDO-Im treated cells could increase their sensitivity towards Cerulenin, indicating that
triterpenoids function to enhance the efficacy of other compounds when used
simultaneously (180).

Consistent with these studies, the rexinoid LG100268 and

CDDO-Me also exert similar synergistic effects on tumor burden in in vivo breast cancer
models by targeting different signaling pathways (181). CDDO-Me is a powerful agent
that can block constitutive phosphorylation of STAT3 and the degradation of IKBα in
ER-negative breast cancer cells (181). While LG100268 also blocks IKBα degradation, it
is also a potent agent that can trigger the release of IL-6 in RAW264.7 macrophage-like
cells, inhibit the ability of endothelial cells to organize into networks and block
angiogenesis in vivo (181). However, when used in combination, LG100268 and CDDOMe are significantly more potent at preventing the formation of ER-negative breast
tumors compared to LG1000268 or CDDO-Me alone (181).
Perhaps, the most interesting fact about the triterpenoids is their ability to not only
work synergistically with other ligands and inhibitors to elicit a positive effect in cancer
cells but also function synergistically with other inhibitors to overcome the
chemoresistance that tumor cells may have acquired from conventional chemotherapy
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(157). As such, CDDO-Im and PS341 can work together to overcome the cytoprotective
effects that anti-apoptotic proteins may have as well as NF-κΒ-related drug resistance
(157). This synergistic effect is observed even in bortezomib-resistant multiple myeloma
cells, providing a potential means to improve the outcome of patients with this disease.
From in vivo studies, the combination of CDDO-Im and TRAIL treatment was well
tolerated and was able to effectively reduce tumor burden in an MDA-MB468 tumor
xenograft model (147).

1.11

RATIONALE AND HYPOTHESIS
Cell migration is a complex process that involves many structural proteins,

signaling molecules and transcriptional factors. Extensive research over the past few
decades has been carried out to identify how multiple signaling pathways converge into a
self-regulating network for cell migration. It is also abundantly clear that tumorigenesis
and cancer metastasis are dependent on cell migration. Therefore, it is important to
further our understanding of cell migration and examine how it can contribute to
tumorigenesis.

Although there is substantial evidence that triterpenoids can induce

apoptosis and cell differentiation and exert anti-proliferative effects on tumor cells, there
are very limited data that explains the role of triterpenoids on metastasis. In particular,
prior to my thesis work, there were no studies that focused on how triterpenoids affect
cell migration, an important precursor event to cancer metastasis.
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Therefore, the overall objective of this thesis is to understand the molecular
biology of triterpenoids and their role in cell migration. Specifically, I would like to:
1) Examine the role of CDDO-Im on cell migration
2) Identify proteins that interact with triterpenoids to mediate their influence on cell
migration
3) Manipulate triterpenoid-binding proteins to understand their involvement in cell
migration
Given that triterpenoids are multi-functional compounds that can target different
cellular processes and the fact that Couch et al. have shown that triterpenoids can bind to
β-tubulin and affect microtubule dynamics (83), we hypothesize that triterpenoids will
inhibit cell migration by affecting the cytoskeletal network and the associated proteins
that regulate its dynamics.
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CHAPTER 2
THE SYNTHETIC TRITERPENOID CDDO-IMIDAZOLIDE
ALTERS TGFβ-DEPENDENT SIGNALING AND CELL
MIGRATION BY AFFECTING THE CYTOSKELETON AND
THE POLARITY COMPLEX.

A version of this chapter has been published: To C, Kulkarni S, Pawson T, Honda T,
Gribble GW, Sporn MB, Wrana JL, Di Guglielmo GM. The synthetic triterpenoid 2cyano-3,12-dioxooleana-1,9-dien-28-oic acid-imidazolide alters transforming growth
factor beta-dependent signaling and cell migration by affecting the cytoskeleton and the
polarity complex. J Biol Chem. 2008 Apr 25;283(17):11700-13.
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CHAPTER 2

2.1

CHAPTER SUMMARY

The anti-tumor synthetic triterpenoid CDDO-Imidazolide (CDDO-Im) ectopically
activates the TGFβ-Smad pathway and extends the duration of signaling by an undefined
mechanism.

Here, I showed that CDDO-Im-dependent persistence of Smad2

phosphorylation was independent of Smad2 phosphatase activity and correlates with
delayed TGFβ receptor degradation and trafficking. Altered TGFβ trafficking paralleled
the dispersal of EEA1-positive endosomes from the peri-nuclear region of CDDO-Imtreated cells. The effect of CDDO-Im on the EEA1 compartment led to an analysis of the
cytoskeleton, and we observed that CDDO-Im altered microtubule dynamics by
disrupting the microtubule-capping protein, CLIP170.

Interestingly, biotinylated

triterpenoid was found to localize to the polarity complex at the leading edge of migrating
cells. Furthermore, CDDO-Im disrupted the localization of IQGAP1, PKCζ, Par6 and
TGFβ receptors from the leading edge of migrating cells and inhibited TGFβ-dependent
cell migration. Thus, the synthetic triterpenoid CDDO-Im interferes with TGFβ receptor
trafficking and turnover, and disrupts cell migration by severing the link between
members of the polarity complex and the microtubule network.
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2.2

INTRODUCTION
Transforming growth factor beta (TGFβ) family members regulate many cellular

functions including proliferation and differentiation and TGFβ is a potent apoptotic agent
in many cells including early stage epithelial tumors (1). However, in late stage epithelial
tumors, TGFβ becomes a metastatic agent and stimulates epithelial to mesenchymal
transition (EMT) and cell migration (2-5). Signaling by TGFβ growth factor is initiated
via ligand-induced heteromeric complex formation of the Ser/Thr kinase type I (TβRI)
and type II (TβRII) transmembrane receptors (6). The phosphorylation of receptorregulated Smad proteins: R-Smad2 and R-Smad3 is facilitated by Smad anchor for
receptor activation protein (SARA), which binds the receptors and recruits R-Smad to the
membrane of EEA1-positive early endosomes (7). Early endosomes also contain other
modulators of TGFβ receptor signaling such as hepatocyte growth factor-regulated
tyrosine kinase substrate (HRS) (8) and cytoplasmic promyelocytic leukemia protein
(cPML) (9).
Inactivation of the TGFβ signaling pathway is carried out by several mechanisms.
Phosphorylated Smad2 is targeted by the nuclear phosphatase PPM1A (10) and the
receptors are the target of inhibitory Smad7, which interacts with TβRI in lipid
rafts/caveolae and recruits the E3 ligases, Smurf1 and Smurf2, which direct ubiquitindependent degradation of the TGFβ receptors (11-13).

Perturbation of lipid rafts

increases signaling and reduces the rate of receptor degradation (14-18). Thus, the signal
transduction pathway initiated by cell surface TGFβ receptor complex is dependent on
receptor internalization and trafficking via distinct endocytic pathways (19).
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Endocytosis of cell surface proteins is dependent on the microtubule cytoskeleton
(20-22). Microtubules are dynamic protein filaments that span the cell interior and
provide a mechanical framework for chromosome sorting, cell polarity and organelle
localization, among other functions (23-28). Microtubules grow and shrink from their
plus-ends and their minus-ends are usually located at the microtubule-organizing center,
but are also found at the apical domain in epithelial cells (29).
Polarized migration of cells as well as the movement of vesicles along the
microtubules is dependent on molecular motors and microtubule binding proteins, such as
the capping protein, CLIP170 (30,31). Furthermore, the association of microtubulebound CLIP170 at the cell membrane with the Rac1/Cdc42 binding protein, IQGAP1, is
an essential mediator between microtubules and the leading edge of migrating cells
(32,33). Cdc42 also binds to the Par6-PKCζ polarity complex, which in turn links Cdc42
to APC and the microtubule network to form a focal point for directional cellular
movement (26). These molecular links, in combination with the observation that Par6
associates with TGFβ receptors (34), have introduced a new area of study to the field of
TGFβ-dependent signaling in cell migration and metastasis (2).
Chemotherapeutic agents that block TGFβ-dependent signaling and TGFβdependent metastasis have been a major focus in cancer chemotherapy (35). Recently, 2cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid (CDDO), has been shown to be a
promising cancer therapeutic agent that is currently in Phase I clinical trials (36).
Interestingly, both CDDO and its imidazolide derivative, CDDO-Im, have been shown to
synergistically increase cellular responses to factors such as TGFβ in cell culture studies
(37-39). The mechanism whereby CDDO-Im does this has yet to be elucidated. In this
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study, I demonstrate that CDDO-Im alters TGFβ cell signaling, receptor trafficking and
inhibits cell migration by disrupting cytoskeletal attachments to the polarity complex.
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2.3

MATERIALS AND METHODS

2.3.1

Cell Lines and Antibodies

Mv1Lu cells were cultured in minimal essential medium (MEM) supplemented with 1%
non-essential amino acids (NEAA). Mv1Lu cells stably transfected with the HA-epitope
tagged TGFβ type II Receptor (HAT cells) were cultured in MEM/1% NEAA and
0.3mg/ml Hygromycin.

Cos-7, C2C12, HEK293 and Rat2 cells were cultured in

Dulbecco's modified Eagle’s medium (DMEM). All media was supplemented with 10%
fetal bovine serum (FBS) unless otherwise stated. Texas Red-conjugated phalloidin, anticaveolin-1 (610059), anti-EEA1 (610456), anti-Rac1 (610650), anti-GM130 (610822),
anti-Smad2 (610842) and anti-LAMP1 (555798) antibodies were purchased from BD
Transduction Laboratories (Mississauga, ON, Canada).

Monoclonal anti-tubulin

(Tub2.1), anti-Flag (M2), and polyclonal anti-actin (A2668) antibodies were purchased
from Sigma (Oakville, ON, Canada). Polyclonal anti-PKCζ (C-20), anti-TGFβ type II
receptor (C-16), anti-Par6 (H-90), anti-IQGAP1 (H-109), anti-HA (Y-11), and goat antilamin A/C antibodies (sc-6215) were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-phospho-Smad2 (AB3849) antibodies were purchased from Chemicon
(Temecula, CA). The polyclonal phospho-Par6 (S345) antibody was used as previously
described (34). The polyclonal anti-CLIP170 (N-terminal) antibody was a generous gift
from Dr. K. Kaibuchi (Nagoya University, Nagoya, Japan) and the polyclonal antiCalnexin was kindly provided by Dr. J. J. M. Bergeron and Ms. P. H. Cameron (McGill
University, Montreal, Canada). The GFP-tagged CLIP170 construct was a generous gift
from Dr. F. Perez (CNRS, Paris, France).
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2.3.2

Affinity Labeling
Cells were pre-incubated in control media or media containing 1 µM CDDO-Im

for 1 hour at 37˚C, placed on ice and incubated with 250 pM

125

I-TGFβ in KRH-0.5 %

BSA at 4°C for 2 hours. Following cross-linking with DSS, cells were lysed (Time 0) or
incubated at 37˚C for 2, 4 or 8 hours prior to lysis. Receptors were visualized by SDSPAGE and quantified using phosphoimager analysis (Molecular Dynamics).

2.3.3
2.3.3.1

Subcellular Fractionation
Cytoskeleton
Fractions containing the cytoskeleton were separated from those containing

detergent-solubilized membranes and cytosol by the method described by Contin and
colleagues (40). Briefly, Cos-7 cells were incubated for 3 hours in control medium or
media containing 10 µM nocodazole or 1 µM CDDO-Im and then rinsed with
microtubule stabilization buffer (MSB; 90 mM Mes (pH 6.7), 1 mM EGTA, 1mM
MgCl2, 10% (v/v) glycerol) that had been pre-heated to 37˚C. Cells were then lysed with
MSB containing 10 µM placitaxel (Sigma; St. Louis, MO), 0.5% TX-100 and protease
inhibitors for 4 minutes at 37˚C. The solubilized fractions were then collected. To
collect the remaining cellular structures containing the cytoskeleton, SDS-PAGE sample
buffer was added to the culture dishes. Following scraping and passaging through a
syringe, the fractions containing the cytoskeleton were collected.
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To analyze the partitioning of cytoskeletal proteins, fractions containing the
soluble proteins or the cytoskeleton were subjected to SDS-PAGE followed by
immunoblotting with anti-Rac1, anti-tubulin, anti-actin, anti-IQGAP1, anti-EEA1, antiCalnexin, anti-LAMP1, anti-GM130 or anti-CLIP170 antibodies.

2.3.3.2

Nuclear Fractionation
To quantify the amount of Smad2 present in the nucleus in the presence of

CDDO-Im, subcellular fractionation was carried out as described by Cong and Varmus
(41). Briefly, cells were incubated with 0.5 µM TGFβ for 30 minutes in the absence or
presence of 1 µM CDDO-Im, washed and incubated in media containing DMSO
(Control), 1 µM CDDO-Im, 10 µM SB431542 or both compounds (CDDO-Im +
SB431542) at 37˚C for an additional 1 or 4 hours. The cells were then scraped into ice
cold PBS and collected by centrifugation at 1000xgav for 5 minutes. The cells were then
washed once again with PBS and resuspended in hypotonic buffer (10mM Hepes-KOH;
10mM NaCl; 1 mM KH2PO4; 5 mM NaHCO3; 1mM CaCl2; 0.5 mM MgCl2; pH 7.4).
After a 5-minute incubation on ice, cells were homogenized with 50 strokes using a
Dounce homogenizer. Cells were then centrifuged at 1000 x gav for 5 min. The pellets
were washed twice with hypotonic buffer and resuspended in nuclear isolation buffer (10
mM Tris (pH 7.5); 300mM sucrose; 0.1% Nonidet P-40). The pellets in the nuclear
isolation buffer were then further homogenized 50 times using a Dounce homogenizer
and centrifuged at 1000 xgav for 5 minutes. The nuclear pellet was resuspended with
nuclear isolation buffer with 1 % Trition X-100 to generate the nuclear fraction. The
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nuclear fractions were subjected to SDS-PAGE and immunobloted with mouse antiSmad2 or goat anti-lamin A/C antibodies. The levels of Smad2 were quantitated using
QuantityOne software (Biorad) and normalized to the amount of lamin A/C in each
fraction.

2.3.4

Phospho-Smad2 Timecourse
Cells were incubated with 0.5 µM TGFβ for 30 minutes, in the absence or

presence of 1 µM CDDO-Im, washed and incubated in media containing DMSO
(Control), 1 µM CDDO-Im, 10 µM SB431542 (Sigma; St. Louis, MO) or both
compounds (CDDO-Im + SB431542) at 37˚C for an additional 1 or 4 hours prior to lysis.
Cell lysates were then analyzed by SDS-PAGE and immunoblotted with mouse antiSmad2 or rabbit anti-phospho-Smad2 antibodies.

Quantitation of the amount of

phosphorylated Smad2 was carried out using QuantityOne software and normalized to
Smad2 levels.

2.3.5
2.3.5.1

Immunofluorescence Microscopy
Smad2 Nuclear Accumulation
Cells were incubated with 0.5 µM TGFβ for 30 minutes in the absence or

presence of 1 µM CDDO-Im, washed and incubated in media containing DMSO
(Control), 1 µM CDDO-Im, 10 µM SB431542 or both compounds (CDDO-Im +
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SB431542) at 37˚C for an additional 1, 4 or 8 hours prior to fixation and
permeabilization. Cells were then immunostained with anti-Smad2/3 antibody followed
by Cy2-conjugated secondary antibody. DAPI staining was used to visualize cell nuclei.
To quantify the amount of Smad2 nuclear localization, nuclear vs. cytoplasmic intensity
profiles were generated from individual cells using ImagePro software. The quantitation
of ≥ 100 cells/condition from 3 experiments was graphed as the nuclear signal minus the
cytoplasmic signal vs. time (± SD).

2.3.5.2

Receptor Traffic
Receptor internalization studies were carried out as previously described (15).

Briefly, HAT cells expressing extracellularly HA-tagged TβRII receptors were incubated
with biotinylated-TGFβ for 2 hours at 4°C, washed and incubated with Cy3-streptavidin
(Jackson Immunoresearch, West Grove, PA). Cells were then washed and incubated at
37°C for 1 hour with or without CDDO-Im. After the 37°C incubation, cells were fixed
and incubated with mouse monoclonal anti-EEA1 antibodies and rabbit polyclonal anticaveolin-1 antibodies. Anti-EEA1 and anti-caveolin-1 were detected using anti-mouse
Cy5-conjugated antibodies and anti-rabbit Cy2-conjugated antibodies (Jackson
Laboratories Inc.) respectively. Acid washing was carried out as previously described
(15). Images were captured using an Olympus 1X81 inverted microscope equipped with
fluorescence optics and deconvolved using ImagePro software.
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2.3.5.3

EEA1 Distribution
To visualize the effect of CDDO-Im on EEA1-positive endosomes I assessed the

staining pattern of the EEA1 compartment via immunofluorescence microscopy as
described above with the exception that Cy2-labelled secondary antibodies were used.
DAPI staining was used to visualize cell nuclei.
Staining observed to be localized to an area no greater than one half of the cell
area and located more intensely on one side of the nucleus was scored as ‘peri-nuclearpositive’. If the intensity and distribution of the stain was equal throughout the cell body,
it was scored as ‘dispersed’.

The quantitation of ≥ 100 cells/condition from 3

experiments was graphed (± SD).

2.3.5.4

Cytoskeleton Studies
To visualize the effect of CDDO-Im on the microtubule cytoskeleton, cells were

incubated for 1 hour with or without 1 µM CDDO-Im or 10 µM nocodazole (Sigma;
Oakville, Canada) at 37˚C.

Following fixation and permeabilization, cells were

incubated with monoclonal anti-tubulin antibody followed by FITC-conjugated
secondary antibodies. To assess the effect of CDDO-Im on the actin cytoskeleton, cells
were incubated with 1 µM CDDO-Im or 10 µM cytochalasin B for 1 hour prior to
fixation and permeabilization. The cells were then incubated for 30 minutes with Texas
Red-conjugated phalloidin.
microscope.

Images were collected from a Leica DMIRE inverted
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2.3.6

Scratch Assays
Rat2 fibroblasts were grown to confluency and the cell monolayer was scratched

with a sterile pipette tip to create a ‘wound’. For brightfield or DIC microscopy, images
were collected using an Olympus IX81 inverted microscope. For immunofluorescence
studies, cells were fixed, permeabilized and incubated with anti-CLIP170, anti-tubulin,
anti-Rac1, anti-TβRII, anti-IQGAP1, anti-Par6 or anti-PKCζ antibodies.

Following

fluorescently-tagged secondary antibody incubation, the nuclei of cells were stained with
DAPI and cells were visualized using an Olympus IX81 microscope controlled by QED
Invivo software (Olympus, Canada).
The quantitation of the number of cells containing proteins at the leading edge of
the cell was carried out using ≥ 100 cells/condition from 3 experiments (± SD). Briefly, a
cell containing a positive immunofluorescence signal only along the edge of the plasma
membrane that was directly adjacent to the scratch was scored as positive for leading
edge localization. If a cell contained no signal along the adjacent edge to the scratch or
contained dispersed signal along the complete cell periphery, it was scored as negative
for leading edge staining.

2.3.7

CLIP170 Movies
Rat2 fibroblasts were microinjected with 0.25 nM cDNA encoding GFP-tagged

CLIP170 protein and incubated at 37˚C for 4 hours. The cells were then incubated in
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control media or media containing 0.1 µM or 1 µM CDDO-Im. Expressed GFP-tagged
CLIP170 was visualized by immunofluorescence and time-lapse images were collected
using a Leica DMIRE inverted microscope utilizing Openlab 3.0 software.

2.3.8

Cell Transfection
Cells were transfected with the constructs described in the figure legends using

the calcium phosphate method as previously described (15).

2.3.9

Immunoprecipitation
Cells were lysed (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5 %

Triton X-100, 1 mM PMSF, and cocktail protease inhibitors) and centrifuged at 15,000 ×
gav at 4°C for 5 minutes. Aliquots of supernatants were collected for analysis of total
protein concentration. The remaining cell lysates were incubated with primary antibody
followed by incubation with protein G-sepharose. The precipitates were washed 3 times
with lysis buffer, eluted with Laemmli sample buffer and subjected to SDS-PAGE and
immunoblot analysis.
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2.3.10 CDDO-Biotin Subcellular Localization
Rat2 fibroblasts were grown to 100% confluency and scratched to create a wound.
The cells were then incubated at 37˚C for 6 hours to allow for the establishment of
polarity. The cells were then fixed, permeabilized and incubated with Rac1 antibodies
followed by Cy2-labelled secondary antibodies. The cells were then incubated with 10
µM biotin, CDDO or CDDO-biotin for 2 hours, followed by incubation with Cy3labelled streptavidin and DAPI. Cells were visualized using an Olympus IX81 inverted
microscope.

2.3.11 Protein Concentration
Protein concentrations of lysates were measured using the Lowry method (Fisher
Scientific, Ottawa, ON, Canada).

2.3.12 Statistical Analyses
Results are provided as means ± SD. One-way ANOVA analysis followed by a
Tukey’s post-hoc test was performed using GraphPad PRISM 5 Software to assess
statistical differences between experimental groups.
statistically significant.

P<0.0001 was considered
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2.4

RESULTS

2.4.1

CDDO-Im extends TGFβ-dependent signaling by increasing Smad2
phosphorylation and its accumulation in the nuclei
The

triterpenoid,

1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl)

imidazolide

(CDDO-Im) extends TGFβ signal transduction in several cell lines (37,39), however, the
mechanism(s) and functional consequences have yet to be fully elucidated.
In order to study the mechanism of how CDDO-Im extends TGFβ-dependent
signaling, I first attempted to identify cell lines in which TGFβ-dependent Smad2
phosphorylation is transient. I treated various cell lines with a 30 minute-pulse of TGFβ
and investigated the state of Smad2 phosphorylation by immunoblot analysis using a
phospho-Smad2 specific antibody. I observed that the phosphorylation of Smad2 was
transient in Rat2, Cos-7 and C2C12 cells (≤ 4.5 hours) whereas it was prolonged (> 8
hours) in HepG2 and Hela cells (Figure 2.1 and data not shown). In Rat2 and Cos-7 cells,
Smad2 phosphorylation was observed 30 minutes after TGFβ stimulation and attenuated
over the remainder of the time course (Figure 2.1A and B, lanes 1-4). In C2C12 cells,
Smad2 phosphorylation returned to background levels within 1 hour of ligand removal
from the culture medium (Figure 2.1C, lanes 1-4). Having observed transient Smad2
phosphorylation in Rat2, C2C12 and Cos-7 cells, I next assessed the effect of coincubating cells with TGFβ and CDDO-Im. I observed that CDDO-Im increased both the
extent and duration of TGFβ-dependent Smad2 phosphorylation in all of the three cell
types tested (Figure 2.1, lanes 5-8).
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Figure 2.1 CDDO-Im extends TGFβ-dependent
independently of Smad2 phosphatase activity.

Smad2

phosphorylation

Rat2 (A) Cos-7 (B) or C2C12 (C) cells were incubated with 0.5 µM TGFβ for 30 minutes
in the absence or presence of 1 µM CDDO-Im, washed and incubated in media
containing DMSO (Control), 1 µM CDDO-Im, 10 µM SB431542 or both compounds
(CDDO-Im + SB431542) at 37˚C for an additional 1 or 4 hours prior to lysis. One
hundred micrograms of cell lysates were then processed for SDS-PAGE and
immunoblotted with anti-phosphospecific Smad2 (α-P-Smad2) or Smad2/3 (α-Smad2/3)
antibodies. The bands corresponding to phosphoserine-modified Smad2 (P-Smad2) and
Smad2 (Smad2) are indicated. Representative blots from 4 experiments are shown.
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I next investigated if the effect of CDDO-Im on the duration of Smad2
phosphorylation could be due to an inhibition of Smad2 phosphatase activity. In order to
test this, I employed one of the strategies used by Lin and colleagues to identify PPM1A
as the nuclear Smad2 phosphatase (10). Briefly, the TGFβ type I receptor inhibitor,
SB431542, was added to the cell culture media after a pre-incubation of the cells with
TGFβ.

The addition of the inhibitor would assess if TGFβ receptor activity would

influence the effect of CDDO-Im on TGFβ-dependent Smad2 phosphorylation. In Rat2,
Cos-7 and C2C12 cells, the SB431542 inhibitor greatly reduced the phosphorylation of
Smad2 within 1 hour of incubation, indicating that these cell types have functional
phosphatase activity (Figure 2.1, lanes 9-12).

I next assessed if CDDO-Im would

influence Smad2 phosphatase by co-incubating cells with SB431542 and CDDO-Im. I
observed that CDDO-Im did not extend TGFβ-dependent Smad2 phosphorylation in
Rat2, Cos-7 or C2C12 cells when SB431542 was present in the culture media (Figure
2.1, lanes 13-16). These results suggest that the Smad2 phosphatase was not a CDDO-Im
target since CDDO-Im was unable to extend the duration of Smad2 phosphorylation after
TGFβ receptor inactivation.
As a second line of investigation, I assessed TGFβ-dependent Smad2 nuclear
translocation using immunofluorescence microscopy (Figure 2.2). I found that in the
absence of TGFβ, Smad2 staining was observed throughout the cytoplasm of C2C12
cells (Figure 2.2A).

After 1 hour of TGFβ stimulation, Smad2 staining was only

observed in the nuclei of cells regardless of treatment (Figure 2.2 B-E, top panels). Eight
hours after TGFβ was removed from the cell culture medium, Smad2 cytoplasmic
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Figure 2.2 CDDO-Im extends TGFβ-dependent Smad2 nuclear accumulation
independently of Smad2 phosphatase activity.
Unstimulated C2C12 cells (A) or C2C12 cells pulsed with 0.5 µM TGFβ for 30 minutes
in the absence or presence of 1 µM CDDO-Im were incubated in media containing
DMSO (B), 1 µM CDDO-Im (C), 10 µM SB431542 (D) or both compounds (E) at 37˚C
for 1 or 8 hours. The cells were then processed for immunofluorescence microscopy and
probed with DAPI (blue) to indicate nuclei and anti-Smad2/3 (Smad2) antibodies (green).
Nuclear and cytoplasmic Smad2 from 3 experiments (±SD) were quantitated using
ImagePro software and graphed as nuclear-cytoplasmic Smad2 ratio vs. time (F). Bar =
10 µm.
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staining reappeared in both control and CDDO-Im treated cells (Figure 2.2B and C,
bottom panels).
Consistent with the phospho-Smad2 time course studies, the TGFβ type I receptor
inhibitor, SB431542, increased cytoplasmic Smad2 staining after 8 hours of incubation
(Figure 2.2D) and this was also observed if the cells were co-incubated with SB431542
and CDDO-Im (Figure 2.2E). These results were supported by the quantitation of three
experiments (Figure 2.2F) and similar results were obtained with the use of Rat2 or Cos-7
cells (data not shown).
Finally, to further evaluate TGFβ dependent nuclear accumulation of Smad2 in
the presence or absence of CDDO-Im and/or SB431542, I carried out subcellular
fractionation studies. I assessed TGFβ-dependent Smad2 nuclear accumulation by
immunoblotting isolated nuclear fractions with anti-Smad2 antibodies (Figure 2.3). In
control cells I observed Smad2 in the nuclear fractions after 0.5 hours of TGFβ
stimulation and the signal attenuated after 4.5 hours of stimulation (Figure 2.3, lanes 1-3).
This was accentuated if the cells were incubated CDDO-Im (Figure 2.3, lanes 4-6). I
observed that the TGFβ type I receptor inhibitor, SB431542, decreased the amount of
Smad2 in the nuclear fractions after 4 hours of incubation (Figure 2.3, lanes 7-9) and this
was also observed if the cells were co-incubated with SB431542 and CDDO-Im (Figure
2.3, lanes 10-12).
Taken together, these results support the conclusion that CDDO-Im increases
TGFβ-dependent Smad2 phosphorylation and nuclear accumulation in a process that is
independent of Smad2 phosphatase activity.
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Figure 2.3 CDDO-Im extends TGFβ-dependent Smad2 accumulation in nuclear
fractions.
Rat2 cells were incubated with 0.5 µM TGFβ for 30 minutes in the absence or presence
of 1 µM CDDO-Im, washed and incubated in media containing DMSO (Control), 1 µM
CDDO-Im, 10 µM SB431542 or both compounds (CDDO-Im + SB431542) at 37˚C for
an additional 1 or 4 hours. Following subcellular fractionation, 100 µg of nuclear
fractions were processed for SDS-PAGE and immunoblotted with anti-Smad2/3 (αSmad2/3) or lamin A/C (α-lamin A/C) antibodies. The bands corresponding to Smad2 or
lamin A/C are indicated. Smad2 levels were quantitated using QuantityOne software and
normalized to the levels of lamin A/C (bottom graph). Representative blots from 6
experiments are shown.
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2.4.2

CDDO-Im interferes with TGFβ receptor degradation and trafficking
Efficient phosphorylation and nuclear translocation of Smad2 is dependent on the

proper targeting of TGFβ receptors to the early endosomal compartment (8,9,15,42-45).
Inhibition of the signal transduction pathway is dependent on Smad2 phosphatase activity
(10) and on the association of TGFβ receptors with the Smad7/Smurf2 complex, which
inhibits TGFβ receptor kinase activity and promotes receptor complex degradation
(11,12). Since I concluded that Smad2 phosphatase activity was not targeted by CDDOIm, I attempted to determine if CDDO-Im regulates the kinetics of Smad activation by
altering TGFβ receptor degradation.

I therefore assessed TGFβ receptor turnover in

C2C12 and Cos-7 cells by affinity-labeling receptors with

125

I-TGFβ at 4˚C followed by

incubation at 37˚C, SDS-PAGE and phosphoimaging analysis. I observed that both
C2C12 and Cos-7 cells exhibited a receptor half-life of approximately 2 hours and that
treating cells with CDDO-Im greatly reduced the rate of TGFβ receptor degradation
(Figure 2.4A).

I also carried out TGFβ receptor degradation studies in mink lung

epithelial cells, Mv1Lu cells, a cell line that has been used to study TGFβ signaling and
degradation (12,13).

In Mv1Lu cells, the receptor half-life was observed to be

approximately 3 hours (Figure 2.4A). Consistent with the results observed with Cos-7
and C2C12 cells, the rate of TGFβ receptor degradation was delayed to at least 8 hours in
the CDDO-Im treated Mv1Lu cells.
A delay in receptor degradation might be due to receptor exclusion from the
compartment where degradation occurs or to a reduction in receptor trafficking to that
compartment. To clarify this, I investigated receptor internalization and co-localization
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Figure 2.4 CDDO-Im delays TGFβ receptor degradation and trafficking.
A) C2C12, Cos-7, or Mv1Lu cells were affinity labeled with 125I-TGFβ at 4˚C, crosslinked and lysed (0 time control) or incubated at 37˚C for 2, 4 or 8 hours prior to lysis.
One hundred micrograms of cell lysates were then subjected to SDS-PAGE followed by
autoradiography and phosphoimager analysis. The bands representing TGFβ type I
receptors (TβRI) or type II receptors (TβRII) are indicated on the left side of each panel.
Total receptor levels were quantified and graphed (right panel) as receptor levels (% of
control) vs. time (n = 3 ± SD).
B) Mv1Lu cells stably expressing TβRII were incubated at 4˚C with biotinylated TGFβ
(bTGFβ) followed by streptavidin Cy3 (red). The cells were then incubated at 37˚C in
the absence (left panel; Control) or presence (right panel) of 1 µM CDDO-Im for 1 hour.
Cells were then fixed, permeabilized and immunostained with anti-caveolin-1 (Cav-1;
green) and anti-EEA1 (EEA1; blue) antibodies. Areas of interest (white boxes) are
magnified for both the control and CDDO-Im treated cells and are shown underneath
each panel (insets). Representative cells shown indicate the co-localization of bTGFβ
with either caveolin-1 or EEA1 as described in the key and by yellow or magenta
arrowheads, respectively. The contour (dotted line) of each cell was established using
brightfield images and overlayed on the DAPI nuclear stain. Representative micrographs
from 3 experiments are shown. Bar = 10 µm.
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with EEA1- or caveolin-1-positive vesicles in the same cell. As previously reported,
Mv1Lu cells expressing HA-tagged TβRII internalize biotinylated TGFβ into both
EEA1- and caveolin-1-positive vesicles using deconvolution immunofluorescence
microscopy (15) and we have confirmed this phenomenon as well (Figure 2.4B; left
panel). In the presence of CDDO-Im, the amount of TGFβ receptor trafficking was
reduced, as the majority of receptors after 1 hour of incubation at 37˚C did not
accumulate in the peri-nuclear regions of cells (Figure 2.4B; right panel). However, colocalization with EEA1 or caveolin-1-positive compartments, even in regions close to the
plasma membranes of cells was still readily apparent (Figure 2.4B, inset). Although this
suggested that TGFβ receptors had indeed internalized from the plasma membrane, I
wanted to test this further by carrying out acid washing experiments (Figure 2.5).
Briefly, Mv1Lu cells stably expressing TβRII were incubated at 4˚C with biotinylated
TGFβ followed by streptavidin-Cy3. The cells were then either acid washed to remove
any cell surface labeling or incubated at 37˚C in the absence or presence of 1 µM CDDOIm for 1 hour prior to incubation in acidic conditions. I observed that fluorescent probes
bound to cell surface receptors at 4˚C were susceptible to acid washing and were
removed. However, receptor-bound probes were not removed by acidic treatment after
the cells had been incubated at 37˚C for 1 hour either in the presence or absence of
CDDO-Im (Figure 2.5).

This demonstrated that although CDDO-Im altered TGFβ

receptor trafficking, it did not inhibit receptor internalization from the plasma membrane.
Interestingly, I noted that caveolin-1-positive vesicles were closer to the plasma
membrane in CDDO-Im-treated cells (Figure 2.4B). Moreover, co-localization of TGFβ
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Figure 2.5 CDDO-Im does not inhibit TGFβ receptor internalization.
Mv1Lu cells stably expressing HA-tagged TGFβ type II receptors (TβRII) were
incubated at 4˚C with biotinylated TGFβ (bTGFβ) followed by streptavidin-Cy3 (red).
The cells were then acid washed or incubated at 37˚C in the absence (left panel) or
presence (right panel) of 1 µM CDDO-Im for 1 hour prior to acid washing. Bar = 10
µm.
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receptors with the caveolin-1-positive compartment became quite prominent. The EEA1positive vesicles also appeared to have an altered subcellular distribution in cells treated
with CDDO-Im.
To further assess the effect of CDDO-Im on the EEA1-positive endosomal
compartment, I stained untreated or CDDO-Im-treated cells with anti-EEA1 antibodies
and scored the number of cells that demonstrated a peri-nuclear staining pattern versus
cells with a dispersed EEA1 staining pattern (Figure 2.6).

In cells that were not

incubated with CDDO-Im, 72 ± 5% of the cells counted displayed EEA1 in a peri-nuclear
distribution, whereas CDDO-Im treated cells only had 27 ± 4% peri-nuclear staining
(Figure 2.6B). These data indicate that although CDDO-Im does not affect TGFβ
entrance into either the EEA1 or caveolin-1-positive compartments, it interferes with the
dynamics of their trafficking.
Furthermore, CDDO-Im leads to the dispersal of the EEA1 compartment and an
accumulation of caveolin-1-positive structures in close proximity to the plasma
membranes of cells.

2.4.3

CDDO-Im interferes with TGFβ-dependent cell migration
In order to investigate a functional consequence of extending TGFβ-dependent

Smad signaling by CDDO-Im, I assessed TGFβ-dependent cell migration because
CDDO-Im, as well as the parental CDDO compound, exhibit potent anti-metastatic
activity in animal models (36). To assess polarized cell movement I carried out ‘wound
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Figure 2.6 CDDO-Im disperses the EEA1-early endosomal compartment.
A) Vehicle-treated Mv1Lu cells (Control) or Mv1lu cells treated with 1 µM CDDO-Im
for 1 hour at 37˚C were fixed, permeabilized and immunostained with anti-EEA1
antibodies (EEA1; green). The nuclei were visualized using DAPI staining (blue). A
representative cell (inset) was magnified and shown at the bottom. Bar = 10 µm.
B) Three experiments were carried out as described in Panel A. One hundred cells from
each experimental condition were analyzed, scored on the basis of peri-nuclear or
dispersed staining of EEA1 protein and graphed (n = 3 ± SD).
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healing’ assays using Rat2 fibroblasts. In this assay, regions of confluent Rat2 cells were
removed and cell migration into the cell-free space was assessed (Figure 2.7A). When
cells were incubated in medium containing low serum, the ‘wound’ was observed even
after 12 hours of incubation at 37˚C (Figure 2.7A; top panel). The addition of TGFβ to
the media containing low serum induced the cells at the edge of the scratch to migrate
perpendicularly into the cell-free space (Figure 2.7A; middle panel). Interestingly, the
co-incubation of TGFβ and CDDO-Im inhibited TGFβ–dependent cell migration (Figure
2.7A; bottom panel).
One possibility for this inhibition is that it could be due to a dissociation of TGFβ
receptors from the polarity complex protein Par6. This is based on the observation that
the association between TGFβ receptors and Par6 is essential for epithelial to
mesenchymal transition (EMT) and cell migration (2). I therefore carried out coimmunoprecipitation studies and observed that TGFβ type I and II receptors associate
with Par6 in untreated or CDDO-Im treated cells (Figure 2.7B). To assess the specificity
of association, I used a Par6 mutant that lacks the PB1 domain (Par6-∆PB1). This
domain was previously shown to be essential for Par6-TGFβ receptor association (34).
As expected, I observed little association between the Par6-∆PB1 mutant and TGFβ
receptors (Figure 2.7B). I next assessed the phosphorylation of Par6 by the TGFβ type II
receptor using a phospho-Serine 345-specific antibody. The phosphorylation of S345 by
TGFβ type II receptors has been shown to be necessary for TGFβ-dependent EMT (34).
As seen in the co-immunoprecipitation studies, I did not observe a change in TGFβ
receptor dependent phosphorylation of Par6 in the presence of CDDO-Im (data not
shown).
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Figure 2.7 CDDO-Im delays TGFβ-dependent cell migration but does not disrupt
the association of TGFβ Receptors with Par6 protein.
A) Confluent monolayers of Rat2 fibroblasts were scratched and incubated at 37˚C for 12
hours in media supplemented with 0.2% FBS (Control; top panel), in media
supplemented with 0.2% FBS + 0.5 nM TGFβ (middle panel) or media supplemented
with 0.2% FBS + 0.5 nM TGFβ + 0.5 µM CDDO-Im (bottom panel). Cells were then
fixed and imaged using brightfied microscopy. The dotted lines indicate the starting point
of cell migration. Representative micrographs from 3 experiments are shown. Bar = 0.1
mm.
B) HEK293 cells were transiently transfected with cDNA encoding the proteins indicated
and incubated in the absence or presence of 1 µM CDDO-Im for 2 hours prior to lysis
and immunoprecipitation with anti-Par6 antibodies. The immunoprecipitates were then
subjected to SDS-PAGE and immunoblotting with anti-HA or anti-Flag antibodies to
reveal protein complexes. One hundred micrograms of total protein lysates were
immunoblotted (bottom panels) to assess protein expression. The bands corresponding to
TGFβ type I receptors (TβRI), TGFβ type II receptors (TβRII), wild type Par6 (Par6 wt.),
Par6 lacking the PB1 domain (Par6-∆PB1) and IgG heavy chain (IgG HC) are indicated.
Representative immunoblots from 4 experiments are shown.
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These results suggested that the inhibition of TGFβ-dependent migration by
CDDO-Im was not dependent on the association of Par6 with TGFβ receptors or its
phosphorylation, and that other cellular targets could be part of the underlying
mechanism(s).

2.4.4

CDDO-Im alters cytoskeletal dynamics
The cellular cytoskeleton regulates subcellular position of organelles, vesicular

traffic as well as cell polarity and cell migration (46,47). Since I observed that CDDO-Im
affects all of these processes in various cell lines, I examined if the cytoskeletal network
is a potential target for this compound. First, I evaluated the actin cytoskeleton in control
and CDDO-Im-treated cells by staining for filamentous actin (F-actin) using Texas-Redlabeled phalloidin (Figure 2.8A, top and middle panels). In untreated cells, F-actin was
observed as both a membrane bound network, as well as stress fibers. In CDDO-Imtreated cells, the pattern of F-actin staining was indistinguishable from control cells,
suggesting that the actin cytoskeleton is not a target of CDDO-Im. As a positive control,
I treated cells with cytochalasin B, which depolymerizes the actin cytoskeleton, and
observed marked structural differences compared to control or CDDO-Im-treated cells
(Figure 2.8A, bottom panel).
I next assessed how CDDO-Im affected the microtubule network (Figure 2.8B).
Although CDDO-Im did not cause depolymerization of the microtubule network, the
compound had a marked effect on the organization and orientation of microtubules. In
control cells, the microtubule network radiated outward from the microtubule-organizing
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Figure 2.8 CDDO-Im does not affect the actin cytoskeleton but alters the
microtubule cytoskeleton.
A) Control Mv1Lu cells (top panel) or cells treated with 1µM CDDO-Im (middle panel)
or 10 µM cytochalasin B (bottom panel) for 1 hour were fixed and permeabilized. To
visualize the actin cytoskeleton and the nuclei, cells were incubated with Texas Red
(TR)-Phalloidin (red) and DAPI stain (blue), respectively. Representative micrographs
from 3 experiments are shown. Bar = 10 µm.
B) Mv1Lu cells stably expressing the HA-tagged TβRII were incubated at 4˚C with
biotinylated TGFβ followed by streptavidin-Cy3 (red; bTGFβ) and transferred to 37˚C in
the absence (Control) or presence of 1 µM CDDO-Im, 10 µM nocodazole or 10 µM
cytochalasin B. The cells were fixed, permeabilized and probed with anti-β-tubulin
antibodies (Tubulin; green). The nuclei were visualized using DAPI staining (blue). The
micrographs of the microtubule staining for the control (i) or the CDDO-Im treated cells
(ii) were magnified to demonstrate microtubule structural differences (right panels).
Representative micrographs from 5 experiments are shown. Bar = 10 µm.
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center (MTOC) towards the cell periphery (Figure 2.8B; i). However, in CDDO-Im
treated cells, microtubules emanating from the MTOC clearly lacked the characteristic
pattern of the microtubule network, appearing to snake through the cytoplasm in a less
organized fashion (Figure 2.8B; ii). As positive and negative controls, I treated cells with
nocodazole (which causes complete microtubule disruption) and cytochalasin B (which
does not alter microtubule networking), respectively. As expected, nocodazole but not
cytochalasin B depolymerized microtubules, and interfered with the trafficking of TGFβ
receptors. I also examined TGFβ receptor localization after CDDO-Im-treatment and
observed that the drug interfered with the distribution of TGFβ receptors.

Thus,

trafficking of TGFβ receptors to the peri-nuclear region is dependent on proper
microtubule organization and polarity. Together, these data indicate that CDDO-Im
alters the microtubule network in a fashion that is distinct from the microtubule
depolymerizing drug, nocodazole. To further investigate the mechanism of CDDO-Im–
dependent microtubule network interference, I first investigated microtubule-capping
proteins, which modulate membrane association of the microtubule both at the plasma
membrane and with vesicles (48). CLIP170 is a major capping protein that associates
with the plus end of growing microtubules and links the microtubule to vesicles and to
the plasma membrane via interactions with IQGAP1 (32). Given the meandering nature
of the microtubules in CDDO-Im-treated cells, I postulated that membrane and vesicular
attachment might also be affected by CDDO-Im.
To investigate the effect of CDDO-Im on CLIP170 association with microtubules,
Rat2 fibroblasts was transiently transfected with GFP-tagged CLIP170 and its
localization was assessed by immunofluorescence microscopy. In control cells, CLIP170
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was observed to be associated with the positive end of growing microtubules (Figure
2.9A; left panel), but in CDDO-Im-treated cells, CLIP170 was redistributed to large
puncta in the cytoplasm and was no longer associated with microtubules (Figure 2.9A;
right panel).

To further address this, I examined CLIP170 association with the

cytoskeleton by biochemical fractionation.

For this, I solubilized membranes and

separated the soluble fraction from the insoluble cytoskeleton by centrifugation (Figure
2.9B), a method that effectively removes the majority of cellular organelles from the
cytoskeleton fraction (Figure 2.10). As expected, tubulin and most of actin protein was
in the cytoskeletal fraction in control cells (Figure 2.9B), whereas in nocodazole-treated
cells, tubulin, but not actin, partitioned with the soluble fraction. Consistent with the
immunofluorescence studies, CDDO-Im treatment of cells did not induce a solubilization
and loss of tubulin from the cytoskeletal fraction.

Interestingly, CLIP170 was

consistently present in the cytoskeletal fraction regardless of the treatment. This was
surprising because I assumed that the dissociation of CLIP170 from microtubules by
either nocodazole or CDDO-Im treatment would cause the majority of the CLIP170 to be
concentrated in the soluble fraction. However, CLIP170 remained in the cytoskeletal
fraction suggesting that either CDDO-Im did not induce complete CLIP170 dissociation
from the cytoskeleton or that CLIP170 aggregated in punctate masses in response to
CDDO-Im.

In order to distinguish between the two possibilities, the dynamics of

CLIP170 mobility was visualized in real time by microinjecting cDNA encoding GFPCLIP170 into Rat2 fibroblasts and carrying out time-lapse immunofluorescence
microscopy. In control cells, the GFP-CLIP170 followed the growing microtubules
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Figure 2.9 CDDO-Im induces CLIP170 to dissociate from microtubules.
A) Rat2 fibroblasts transiently expressing GFP-CLIP170 were incubated in the absence
(left panels) or presence of 1µM CDDO-Im (right panels) for 1 hour and were then fixed,
permeabilized and immunostained with anti-β-tubulin antibodies (red). The colocalization of GFP-CLIP170 (green) and microtubules (red) results in yellow staining.
Bar = 10 µm.
B) Cos-7 cells were incubated in the absence (Control) or presence of 1 µM CDDO-Im or
10 µM nocodazole (Nocod.) for 1 hour and then subjected to lysis at 37˚C to separate
soluble proteins (S) from the cytoskeleton (C). Following processing for SDS-PAGE,
cell lysates were immunoblotted with antibodies raised against CLIP170, IQGAP1,
tubulin, actin or Rac1. The relative position of each resolved protein is indicated.
Representative blots from 4 experiments are shown.
C) Rat2 fibroblasts were microinjected with a GFP-CLIP170 cDNA and incubated for 4
hours at 37˚C. The movement of GFP-tagged CLIP170 in control cells (top time course)
or cells incubated with 0.1 µM CDDO-Im (bottom time course) were imaged using timelapse immunofluorescence microscopy.
The starting point of movement of a
representative CLIP170 cap is indicated by a red bar and the white arrow follows the
movement of the CLIP170 signal along microtubules in the control cell and in large
aggregates in the CDDO-Im treated cell. Representative images from 3 experiments are
shown. Bar = 10 µm.
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Figure 2.10 Characterization of the soluble and cytoskeletal fractions.
Cos-1 cells were lysed at 37˚C to separate soluble proteins (S) from the cytoskeleton (C).
Following processing for SDS-PAGE, cell lysates were immunoblotted with antibodies
raised against proteins enriched in the cytoskeleton, anti-tubulin and actin; the early and
late endosome, EEA1 and LAMP-1, respectively; the endoplasmic reticulum, Calnexin;
and the Golgi apparatus, GM130. The relative migration of each protein is indicated.
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(Figure

2.9C

and

please

see

supplementary

movie

1:

http://www.jbc.org/content/suppl/2008/04/25/M704064200.DC1/Supp_Movie_1_clip170_control.mov). In the CDDO-Im treated cells, the punctate aggregates that contained
the GFP-CLIP170 remained mobile at lower triterpenoid concentrations (0.1 µM; Figure
2.9C

and

please

see

supplementary

movie

2:

http://www.jbc.org/content/suppl/2008/04/25/M704064200.DC1/Supp_Movie_2_clip170_Im_0.1_micro.mov), but were immobilized at higher doses (1 µM; please see
supplementary

movie

3:

http://www.jbc.org/content/suppl/2008/04/25/M704064200.DC1/Supp_Movie_3_clip170_Im_1_micro.mov), thereby stalling the formation of a normal microtubule network.
These data suggest that CDDO-Im affects the organization of the microtubular network
by interfering with the function of the capping protein, CLIP170.

2.4.5

CDDO-Im targets the polarity complex
In order to evaluate the cellular target of triterpenoids, I attempted to identify the

subcellular localization of triterpenoids by utilizing a biotinylated version of CDDO. The
biotinylated compound elicits identical cellular responses as the CDDO-Im, albeit at
higher concentrations (49) and allows for the assessment of triterpenoid subcellular
localization by immunofluorescence microscopy (Figure 2.11). As controls, biotin or
CDDO did not exhibit any fluorescence signal (Figure 2.11A and B). However, I
observed that CDDO-biotin localized in the nuclei and at the cell membrane in patches
that were consistent with the leading edge of migrating cells. To confirm this possibility,
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Figure 2.11 Subcellular targeting of biotinylated CDDO.
Rat2 fibroblasts were grown to 100% confluency and scratched to create a wound. After
incubation for 6 hours to allow cell polarization and migration, cells were fixed,
permeabilized and incubated with monoclonal anti-Rac1 antibodies (Rac1; green) and
biotin (A), CDDO (B), or biotinylated CDDO (CDDO-biotin; C) followed by Cy2labeled anti-mouse antibody and Cy3-labeled streptavidin. The co-localization of Rac1
(green) with CDDO-biotin (red) at the leading edge of migrating cells is demonstrated in
the inset (yellow arrowheads). The white arrow indicates the direction of cell movement
and DIC microscopy was included to visualize the leading edge of migrating cells.
Representative images from 4 experiments are shown. Bar = 10 µm.
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I immunostained scratched Rat2 fibroblasts using CDDO-biotin and Rac1 antibodies and
observed that Rac1 co-localized with biotinylated CDDO-biotin at the leading edge of the
migrating cells (Figure 2.11C).
I next examined the subcellular localization of molecules known to be involved in
the leading edge of polarized cells (Figure 2.12). To carry this out I first assessed the
morphology of the leading edge of migrating Rat2 cells by DIC microscopy and observed
that untreated cells were elongated, and had distinct lamellipodia whereas CDDO-Im
treated cells were round. In order to assess this in a dynamic fashion, I carried out a realtime study where Rat2 fibroblasts were wounded and incubated in control or CDDO-Im
containing media over time.
arranged

in

a

Brightfield images were collected over 13 hours and

movie

(please

see

supplementary

movie

4:http://www.jbc.org/content/suppl/2008/04/25/M704064200.DC1/Supp_Movie_4_Rat2_
migration.mov).
The positioning of CDDO-biotin at the leading edge of migrating cells (Figure
2.11C) and the CDDO-Im-dependent loss of lamellipodia (Figure 2.12A, bottom panel)
prompted us to investigate the link between microtubules and the polarity complex, found
at the leading edge of migrating cells (Figure 2.12B). For this line of investigation, I
carried out wound-healing assays by first scratching Rat2 cells, allowing them to polarize
and migrate for 6 hours and then incubate them in media containing CDDO-Im or
nocodazole for an additional 2 hours. This experimental approach would allow us to
study the effects of the drugs on the fate of the polarity complex after it had been preestablished for 6 hours. I therefore first assessed tubulin and CLIP170 in scratched Rat2

113

fibroblasts (Figure 2.12C). In addition to the cell body, control cells displayed
endogenous CLIP170 decorating the leading edge of migrating cells, where tubulin
extended to the plasma membrane. In contrast, CDDO-Im caused endogenous CLIP170
to disperse from the leading edge into punctate structures reminiscent of those observed
after GFP-CLIP170 expression (see Figure 2.9A). I also examined the localization of
tubulin and CLIP170 proteins in nocodazole-treated cells. As expected, microtubules
were disrupted, but despite the accompanying alteration in cellular morphology, tubulin
and CLIP170 staining remained co-localized to the leading edge in these cells (Figure
2.12C, bottom panel). This was notably different from the CDDO-Im treated cells, where
there was an absence of CLIP170 staining at the leading edge. The association of
microtubules to the leading edge of cells is facilitated by CLIP170, which links
microtubules to IQGAP1 (32). Since CLIP170 failed to localize to the leading edge of
CDDO-Im-treated cells, I examined if CDDO-Im also affects IQGAP1 targeting to the
leading edge of polarized cells. In untreated cells, IQGAP1 localized to the leading edge
of migrating cells and CDDO-Im-treatment abrogated this localization (Figure 2.13A).
Moreover, general microtubule destabilization with nocodazole did not affect IQGAP1
localization, consistent with my observation that this drug does not affect polarity
complex once it has already been established (Figure 2.13A and B). Finally, in order to
determine if CDDO-Im causes a complete dissociation of proteins present in the polarity
complex, I assessed the association of IQGAP1 with Rac1 (Figure 2.13C). I did not find
any appreciable dissociation of Rac1 that was co-immunoprecipitated with IQGAP1
antibodies either in CDDO-Im- or nocodazole-treated cells. These data, in conjunction to
the observation that CDDO-Im induced the redistribution of IQGAP1 at the plasma

114

Figure 2.12 CDDO-Im interferes with cell morphology and the localization of
CLIP170 at the leading edge of migrating cells.
A) Rat2 fibroblasts were grown to 100% confluency and scratched to create a wound.
The cells were then incubated for 4 hours at 37˚C and then treated with control medium
or medium containing 1 µM CDDO-Im for an additional 2 hours before being fixed and
processed for DIC microscopy. The dotted lines indicate the starting point of cell
migration. Representative micrographs from three experiments are shown. White arrows
indicate the direction of cellular movement. Bar = 10 µm.
B) Model of microtubule association with a subset of polarity complex proteins at the
leading edge of migrating cells. The microtubule capping protein, CLIP170, associates
with IQGAP1. PKCζ is shown in this model as a member of the polarity complex and
the white arrow indicates the direction of cellular movement.
C) Rat2 fibroblasts were grown to 100% confluency, scratched and then incubated for 6
hours at 37˚C. Cells were then incubated an additional 2 hours in control medium
(Control; top panels), or media containing 1 µM CDDO-Im (middle panels) or 10 µM
nocodazole (bottom panels) prior to fixation, permeabilization and immunostaining with
anti-CLIP170 (CLIP170) and anti-tubulin (Tubulin) antibodies. The scratches were
subjected in the horizontal plane above the cells shown, and the leading edge of
migrating cells containing microtubule ends and CLIP170, are indicated with green and
red arrowheads, respectively.
Yellow arrowheads show the co-localization of
microtubule ends and CLIP170. White arrows indicate the direction of cellular
movement. Bar = 10 µm.
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Figure 2.13 Reduction of IQGAP1 localization at the leading edge of migrating cells
in response to CDDO-Im treatment.
A) Cells were scratched and allowed to migrate into the wound for 6 hours in order to
establish cell polarity prior to incubation with control medium (top panels) or media
containing 1µM CDDO-Im (middle panels) or 10 µM nocodazole (bottom panels) for an
additional 2 hours. Cells were then fixed, permeabilized and immunostained for
endogenous Rac1 (green) and IQGAP1 (red) protein. A representative area of interest
(white box) from each condition was enlarged and shown (inset). Green and red arrows
indicate Rac1 and IQGAP1 at the leading edge of migrating cells, respectively. The colocalization of Rac1 with IQGAP1 is indicated by yellow arrowheads. The white arrows
indicate the direction of cellular movement. Bar = 10 µm.
B) Quantitation of cells containing Rac1 or IQGAP1 at the leading edge of migrating
cells was carried out as described in the Experimental Procedures and graphed (n=3 ±
SD). *,#: p<0.0001.
C) Untreated cells (Control) or cells incubated with either CDDO-Im or nocodazole
(Nocod.) were lysed and immunoprecipitated with non-immune IgG (Non-IM IgG) or
anti-IQGAP1 antibodies (α-IQGAP1) and immunoblotted (Blot) with anti-IQGAP1 or
anti-Rac1 antibodies. The relative mobilities of Rac1 or IQGAP1 are indicated on the
left of each panel. One hundred micrograms of total protein lysates were immunoblotted
and shown on the left. Representative blots from 3 experiments are shown.
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membrane, suggested that the localization of Rac1 and IQGAP1 to the leading edge
might be affected by triterpenoid treatment.
To expand my analysis to other members of the polarity complex, I assessed the
localization of Rac1 and PKCζ, both of which normally localize to the leading edge of
cells undergoing polarized cell movement (Figure 2.14). In untreated cells, both Rac1
and PKCζ were observed to co-localize at the leading edge of migrating cells (Figure
2.14A). However in response to CDDO-Im, I observed that although Rac1 localized to
the membrane, it was less organized and dispersed along the cell membrane.
Furthermore, PKCζ staining was altogether absent from the cell membrane of CDDO-Imtreated cells (Figure 2.14B). Nocodazole treatment altered the morphology of leading
edge cells, and Rac1 was now found in numerous protrusive structures all around the cell
(Figure 2.14C). In these cells, PKCζ remained co-localized with Rac1, consistent with
the lack of change in IQGAP1 or CLIP170 localization observed after nocodazole
treatment. These results indicate that the function and assembly of the polarity complex
is disrupted in response to CDDO-Im treatment and that this effect is not dependent on
general microtubule disruption since polarity complex constituents remained associated
in nocodazole-treated cells.
Based on my observations that CDDO-Im does not disrupt the association
between Par6 and TGFβ receptors (Figure 2.7B) but does disrupt the localization of
members of the polarity complex (Figures 2.12, 2.13, 2.14), I predicted that the
localization of TGFβ receptors and Par6 at the leading edge might be reduced and/or
abrogated in the presence of CDDO-Im. To test this, I assessed the localization of Par6
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Figure 2.14 CDDO-Im disrupts PKCζ localization at the leading edge of polarized
cells.
Rat2 fibroblast monolayers were scratched and allowed to grow into the wound for 6
hours in order to polarize before being incubated in the absence (Control; A), or presence
of 1 µM CDDO-Im (B) or 10 µM nocodazole (C) for an additional 2 hours. Cells were
then fixed, permeabilized and immunostained for endogenous Rac1 (green) or PKCζ
(red) using anti-Rac1 and anti-PKCζ antibodies, respectively. A representative area of
interest (white box) from each condition was enlarged and shown (inset). Green and red
arrows indicate Rac1 and PKCζ at the leading edge of migrating cells, respectively. The
co-localization of Rac1with PKCζ is indicated by yellow arrowheads. The white arrows
indicate the direction of movement. Representative images from 4 experiments are
shown. Bar = 10 µm. *,#: p<0.0001.
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and TβRII by immunofluorescence microscopy (Figure 2.15). In untreated cells, I
observed that both Par6 and TGFβ receptors were indeed present at the leading edge of
migrating cells and that they both co-localized with Rac1 (Figure 2.15). However, in
response to CDDO-Im treatment, the amounts of Par6 and TβRII at the leading edge of
cells were markedly reduced (Figure 2.15). These results further support my observations
that CDDO-Im disrupts TGFβ-dependent cell migration by disrupting the polarity
complex.
Taken together, my results demonstrate that the triterpenoid CDDO-Im alters
TGFβ receptor trafficking and signal transduction, microtubule-plasma membrane
attachments, as well as vesicular transport. The mechanism of affecting cell polarity and
migration is dependent on the disruption of CLIP170 capping of microtubules, which
causes the disruption of microtubule attachments with the polarity complex. Furthermore,
the co-localization of triterpenoid with Rac-1 at the leading edge of migrating cells
positions it to interfere with cell polarity by disrupting the localization of IQGAP1,
PKCζ, Par6 and TGFβ receptors at the leading edge of migrating cells.

122

Figure 2.15 CDDO-Im disrupts Par6 and TGFβ Receptor localization at the leading
edge of migrating cells.
Rat2 fibroblast monolayers were scratched and allowed to grow into the wound for 6
hours before being incubated in the absence (Control), or presence of 1 µM CDDO-Im
for an additional 2 hours. Cells were then fixed, permeabilized and immunostained for
endogenous Rac1 (green) and Par6 (red) using anti-Rac1 and anti-Par6 antibodies (A) or
for endogenous Rac1 (green) and TGFβ type II receptor (TβRII; red) using anti-Rac1 and
anti-TβRII antibodies, respectively (B). A representative area of interest (white box) from
each condition was enlarged and shown (inset). Green arrowheads indicate Rac1 and red
arrowheads indicate Par6 or TβRII at the leading edge of migrating cells. The colocalization of Rac1 with Par6 or TβRII is indicated by yellow arrowheads. The white
arrows indicate the direction of movement. Bar = 10 µm. Cells containing Rac1, Par6 or
TβRII at the leading edge were quantitated from 3 experiments carried out as described in
Panels A and B (± SD) and graphed (C). *,#: p<0.0001.
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2.5

DISCUSSION
TGFβ is a growth factor that acts as a tumor suppressor or promoter depending on

cellular context (4,50). TGFβ receptors propagate several signaling pathways, two of
which are essential for epithelial to mesenchymal transition (EMT), the Smad pathway
(51,52) and the Par6 pathway (34,53). In this study I found that CDDO-Im inhibits
TGFβ-dependent cell migration. In order to identify the mechanism I first assessed its
effect on TGFβ signaling. As previously described in studies using U937 and HL60 cells
(37,39), I found that CDDO-Im extended the phosphorylation profile of Smad2, however,
further investigation suggested that this was not due a decrease in Smad2 phosphatase
activity (Figures 2.1, 2.2 and 2.3). I next assessed receptor trafficking and degradation.
Previous studies indicated that by perturbing the lipid raft compartment, the distribution
of internalized cell surface TGFβ receptors could be shifted from the caveolin-1-positive
compartment to the EEA1-early endosomal compartment, leading to enhanced signaling
and delayed receptor degradation (15). I observed that CDDO-Im did delay receptor
degradation however, unlike lipid-raft destabilizing agents such as nystatin, CDDO-Im
did not shift receptor equilibrium toward the caveolin-1-positive compartment. Instead,
CDDO-Im delayed overall receptor traffic and induced both caveolin-1- and EEA1positive vesicles to be localized to the peri-plasma membrane regions of cells (Figures
2.4 and 2.6).

This led us to conclude that the compound was affecting a cellular

structural component and quite possibly the cytoskeleton, as both the actin and
microtubule cytoskeleton have been shown to be important for the trafficking of vesicles
from the plasma membrane to the cell interior (21,46,54,55).
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Further study revealed that although the actin cytoskeleton was not
morphologically affected, the microtubule network became disorganized (Figure 2.8).
The disorganization of vesicular positioning in the cell is a hallmark of microtubule
catastrophe brought on by destabilizing drugs such as nocodazole (20). Indeed the
microtubule network will disperse if cells are treated with high triterpenoid
concentrations (56).

However, in the present study I used lower concentrations of

CDDO-Im, consistent with the concentrations used in animal studies (57-59), and found
that CDDO-Im does not dissolve the microtubule cytoskeleton. Rather, I observed that
microtubules in CDDO-Im treated cells take on a looping morphology that is reminiscent
of a lack of proper attachment to the cell membrane and loss of cell polarity. I therefore
tested if microtubule-capping proteins might be affected since they act as anchorage
points both between microtubules and vesicles, and between microtubules and the cell
membrane (26,48). The latter process involves a number of intermediate molecules, such
as CLIP170, and members of the polarity complex, Cdc42/Rac1, via IQGAP1 (32,33,48).
Interestingly, CLIP170 and IQGAP1 were found to dissociate from the leading
edge of cells in response to CDDO-Im. These observations explain both the loss of
vesicular traffic to the cell interior as well as the loss of microtubule targeting and
association with the leading edge of cells (Figure 2.9, 2.12 and 2.13).

Of note,

nocodazole, a drug that disrupts microtubules, was unable to affect the polarity complex
after the cells were allowed to polarize in the absence of drugs. These observations
indicate that the effects of CDDO-Im on CLIP170 dissociation from microtubules and the
loss of concentration of molecules in the polarity complex are distinct from compounds
that dissociate CLIP170 from microtubules via microtubule catastrophe. My results also
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suggest that the association of different members of the polarity complex have variable
stability. Indeed, I found that Rac1 remains associated with IQGAP1 regardless of the
pharmacological treatment (Figure 2.13). This stable association is also reflected in the
fractionation studies, as the majority of Rac1 and IQGAP1 both partitioned with the
soluble fractions while CLIP170 was concentrated in the cytoskeletal fractions (Figure
2.9). However, the dissociation of CLIP170 from microtubules and the loss of PKCζ
from the polarity complex were exquisitely sensitive to CDDO-Im treatment. This has
implications not only for TGFβ-dependent cell migration, but migration dependent on
other growth factors and receptors as well. Indeed, CDDO-Im inhibits serum-stimulated
Rat2

fibroblast

migration

(please

see

supplementary

movie

4:http://www.jbc.org/content/suppl/2008/04/25/M704064200.DC1/Supp_Movie_4_Rat2_
migration.mov). However, in the case of TGFβ-dependent cell migration, my results
indicate that the location of Par6 and TGFβ receptors is important.
It was interesting that TGFβ receptors remained associated with Par6 even as
TGFβ-dependent migration was abrogated by CDDO-Im. When I assessed the
association of Par6 with TGFβ receptors, I detected no difference in the association or
phosphorylation of Par6 in response to CDDO-Im treatment. Therefore this aspect of
TGFβ dependent migration was not perturbed. The localization of the triterpenoid to the
leading edge of migrating cells was intriguing (Figure 2.11) as it may suggest that the
mechanism of CDDO-Im block could be the modulation of proteins at this locus. I
reasoned that perhaps the loss of IQGAP1, PKCζ and Rac1 at the leading edge of
migrating cells would be accompanied with a loss of Par6 and TGFβ receptors. This was
confirmed when I assessed Par6 and TGFβ receptor localization by immunofluorescence
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microscopy and found both partners to be greatly reduced at this site (Figure 2.15).
Further investigation of how CDDO-Im modulates TGFβ receptor signaling will be
interesting as the concentration of TGFβ receptors in various subcellular locations has
been shown to be essential to stimulate Smad2 phosphorylation on endosomal
membranes (8,9,15,42-45), EMT at tight junctions (34) and degradation of RhoA in
lamellipodia and filopodia (60-62).
Finally, my results may also give some insight into the mechanism of the antimetastatic and anti-proliferative effects of CDDO-Im in animal studies (57-59) and
would be an interesting area of study particularly for understanding mechanisms of cell
migration and metastasis in human cancer. A general class of anti-metastatic agents,
microtubule destabilizing drugs, affect cell motility, migration and metastasis (63).
Therefore combining anti-microtubule drugs with drugs such as CDDO-Im that target the
attachment sites between microtubules and the cell membrane may be an effective
therapeutic approach to metastasis.
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CHAPTER 3

3.1

CHAPTER SUMMARY

Synthetic triterpenoids are anti-tumor agents that affect numerous cellular functions
including apoptosis and growth. Here, I used mass spectrometric and protein array
approaches and uncovered that triterpenoids associate with proteins of the actin
cytoskeleton, including Actin-related protein 3 (Arp3). Arp3, a subunit of the Arp2/3
complex, is involved in branched actin polymerization and the formation of lamellipodia.
CDDO-Im and CDDO-Me were observed to 1) inhibit the localization of Arp3 and actin
at the leading edge of cells, 2) abrogate cell polarity and 3) inhibit Arp2/3-dependent
branched actin polymerization. I confirmed our drug effects with siRNA targeting of
Arp3 and observed a decrease in Rat2 cell migration. Taken together, my data suggest
that synthetic triterpenoids target Arp3 and branched actin polymerization to inhibit cell
migration.
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3.2

INTRODUCTION
Cell migration is crucial in many physiological processes such as embryogenesis,

cell differentiation, cell renewal and immune system responses. During these processes,
cells undergo highly regulated and coordinated cell migration to enable growth or repair
of cells. Cell migration is also important in the metastasis of tumor cells. Indeed, it is a
hallmark of the most aggressive and advanced epithelial tumors prior to entering the
metastatic stage. These tumor cells often undergo epithelial to mesenchymal transition
(EMT) and migrate in a deregulated manner. As a result, they invade other tissues and
take over the host organism (1), causing 90% of cancer-related deaths (2).
Cell migration occurs through the coordination of numerous cellular proteins.
This process includes directional sensing of cell, anchorage of cells at the leading edge
and the reorganization of different components in the cell to assist in cell movement. The
orientation of cell movement is largely dependent on the reorganization of the
cytoskeleton, which consists of microtubules, intermediate filaments and actin
cytoskeleton. Although microtubules, intermediate filaments and leading edge proteins
are pivotal in the structure and organization of migrating cells, the actin cytoskeleton also
plays an essential role in cell polarity and cell migration. For instance, actin is involved
in the formation of the lamellipodia and filopodia, which are membrane and fingerlike
projections respectively, at the leading edge of migrating cells. Both lamellipodia and
filopodia are important for directional and environmental sensing even though they may
be formed through two distinct actin-assembly machineries with different actin dynamic
properties (3). Lamellipodia are formed by actin-related protein (Arp2/3) complexes
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through branched actin nucleation whereas filopodia are formed by formin by progressive
unbranched actin nucleation. Although the processes of the two are similar in that they
are both activated by small Rho GTPases and a nucleation-promoting factor is required
for actin polymerization, the key effectors that enable these processes are distinct. For
instance, Cdc42 activates neural Wiskott-Aldrich Syndrome protein (n-WASp), which in
turn promotes nucleation and branched actin polymerization, while the activation of the
RhoA induces formin-dependent unbranched actin polymerization. Interestingly, Rac1,
another small Rho GTPase, has been shown to be involved both indirectly and directly in
branched and unbranched actin polymerization, respectively. The understanding of the
two distinct actin polymerization processes is crucial in understanding how cell migration
is coordinated with other key cellular processes.
Since cell migration is a precursor event of cancer metastasis, chemotherapeutic
agents that block cell migration have been an important focus in the field of cancer
chemotherapy. Recently, the parental synthetic oleanane triterpenoid (CDDO) and its
more potent derivatives (CDDO-Im and CDDO-Me) have been suggested to be
promising therapeutic agents. Specifically, CDDO and its methyl ester (CDDO-Me) and
imidazolide (CDDO-Im) derivatives have been shown to inhibit tumor growth and induce
apoptosis (4-18).

CDDO and its derivatives also disrupt the intracellular REDOX

(reduction-oxidation reaction) balance (19-24) and are potent suppressors of nitric oxide
production and at least two inflammatory enzymes, iNOS and COX-2, which are
implicated with enhanced carcinogenesis in many organs (25). These mechanisms have
been evident in various cancers including lymphoma (26, 27-30), leukemia (12), (26),
(31-35), glioblastoma (36), neuroblastoma (36), osteosarcoma (37) and in cancer cell
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lines of the lung (8,38-41), breast (10), (42,43,44), ovaries (45), pancreas (46), colon (5),
and prostate (6). In addition, CDDO-based compounds have been shown to sensitize
resistant CLL B cells (47) and TRAIL (Tumor necrosis factor Related ApoptosisInducing Ligand)-resistant cancer cells to induce apoptosis (43,48). However, even
though recent studies have shown that CDDO-Im is highly effective in various cancer
cell lines and animal studies for inhibiting tumor growth and inducing apoptosis, the
effect of the synthetic triterpenoids on cell migration and metastasis remains unclear.
Thus far, CDDO-Im has been shown to target proteins at the leading edge of the cells and
causes the disruption of the microtubule network through a mechanism that differs from
microtubule-depolymerizing agents such as Nocodazole (49). The present study aims to
explore in further detail how other derivatives of CDDO may affect general cell
migration.
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3.3

MATERIALS AND METHODS

3.3.1

Cell Culture, Antibodies and Reagents

Rat2 fibroblasts were cultured in a 37˚C incubator with 5% CO2, and Dulbecco’s
Modified Eagle Medium (DMEM) with 10% Fetal Bovine Serum (FBS). Alexa Fluor
555-conjugated phalloidin (A34055) was purchased from Invitrogen Molecular Probes
(Oregon, USA). Monoclonal anti-Rac1 (610650), and anti- paxillin (610051) were
purchased from BD Transduction Laboratories (Mississauga, Ontario). Monoclonal antiβ-tubulin (Tub2.1), anti-Arp3 (A5979) and polyclonal anti-actin (A2668) antibodies were
purchased from Sigma (Oakville, Ontario).

Monoclonal anti-cdc42 (sc8401) and

polyclonal anti-RhoA (sc179) anti-n-WASp (sc-20770), and anti-GAPDH (sc-25778)
antibodies were purchased from Santa Cruz Technology (Santa Cruz, CA). CDDO,
CDDO-Im, CDDO-Me, biotinylated CDDO (b-CDDO) and biotinylated CDDO-Me (bCDDO-Me) are generous gifts from Dr. M. B. Sporn (Hanover, NH). The biotinylated
form of CDDO and CDDO-Me has been previously characterized and is referred to as
compound 5 and 6 respectively by Honda and colleagues (50). The Arp3 inhibitor, CK869, and the inactive control, CK-312, were purchased from Calbiochem.

3.3.2

Scratch Assays and Immunofluorescence Microscopy

Rat2 fibroblasts were grown to confluency and the monolayer was scratched with a
pipette tip. Cells were given 4 hours to establish polarity and leading edges before being
treated with 10 µM biotin, CDDO, CDDO-biotin, CDDO-Me or CDDO-Me biotin for
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subcellular localization studies or with DMSO (vehicle) or CDDO or CDDO-Im or
CDDO-Me for 2 hours for cell migration studies and immunofluorescence microscopy.
For biotinylated subcellular localization studies, cells were fixed and permeabilized
followed by incubation with anti-Rac1 antibody to visualize the leading edge. Cy2labelled secondary antibodies, Cy3-labelled streptavidin and DAPI were then used to
visualize Rac1, biotinylated CDDO or biotinylated CDDO-Me and the nuclei of cells,
respectively. Cells were visualized using an Olympus IX81 inverted microscope. For cell
migration studies, DIC images were collected using an Olympus IX81 inverted
microscope at the beginning of the experiment (Time 0) and after 12-16 hours. The extent
of cell migration was measured by taking the width of the wound at 0 time and 16 hours
six times in duplicate. The results were averaged from four different experiments ± SD.
Statistical analyses were done using one-way ANOVA. For immunofluorescence
microscopy studies, cells were fixed, permeabilized, and incubated with anti-Arp3, antin-WASp, anti-actin and anti-paxillin antibodies and phalloidin for stress fibers.
Visualization was carried out using an Olympus IX81 inverted microscope. Micrograph
deconvolution was carried out using ImagePro software (Media Cybernetics Inc.).
Quantitative analysis for immunofluorescence studies were done as described previously
(49).

3.3.3

Affinity Pull-down using Biotinylated CDDO Derivatives

Subconfluent Rat2 fibroblasts or 2.5 µg of purified Arp2/3 complex protein were
incubated with vehicle (DMSO), 10 µM biotin or 10 µM biotinylated-CDDO (b-CDDO)
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or 10 µM biotinylated-CDDO-Me (b-CDDO-Me) for 2 hours before lysis, followed by
incubation with neutravidin-agarose beads to precipitate proteins that associated with the
biotinylated form of the synthetic triterpenoids. SDS-PAGE and silver staining were
performed and proteins that were uniquely stained in biotinylated-CDDO and
biotinylated CDDO-Me treated samples were excised from the gel, trypsinized and
analyzed by electrospray mass spectrometry (ESI-MS). This approach was repeated three
times. To confirm or identify the potential synthetic triterpenoid binding proteins, lysates
were processed for SDS-PAGE followed by immunoblotting with anti-tubulin, anti-actin,
anti-Rac1, anti-Arp3, anti-Cdc42, or anti-RhoA antibodies.

3.3.4 Invitrogen Protoarray
The identification of triterpenoid binding proteins was done by following the protocol
described in the Invitrogen Protoarrray kit. Biotin or Biotinylated CDDO-Me were
incubated with a protein chip with about 8,000 human proteins spotted on a nitrocellulose
membrane in duplicate for 2 hours before incubating with streptavidin-Cy3. The chip
was then washed and dried before being read by the Biorad VersArray ChipReader 3m
system. Data were normalized against background and only signals that were at least two
fold or more than the background were considered to be potential interacting candidates
of the synthetic triterpenoids.
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3.3.5 Rho small GTPases Activation Assays
Subconfluent Rat2 fibroblasts were serum starved overnight before treating with vehicle
(DMSO) or with CDDO-Im for 2 hours. For Rac1 and Cdc42 activation assays, cells
were lysed and incubated with purified GST protein, or GST-PAK for two hours before
being processed for SDS-PAGE and immunoblotted for activated Rac1 and activated
Cdc42 using anti-Rac1 and anti-Cdc42 antibodies respectively. For RhoA activation
assays, cells were lysed and incubated with purified GST or GST-Rhotekin for 2 hours
before being processed by SDS-PAGE and immunoblotted for activated RhoA using
RhoA antibody. Total protein lysates were also immunoblotted and shown. Quantitative
analyses were done using densitometry (BioRad VersaDoc).

3.3.6

In-vitro Actin Polymerization Assays

Purified pyrene labeled actin was resuspended and incubated in general actin buffer
provided by Cytoskeleton Inc™ Actin Polymerization Kit for 1 hour on ice to
depolymerize any actin oligomers followed by micro-centrifugation at 4˚C for 30 min.
Two µM of actin alone or 2 µM of actin, 13 nM of Arp2/3 complexes and 100 nM of
VCA domain of WASp protein were incubated with DMSO (control) or different
concentrations (0, 50, 100 µM) of CDDO-Im and CDDO-Me for 15 minutes on ice
before pyrene actin fluorescence was measured over time.
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3.3.7 Docking Experiments
AutoDock version 4.2 was used to carry out the docking experiments (51). The crystal
structures of the Arp2 and Arp3 subunits (PDB-ID 3DXM; Ref. (52)) were used for the
docking procedure, with the docking surface encompassing the interface between the two
subunits as well as all of the internal cavities. The structure of CDDO-Me was obtained
from the Cambridge Structural Database (CSD-ID UFEHOC (53)). The CDDO-Im
structure was constructed by merging the CDDO-Me structure with a suitable imidazolecontaining compound (CSD-ID HEWQOQ). Both CDDO-Me and CDDO-Im are mostly
rigid structures. For CDDO-Me, only the C17-C28 bond (which attaches the acid ester to
the triterpenoid) was allowed to rotate; for CDDO-Im, both the C17-C28 bond and the
bond between C28 and the imidazole nitrogen were rotatable. All other bonds in CDDOMe and CDDO-Im were fixed, as was the structure of the Arp2 and Arp3 complex. The
rigidity of CDDO-Me and CDDO-Im aided the docking procedure and also limited the
number of potential solutions

3.3.8 Competitive Binding Studies
Arp2/3 protein complex (2.5 µg) was incubated with either DMSO or increasing
concentrations (10-100µM) CDDO-Me or CK-869 for 15 min at 37˚C.

Following

incubation with 10 µM b-CDDO-Me for an additional 15 min, 50% neutravidin-agarose
beads were added and incubated at room temperature for 10 min. The beads were
washed three times with TNTE buffer and subjected to SDS-PAGE and immunoblotting
for Arp3.
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3.3.9

Statistical Analyses
Results are provided as means ± SD. One-way ANOVA followed by a Tukey’s

post-hoc test was performed using GraphPad PRISM 5 Software to assess statistical
differences between experimental groups. P<0.05 was considered statistically significant.

144

3.4

RESULTS
I have shown that CDDO-Im inhibits cell migration and causes the disruption of

the microtubule network through a mechanism distinct from microtubule-depolymerizing
agents such as Nocodazole (49). However, the molecular target(s) of this inhibition
remain(s) unknown and I sought to identify them through the use of mass spectrometry
and protein array analyses. For these techniques, I opted to use biotinylated synthetic
triterpenoids that could be used for the purification and identification of associated
proteins. Since the active nature of the Imidazolide side group of CDDO-Im complicated
its biotinylation, I used the CDDO and the methyl ester derivative (CDDO-Me) in my
studies. CDDO-Me is a suitable substitute as it has been shown to be as potent as
CDDO-Im in many cellular assays (7, 13, 17, 24, 54), compared to the weaker CDDO
parental compound.

3.4.1 Synthetic triterpenoids inhibit cell migration and localize to the leading edge of
migrating cells.
I first set out to establish the effectiveness of the CDDO-Me compound in cell
migration by comparing its rate of cell migration with CDDO and CDDO-Im treated cells
(Figure 3.1). Briefly, Rat2 fibroblasts were grown to confluency before a ‘wound’ was
created by scratching the cells off of the surface of the culture dish. The cells were
treated with varying concentrations of synthetic triterpenoids (Figure 3.1). Brightfield
images were taken at 0 time and again after 16 hours of incubation at 37˚C to examine

145

Figure 3.1 CDDO-Im and CDDO-Me inhibit cell migration.
A) Confluent Rat2 fibroblasts were scratched to create a ‘wound’ and treated with 1 µM
CDDO, CDDO-Im or CDDO-Me for 16 hours. Brightfield images (magnification 10X)
were taken at the beginning of the experiment (0h) and after 16 hours (16h) of incubation
at 37˚C. The white dotted lines indicate the leading edge of migrating cells (top panels).
Cells were treated with increasing concentrations of CDDO-Im or CDDO-Me (0-1.5 µM,
as shown) and imaged. Cell migration was quantified using ImagePro software and
graphed as cell migration (percentage of control) vs. triterpenoid concentration
(n=3±SD). *p<0.05 (bottom panel).
B) Confluent Rat2 fibroblasts were scratched and incubated with DMSO (Control), 1 or 5
µM CDDO (top panels). Cells treated with increasing concentrations of CDDO (110 µM, as shown) and imaged. Cell migration was quantitated as described in Panel A
and graphed as cell migration (percentage of control) vs. triterpenoid concentration
(n=3±SD). *p<0.05.
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Figure 3-1
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whether the rate of cell migration would be affected by CDDO, CDDO-Im and CDDOMe (Figure 3.1A). I observed that cell migration remained relatively unaltered in the
presence of 1 µM CDDO while cell migration was inhibited >50% in the presence of
either 1 µM CDDO-Im or CDDO-Me (Figure 3.1). Indeed, at 1.5 µM, the rate of cell
migration in CDDO-Im and CDDO-Me treated cells was reduced to 80% while the rate
of migration in CDDO-treated cells did not differ from control. Compared to the
imidazolide and methyl ester derivatives, the parental CDDO is inactive at 1 µM in
inhibiting cell migration and was used as an inactive control in subsequent studies. To
address cell toxicity, the drugs were washed out using PBS and the cells were incubated
with media for an additional 24 hours. I observed that cells incubated with less than 5
µM CDDO and less than or equal to 1.25 µM of CDDO-Im and CDDO-Me migrated and
filled the wound (data not shown). This further confirmed that CDDO is approximately
ten times less potent than the CDDO-Im and Me derivatives.

These more potent

triterpenoids also acted in similar concentration ranges to reduce cell migration.
I previously demonstrated that CDDO localizes to the leading edge of migrating
cells (49) and may target proteins involved in the polarity complex at this cellular locus.
I therefore assessed if CDDO-Me also targets the leading edge of migrating cells using
immunofluorescence microscopy. I observed that biotinylated CDDO-Me (b-CDDOMe) localizes to the leading edge of migrating cells, similar to biotinylated CDDO
(Figure 3.2). These results demonstrate that the subcellular localization of CDDO and
CDDO-Me are similar.
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Figure 3.2 b-CDDO and b-CDDO-Me target the leading edge of migrating cells.
Confluent Rat2 fibroblasts were scratched to create a ‘wound’. After incubation for 4
hours to allow cell polarization and migration, cells were fixed, permeabilized and
incubated with monoclonal anti-Rac1 antibodies (Rac1; green) and biotin, CDDO,
biotinylated CDDO (b-CDDO), CDDO-Me, or biotinylated CDDO-Me (b-CDDO-Me)
followed by Cy2-labeled anti-mouse antibody and Cy3-labeled streptavidin. Cell nuclei
were stained with DAPI (blue). The co-localization of Rac1 (green) with b-CDDO or bCDDO-Me (red) at the leading edge of migrating cells is indicated (yellow arrowheads).
The white arrow indicates the direction of cell movement. Representative images from
four experiments are shown. Bar = 10 µm.
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Figure 3-2
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3.4.2

Several proteins involved in cytoskeletal organization and cell migration are
identified as triterpenoid-binding targets via a two-pronged proteomic approach.
Since CDDO-Im and CDDO-Me exhibited similarities in cellular localization and

inhibition of cell migration, I used b-CDDO-Me to identify potential synthetic
triterpenoid targets using two proteomic approaches (Figure 3.3). In the first approach, I
utilized a Mass Spectrometry-based method and proteins that precipitated with b-CDDO
or b-CDDO-Me were processed by SDS-PAGE followed by silver staining and
trypsinization before being sent for ESI-MS analysis (Figure 3.3A). This mass
spectrometry method was compared to a protein array approach which was purchased
from Invitrogen. The slide, containing >8000 human purified proteins, was incubated
with biotin, biotinylated CDDO or biotinylated CDDO-Me followed by Alexafluor647labelled streptavidin. The triterpenoid-binding proteins were then visualized and proteins
that bound the biotinylated-CDDO-Me ≥ 2 fold higher than biotin alone were counted as
potential triterpenoid-binding targets (data not shown). Using two different proteomic
approaches and by comparative analysis, several proteins involved in cytoskeletal
organization and cell migration were identified (Figure 3.3B). In order to ascertain that
the identified binding partners are also bona fide cellular interacting proteins, I incubated
cells with b-CDDO or b-CDDO-Me, followed by lysis and precipitated b-CDDO or bCDDO-Me with neutravidin beads. Precipitated samples then underwent SDS-PAGE and
and was probed with antibodies against tubulin and actin (Figure 3.3B). Consistent with
previous published results (55), I found that tubulin interacts with the b-CDDO-Me and
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Figure 3.3 Identification of triterpenoid-binding proteins.
A) Rat2 fibroblasts were incubated with DMSO, 10 µM biotin, 10 µM biotinylatedCDDO or 10 µM biotinylated-CDDO-Me, lysed, and incubated with neutravidin-agarose
beads. SDS-PAGE and silver staining were performed and proteins that were uniquely
stained (dashes) in biotinylated CDDO-Me-treated samples were excised from the gel,
trypsinized and analyzed by electrospray mass spectrometry.
B) Summarized table of cell migration-related proteins from mass spectrometry and
protein array approaches.
C) Rat2 fibroblasts were incubated with DMSO, 10 µM biotin, 10 µM b-CDDO or 10
µM b-CDDO-Me, lysed, and incubated with neutravidin-agarose beads. Precipitated
samples (left panels) were processed by SDS-PAGE and immunoblotted for cytoskeletal
proteins (anti-β-tubulin and anti-actin). Fifty micrograms of total protein lysates were
also immunoblotted for tubulin and actin and shown (right panel).
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Figure 3-3
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was also detected to interact with b-CDDO, albeit to a much lower extent. Interestingly,
actin, a large component of the cytoskeleton, and Actin-related protein 3 (Arp3), were
also found to associate with b-CDDO-Me (Figure 3.3C and 3.4A).
Another group of proteins identified in my proteomic approaches were
modulators of the Rho small GTPase family (Figure 3.3B). Rho small GTPases are a
group of G-proteins that are extensively involved in the establishment of cell polarity and
orientation of the cytoskeletal dynamics during cell migration. They are regulated by
Guanine Exchange Factors (GEFs), which promote the activation of Rho small GTPases,
and by GTPase Activating Proteins (GAPs), which render the protein into its inactive
state. The possibility that triterpenoids affect the activity of one or more of the numerous
GEF and GAP (56) was assessed by directly examining the level of GTP-bound Rac1,
RhoA or Cdc42 in the presence or absence of CDDO-Im. I observed that CDDO-Im only
moderately increased Rac1 activity but was ineffective in altering Cdc42 and RhoA
activities (Figure 3.5A and B). In addition, affinity pull down assays using specific
antibodies against Rac1, Cdc42 and RhoA indicated that b-CDDO-Me does not bind to
these Rho small GTPases (Figure 3.5C).

3.4.3 CDDO-Im and CDDO-Me inhibit branched actin polymerization by targeting
Arp3.
I next directed my attention to molecules that are downstream of GTPases and
alter the cytoskeleton and cell migration: molecules that alter the actin cytoskeleton.
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Figure 3.4 Synthetic triterpenoids interact with the Arp2/3 and inhibit branched
actin polymerization.
A) Purified Arp2/3 protein complex (2.5 µg) was incubated with 10 µM biotin or 10 µM
biotinylated CDDO-Me (b-CDDO-Me) for 2 hours. An affinity pull down assay was
performed by incubating samples with neutravidin beads for 1 hour followed by SDSPAGE and immunoblotting with anti-Arp3 antibodies (left panel). Total input was also
immunoblotted with Arp3 and shown (right panel).
B) Rat2 fibroblasts were incubated with 10 µM Biotin or biotinylated-CDDO-Me (bCDDO-Me) for 2 hours before lysis, followed by incubation with streptavidin-agarose
beads to precipitate proteins that associated with the biotinylated form of the synthetic
triterpenoids. SDS-PAGE was performed followed by immunoblotting for Arp3 with
anti-Arp3 antibody (top panel). Fifty µg of protein lysates was also immunoblotted for
Arp3 and shown (bottom panel).
C) Subconfluent Rat2 fibroblasts were treated with DMSO (Control; C), 1 µM of CDDOIm (Im) or 1 µM of CDDO-Me (Me) for 2 hours before lysis followed by
immunoprecipitation with anti-Arp3 antibody. The immunoprecipitates (IP; left panel)
were then subjected to SDS-PAGE and immunoblotting with anti-n-WASp, anti-actin
and anti-Arp3 antibodies. Fifty micrograms of total lysates were also immunoblotted for
n-WASp, actin and Arp3 and shown (right panel). Note that the association of Arp3 and
n-WASp is not altered by triterpenoid treatment.
D) Purified Arp2/3 complex and GST-VCA domain of nWASp were incubated in the
absence or presence of triterpenoids and immunoprecipitated with anti-GST antibodies.
The immunoprecipitates (IP; left panel) were then subjected to SDS-PAGE and
immunoblotting with anti-GST and anti-Arp3 antibodies. Fifty percent of the input was
also immunoblotted for GST and Arp3 and shown (right panel). Note that the association
of Arp3 and n-WASp is not altered by triterpenoid treatment.
E) Purified pyrene-labeled actin was incubated for 1 hour on ice to depolymerize actin
oligomers. 2 µM of actin (Actin) or actin in the presence of 13 µM of Arp2/3 complex
(Arp2/3) and 100 nM of VCA domain of n-WASp protein (VCA) were incubated with
DMSO, 50 µM or 100 µM of either CDDO-Im (Im), or CDDO-Me (Me). Actin
polymerization was measured by pyrene fluorescence and graphed as fluorescence
intensity (arbitrary unit) vs. time (minutes).
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Figure 3.5 The effect of CDDO-Im on Rho small GTPases.
A) Rat2 fibroblasts were serum starved and treated with vehicle (DMSO) or with CDDOIm for 2 hours. For Rac1 and Cdc42 activity assays, cells were lysed and incubated with
GST-PAK and processed for SDS-PAGE and immunoblotted for the GTP-bound forms
of Rac1 or Cdc42 using anti-Rac1 antibody (top panel) and anti-Cdc42 antibody (middle
panel). For RhoA activity assays, cells were lysed and incubated with GST-Rhotekin
beads. Samples were processed for SDS-PAGE and immunoblotted for the GTP-bound
form of RhoA using anti-RhoA antibody (bottom panel). Fifty micrograms of total
protein lysates were immunoblotted for Rac1, Cdc42 or RhoA and shown (right panels).
B) Densitometric quantitation of Rho small GTPase activity (Rac1, Cdc42 or RhoA) was
performed and graphed as activated Rho small GTPase levels (Arbitrary units) versus
treatment (n=3±SD, *p<0.05).
C) Rat2 fibroblasts were incubated with 10 µM biotin or 10 µM biotinylated-CDDO-Me
for 2 hours before lysis, followed by incubation of neutravidin-agarose beads. Pull down
samples (left panel) were processed by SDS-PAGE and immunoblotted for anti-RhoA,
anti-Rac1 and anti-Cdc42 antibodies. Fifty micrograms of total protein lysates of RhoA,
Rac1 and Cdc42 were immunoblotted and shown (right panel). Note that Rho GTPases
do not associate with b-CDDO-Me.
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There are two different actin assembly machineries that are involved in the formation of
actin with different properties in different areas of migrating cells. Arp2/3 complex is
involved in the assembly of branched actin at the leading edge of migrating cells while
formin is involved in the formation of unbranched actin such as stress fibers (3). I have
previously observed that the actin stress fibers are largely unaffected by triterpenoid
treatment (49), so I examined whether the synthetic triterpenoids have any effect on
branched actin formation by studying actin and Arp2/3 complex. Arp2/3 is a stable
complex that is composed of five subunits: ARPC1, ARPC2, ARPC3, ARPC4, ARPC5
and two actin-related proteins Arp2 and Arp3. In particular, studies have shown that
Arp3 is involved in the nucleation process of branched actin formation (3). I first
attempted to confirm whether Arp3 was a direct target of the synthetic triterpenoid
through affinity pull-down assays by using both purified Arp2/3 complex protein as well
as in Rat2 cells (Figure 3.4). Briefly, Arp2/3 purified protein was incubated with DMSO
(control), biotin, biotinylated CDDO or biotinylated CDDO-Me for 2 hours and
precipitated with neutravidin beads followed by immunoblotting with anti-Arp3 antibody.
My results showed that Arp3 interacted with both CDDO and CDDO-Me in vitro (Figure
3.4A). To confirm this interaction in cells, I incubated Rat2 fibroblasts with b-CDDOMe, precipitated and immunoblotted for Arp3 (Figure 3.4B). These two approaches
confirmed my proteomic analyses and indicate that Arp3 associates with triterpenoids.
In order for the formation of branched actin to occur, Arp2/3 must interact and
work closely with not only actin itself, but also neural-Wiskott Aldrich Syndrome protein
(n-WASp).

Indeed, n-WASp regulates cytoskeletal dynamics by activating Arp2/3

complexes so that it can begin the nucleation process for branched actin polymerization.
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Therefore, I hypothesize that the triterpenoid may inhibit cell migration by targeting Arp3
directly and affecting the association of Arp3 with actin and/or nWASp. To assess this,
co-immunoprecipitation assays were done using Rat2 fibroblasts. Cells were treated with
DMSO, 1 µM CDDO-Im or CDDO-Me, immunoprecipitated with anti-Arp3 antibody
and immunoblotted for actin, n-WASp, and Arp3 antibodies. Results showed that Arp3
remained associated with both n-WASp and actin upon CDDO-Im or CDDO-Me
incubation (Figure 3.4C). These results suggest that the association between Arp3 and nWASp is unaffected by the synthetic triterpenoids in cells or in vitro (Figure 3.4D).
The identification that subunits of the Arp2/3 complex are direct triterpenoidbinding proteins next led us to study the effect of branched actin polymerization in the
presence of CDDO-Im and CDDO-Me. I examined the rate of actin polymerization in
the presence of actin alone or actin and VCA domain of n-WASp and Arp2/3, in the
absence or presence of different concentration of CDDO-Im (Figure 3.4E). I observed
that the rate of actin polymerization was reduced by both CDDO-Me and CDDO-Im,
with 50 µM of either compound effectively reducing the rate of actin polymerization by
about 50%. At 100 µM, both triterpenoids were able to greatly reduce Arp2/3/VCAdependent actin polymerization but did not alter actin polymerization in the absence of
Arp2/3-VCA (Figure 3.4E and data not shown). My results suggest that triterpenoids
target Arp2/3/n-WASp-mediated branched actin polymerization.
I then assessed whether the cellular localization of Arp3 was also affected by
triterpenoid treatment (Figure 3.6). Confluent Rat2 fibroblasts were scratched and cells
were then allowed to polarize and to establish a leading edge before being treated with
DMSO, 1 µM of CDDO-Im or CDDO-Me. The cells were then fixed, permeabilized and
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Figure. 3.6 Synthetic triterpenoids affect the localization of Arp3 and n-WASp at
the leading edge of polarized cells.
A) Rat2 fibroblasts were scratched and incubated for 4 hours at 37˚C to establish cell
polarity and then treated with control medium (Control; top), 1 µM CDDO-Im (CDDOIm; middle panel) or 1 µM CDDO-Me (CDDO-Me; bottom panel) for an additional 2
hours. The cells were then fixed, permeabilized and immunostained with anti-Arp-3
(Arp3; green), phalloidin for stress fibers (Phalloidin; red), and anti-n-WASp (n-WASp;
blue) antibodies. The scratches were made in the horizontal plane above the cells. Arp3, actin, and n-WASp proteins at the leading edge of migrating cells are indicated by
green, red and blue arrowheads, respectively. The white arrowheads indicate the colocalization of all three proteins. White arrows indicate the direction of cellular
movement. DIC microscopy was included to visualize the leading edge of migrating
cells. Bar=10 µm.
B) Quantitation of cells containing Arp-3 or n-WASp at the leading edge of migrating
cells was carried out using ImagePro software and graphed as localization at the leading
edge (% of cells) vs. treatment (n=3±SD). a,b: p<0.05 of Arp3 and nWASp, compared to
respective controls.
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stained for Arp3, n-WASp and F-actin (with phalloidin). I observed that Arp3 and nWASp co-localized at the leading edge of polarized cells in the absence of CDDO-Im;
however, when treated with CDDO-Im, both proteins were displaced from the leading
edge and appeared diffused throughout the cytoplasm of the cell (Figure 3.6). CDDO-Me
gave similar, albeit slightly reduced, effects as the CDDO-Im compound.
To confirm that the action of triterpenoids was specific to Arp3 and branched
actin, I examined the effect of the synthetic triterpenoids on stress fibers and focal
adhesions using immunofluorescence studies (Figure 3.7). Stress fibers are one of the
most common and indicative unbranched actin structures in the cell and paxillin is a
marker of focal adhesions. Confluent Rat2 cells were scratched and treated with the
synthetic triterpenoids for 2 hours before fixation and permeabilization. Fluorescently
tagged antibodies and phalloidin were used to stain for paxillin, stress fibers and actin
respectively. I found that the structures of both stress fibers and focal adhesions were not
diminished by CDDO-Im or CDDO-Me treatment (Figure 3.7). However, consistent
with my in vitro data, branched actin staining was reduced at the leading edge of
migrating cells after the incubation with triterpenoids (Figure 3.7B).
Having observed that triterpenoids inhibit Arp2/3 activity and branched actin
formation, I next assessed if knockdown of Arp3 protein would inhibit Rat2 cell
migration (Figure 3.8). I observed that a 65-70% silencing of Arp3 protein levels (Figure
3.8B), reduced Rat2 cell migration by approximately 35% (Figure 3.8C). These results
suggest that the inhibition of Arp3 activity may be a mechanism whereby triterpenoids
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Figure 3.7 CDDO-Im and CDDO-Me do not affect stress fibers or focal adhesions
but reduce branched actin at the leading edge of migrating cells.
A) Rat2 fibroblasts were scratched and incubated for 4 hours at 37˚C to establish cell
polarity and then treated with control medium (Control; top), 1 µM CDDO-Im (CDDOIm; middle panel) or 1 µM CDDO-Me (CDDO-Me; bottom panel) for an additional 2
hours. The cells were then fixed, permeabilized and immunostained with anti-paxillin
(paxillin; green), phalloidin for stress fibers (Phalloidin; red), and anti-actin (actin; blue)
antibodies. The scratches were made in the horizontal plane above the cells shown and
the leading edge of migrating cells containing paxillin, stress fibers and actin were
indicated by green, red and blue arrowheads, respectively. The white arrowheads
indicate co-localization and the white arrows indicate the direction of cellular movement.
DIC microscopy was included to visualize the leading edges of migrating cells. Bar=10
µm.
B) Quantitation of cells containing actin at the leading edge of migrating cells was carried
out using ImagePro software and graphed as localization at the leading edge (% of cells)
vs. treatment (n=3±SD). *p<0.05.
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Figure. 3.8 Silencing Arp3 expression reduces cell migration.
A) Rat2 fibroblasts were transfected with control siRNA (scrambled), or two siRNA
specific for Arp3 (Arp3 siRNA 1 and 2). When the cells reached confluency, they were
scratched to create a ‘wound’. Brightfield images (magnification 10X) were taken at the
beginning of the experiment (0h) and after 12 hours (12h) of incubation at 37˚C. The
white dotted lines indicate the edge of the leading edge of migrating cells.
B) Representative immunoblots of the cells described in panel A probed with Arp3
antibodies (top panel) or GAPDH (bottom panel).
C) Quantitation of cell migration described in panel A was carried out using ImagePro
software and graphed as cell migration (percentage of control) vs. siRNA treatment
(n=3±SD). *p<0.05.
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inhibit cell migration. To lend additional support for this hypothesis, I used in silico
docking to identify potential high affinity triterpenoid binding sites in Arp3.

3.4.4 CDDO-Me binds to the hydrophobic pocket in Arp3.
To put my observations in the context of the recently characterized Arp2/3
inhibitors (52), docking experiments were carried out using the crystal structures of
Arp2/3 (PDB-ID 3DXM (52)). The structure used for the docking experiments had been
solved with a small molecule inhibitor, CK-548, bound to a hydrophobic pocket in Arp3.
We tested the docking procedure using this inhibitor.

The two top solutions

corresponded to binding of CK-548 in the same hydrophobic pocket, but in two different
orientations, that were the same in terms of predicted interaction energy (-8.9 kcal/mol,
corresponding to a KI of 315 nM). One of these solutions was identical to the position and
conformation observed in the Arp3-CK-548 crystal structure, validating the accuracy of
the docking procedure. A closely related compound, CK-869, docked to an identical
position, with a slightly higher predicted KI of 460 nM. This docked position for CK-869
corresponded very closely to the model for the Arp3-CK-869 complex proposed by
Pollard and co-workers (52).
Interestingly, we observed that the triterpenoid CDDO-Me docked to Arp3 in the
same hydrophobic pocket (Figure 3.9A and 3.9B). The docked position shown in Figure
3.9 has a binding energy of -13.3 kcal/mol and predicted KI of 180 pM; this was the
lowest energy solution obtained for the surface encompassing the Arp2 and Arp3
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Figure 3.9 Docking of CDDO-Me to the Arp2/3 Complex.
The surface and internal cavities of the Arp2/3 complex (PDB-ID 3DXM; Ref. (52)) were
used to find low energy binding sites for CDDO-Me and CDDO-Im with the program
Autodock (51).
A) A hydrophobic pocket provided the lowest-energy binding site for CDDO-Me; the
same pocket is predicted to bind CDDO-Im in an identical position and orientation, but
with even greater affinity (not shown). The pocket is formed by a β-sheet and two αhelices, with the methyl ester moiety of CDDO-Me buried deeply in the pocket. In this
situation, the site of attachment for the biotin tag (which was not included in the docking
experiments) is solvent exposed and accessible. Thus, the best binding site found by in
silico docking is consistent with the biochemical experiments. In unliganded Arp3
structures, a loop comprising residues 79 to 84 (in magenta) closes over the hydrophobic
pocket, blocking access to the site. The change in conformation of this loop represents the
only structural difference associated with drug binding to the hydrophobic pocket (52).
B) The internal surface of the hydrophobic pocket is outlined, with CDDO-Me in the low
energy docked position. CK-869 is also shown in a docked position that is essentially
identical to the position of CK-548 (not shown) in the crystal structure of the Arp2/3-CK548 complex (52). CDDO-Me presents a greater contact surface and is much more rigid
than CK-869, and its predicted affinity for Arp3 is higher.
C) A comparison of the chemical structures of the three compounds used in the docking
experiments; CK-548 was also co-crystallized with Arp3 (52). In docking experiments,
both CK-548 and CK-869 were predicted to bind with highest affinity to the hydrophobic
pocket, in an orientation and position that is virtually identical to that observed for CK548 in the Arp3-CK-548 crystal structure (52).
D) Competitive binding of b-CDDO-Me with CK-869. Purified Arp2/3 complex (2.5µg)
was incubated with 10 µM biotinylated-CDDO-Me in the absence or presence of
increasing concentrations of CDDO-Me or CK-869 (10-100 µM). The biotin-CDDOMe-bound Arp3 was precipitated with neutravidin beads, processed for SDS-PAGE and
immunoblotted with Arp3 antibodies. Fifty percent of the input was also blotted with
Arp3 antibodies and shown on the right.
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interface region, including all of the internal cavities. CDDO-Im, which has an imidazole
group attached to the acid in place of the methyl in CDDO-Me, docked to the same
pocket on Arp3, but with an even higher predicted affinity (KI of 27 pM).

It is

noteworthy that the lowest energy docked positions for both CDDO-Me and CDDO-Im
exposes C23 of the triterpenoid to the solvent: this is the site of attachment for the biotin
label used for isolating the Arp2/3 complex from Rat2 fibroblasts, and therefore the
lowest energy docked position is fully consistent with binding of the biotinylated CDDOMe derivative. As can be seen in Figure 3.9B, the position that CDDO-Me is predicted to
occupy matches closely to the docked position of CK-869, which in turn is virtually
identical to the position of CK-548 in the actual crystal structure (52). Compared to
unliganded Arp3 structures, both CDDO-Me and CDDO-Im require a localized
conformation change in the loop comprising residues 79 to 84, which opens the pocket to
allow binding (Figure 3.9A).

The much tighter predicted binding for CDDO-Me

compared to CK-869 is consistent with the lower concentrations of CDDO-Me required
for biological effects.
To confirm that CDDO-Me and CK-869 bind to the same site in Arp3, binding
competition assays were carried out with CK-869 and non-biotinylated CDDO-Me as a
control (Fig. 3.9D).

With increasing concentrations of CDDO-Me or CK-869, the

amount of Arp3 that precipitated with biotinylated-CDDO-Me was reduced (Fig. 3.9D).
This is consistent with our docking analysis that indicates CK-869 and CDDO-Me bind
in the same hydrophobic pocket.

171

3.4.5 Inhibition of Arp3 attenuates cell migration and cell polarity.
To assess if the inhibition of Arp3 using CK-869 could also abrogate cell
migration, I incubated cells with increasing concentrations of CK-869 (Figure 3.10). I
observed that 7.5 µM CK-869 was able to inhibit cell migration by 50% (Figure 3.10B).
The negative control, CK-312, which was characterized to bind to Arp3 but not inhibit its
function, did not alter cell migration at the concentration range tested (Figure 3.10B). An
interesting observation of the cells treated with the CK-869 Arp3 inhibitor was that the
cells adopted a rounded up morphology and gave the appearance of detaching. However,
over

time

the

cells

flattened

(please

see

supplementary

movie

4:

http://www.jbc.org/content/suppl/2010/06/21/M110.103036.DC1/jbc.M110.1030362.mov). This suggests that the cells may undergo cyclical rounding up and flattening in
the presence of an Arp3 inhibitor.
Finally, I assessed if incubating polarized cells with CK-869 would affect
branched actin polymerization in a manner similar to the triterpenoids. Rat2 fibroblasts
were scratched and cells were then allowed to polarize to establish a leading edge before
being treated with DMSO or 10 µM of CK-869. The cells were then fixed, permeabilized
and stained for Arp3, n-WASp and phalloidin. I observed that Arp3 and n-WASp colocalized at the leading edge of polarized cells in the absence of CK-869, however, both
proteins were displaced from the leading edge and appeared diffused throughout the
cytoplasm of the cell (Figure 3.11). I also observed that phalloidin staining at the leading
edge of polarized cells as well as actin staining were reduced in the CK-869-treated cells
suggesting that the inhibition of branched actin polymerization alters cell polarity (Figure
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Figure 3.10 CK-869 inhibits cell migration.
A) Confluent Rat2 fibroblasts were scratched to create a ‘wound’ and treated with DMSO
(Control), 5 µM CK-312 (inactive control) or 5 µM CK-869 for 12 hours. Brightfield
images (magnification 10X) were taken at the beginning of the experiment (0h) and after
12 hours (12 h) of incubation at 37˚C. The white dotted lines indicate the leading edge of
migrating cells.
B) Cells were treated with increasing concentrations of CK-312 (inactive control) or CK869 (1-10 µM) and imaged. Cell migration was quantified using ImagePro software and
graphed as cell migration (percentage of control) vs. Arp3 inhibitor concentration
(n=3±SD). *p<0.05.
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Figure 3.11 CK-869 affects the localization of Arp3 and n-WASp at the leading edge
of polarized cells.
A) Rat2 fibroblasts were scratched and incubated for 4 hours at 37˚C to establish cell
polarity and then treated with control medium (Control; top), 10 µM CK-312 (middle
panel) or 10 µM CK-869 (bottom panel) for an additional 2 hours. The cells were then
fixed, permeabilized and immunostained with anti-Arp-3 (Arp3; green), phalloidin for
stress fibers (Phalloidin; red), and anti-n-WASp (n-WASp; blue) antibodies. The
scratches were made in the horizontal plane above the cells. Arp-3, actin, and n-WASp
proteins at the leading edge of migrating cells are indicated by green, red and blue
arrowheads, respectively. The white arrowheads indicate the co-localization of all three
proteins. White arrows indicate the direction of cellular movement. DIC microscopy was
included to visualize the leading edge of migrating cells. Bar=10 µm.
B) Quantitation of cells containing Arp-3 or n-WASp at the leading edge of migrating
cells was carried out using ImagePro software and graphed as localization at the leading
edge (% of cells) vs. treatment (n=3±SD). a,b: p<0.05 of Arp3 and n-WASp, compared to
respective controls.
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3.12). Taken together, our results suggest that synthetic triterpenoids target Arp2/3dependent actin polymerization, which contributes to the inhibition of cell migration.
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Figure 3.12 CK-869 does not affect stress fibers or focal adhesions but reduces
branched actin at the leading edge of migrating cells.
A) Rat2 fibroblasts were scratched and incubated for 4 hours at 37˚C to establish cell
polarity and then treated with control medium (Control; top), 10 µM CK-312 (middle
panel) or 10 µM CK-869 (bottom panel) for an additional 2 hours. The cells were then
fixed, permeabilized and immunostained with anti-Paxillin (green), phalloidin for stress
fibers (Phalloidin; red), and anti-Actin (blue) antibodies. The scratches were made in the
horizontal plane above the cells. Paxillin, branched actin and actin proteins at the leading
edge of migrating cells are indicated by green, red and blue arrowheads, respectively.
The white arrowheads indicate the co-localization of all three proteins. White arrows
indicate the direction of cellular movement. DIC microscopy was included to visualize
the leading edge of migrating cells. Bar=10 µm.
B) Quantitation of cells containing actin at the leading edge of migrating cells was carried
out using ImagePro software and graphed as localization at the leading edge (% of cells)
vs. treatment (n=3±SD). *p<0.05.
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3.5

DISCUSSION
Cell migration plays an essential role in development, immune surveillance, and

cellular repair. In cancer, it is the precursor event prior to most advanced cancer
metastases. The diverse roles of cell migration make it difficult to understand its
mechanisms of action clearly especially in the context of cancer, an illness that is made of
multiple different diseases. Therefore, one of the major focuses in chemotherapy is to
study the means of targeting cell migration in order to block tumor cells from migrating
and invading to other parts of the body. Here we show that synthetic triterpenoids, which
are effective at inducing apoptosis and modulate REDOX balance, are also effective at
inhibiting cell migration. I observed that cell migration is inhibited by CDDO-Me and
CDDO-Im in a dose dependent manner, with 1 µM being most effective without inducing
apoptosis over 16 hours (Figure 3.1). I also found that Arp3 was a novel triterpenoid
binding protein (Figure 3.3 and 3.4). Arp3 is an important subunit of the Arp2/3 complex,
which is involved in the nucleation process of branched actin polymerization.
Interestingly, the concentration of triterpenoids necessary to inhibit branched actin
polymerization in vitro (50 µM) was higher than the concentration necessary to inhibit
cell migration (1 µM). This may reflect the possibility that the relative ratios of purified
proteins in vitro rendered the inhibiting compounds less active or that there are other
triterpenoid targets in the cell that have yet to be identified. This second possibility is
supported by my previous observation that the microtubule cytoskeleton is affected by
CDDO-Im (49).
The knockdown of Arp2/3 using siRNA has been observed to reduce cell
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migration (Figure 3.8). My studies further show that the triterpenoids target Arp3 and
inhibit cell migration by specifically affecting branched actin polymerization (Figure 3.4,
3.6-3.7). Branched actin polymerization is essential for the formation of the lamellipodia
at the leading edge of migrating cells, which in turn, allows for proper cell migration.
Therefore, the reduction of branched actin polymerization by synthetic triterpenoids via
Arp3 may provide a novel mechanism for which anti-cancer agents may be able to hinder
cell migration and metastasis.
In this study, I also investigated whether the activities of small Rho GTPases
would be affected by triterpenoid treatment. Although small Rho GTPases play a large
role in cell migration, they do not seem to be major triterpenoid targets (Figure 3.5).
Interestingly, I found that Rac1 activity was slightly elevated by CDDO-Im while the
activities of the other Rho GTPases were not altered. This is contrary to what was
expected with respect to the inhibition of cell migration. We reasoned that this could be
due to a by-product of another triterpenoid specific phenomenon that has yet to be
determined.
Recently, Arp2/3 inhibitors have been characterized by Pollard and colleagues
(52). These inhibitors bind to different sites of the Arp2/3 complex, thereby, inhibiting its
nucleating function. Specifically, CK-636 binds between Arp2 and Arp3; consequently,
preventing Arp2 and Arp3 from forming an active complex for nucleation. CK-548 and
CK-869 associate with Arp3 at its hydrophobic core, resulting in a conformation change
that blocks nucleation of branched actin. This novel insight on how the binding of Arp2/3
inhibitors modulates the activation of Arp2/3 complex may possibly be transferred to the
synthetic triterpenoids. Indeed, we observed that CDDO-Me docked to Arp2/3 in the
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same hydrophobic pocket as CK-869 and was displaced in binding assays (Figure 3.9).
This was further corroborated with functional assays where bona fide Arp3 inhibition
blocked cell migration and polarity (Figure. 3.10-3.12). We therefore conclude that
CDDO-Im and CDDO-Me inhibit Arp2/3 function in a similar manner as the Arp3
inhibitors. Taken together, this suggests that a combined inhibition of microtubule and
branched actin cytoskeletal dynamics are involved in triterpenoid-mediated reduction of
cell migration.
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CHAPTER 4
SYNTHETIC TRITERPENOIDS TARGET GSK3β AND
MODULATE ITS ACTIVITY ON FOCAL ADHESION
DYNAMICS TO INHIBIT CELL MIGRATION

188

4

CHAPTER 4

4.1

CHAPTER SUMMARY

Synthetic triterpenoids are a class of anti-cancer compounds that target cellular functions,
including apoptosis, growth and inflammation in cell culture and animal models.
Currently, their effect on cell migration, a precursor event to cancer metastasis, is being
characterized. Previously, I showed that triterpenoids partially inhibited cell migration
by interfering with Arp2/3-dependent branched actin polymerization in lamellipodia (1).
My current studies revealed that Glycogen Synthase Kinase 3 beta (GSK3β), a kinase
that regulates many cellular processes including cell adhesion dynamics, is a triterpenoidbinding target. Specifically, triterpenoids inhibited GSK3β activity and they appeared to
increase focal adhesion size. To further examine whether these effects on focal adhesions
in triterpenoid-treated cells were GSK3β-dependent, I used GSK3 inhibitors (lithium
chloride and SB216763), to examine cell adhesion and morphology as well as cell
migration. My studies showed that GSK3β inhibitors also altered cell adhesion sizes,
inhibited cell migration and inactivated GSK3β, consistent with what we observed in
triterpenoid-treated cells. Therefore, triterpenoids may affect focal adhesion dynamics as
well as cell migration by targeting and altering the activity of GSK3β.
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4.2

INTRODUCTION
The triterpenoids are a class of compounds biosynthesized in plants by the

cyclization of squalene. Specifically, oleanolic acid is one of the 2,000 triterpenoids
found in nature, and is widely used in Asia for its weak anti-inflammatory and antitumorigenic properties (2). The modification of oleanolic acid to the synthetic oleanolic
triterpenoid, 2-cyano-3,12-dioxooleana-1,9 (11)-dien-28-oic acid (CDDO) and its methyl
ester (CDDO-Me) and imidazolide (CDDO-Im) derivatives increases the biological
activities of these compounds (3). In fact, CDDO and its derivatives are effective in
inducing cytoprotection and apoptosis, as well as in reducing tumor proliferation, as
assessed using animal models and cancer cell culture studies (4). However, very few
studies have examined the effects of triterpenoids on cell adhesion and cell migration,
both of which are important players in tumor metastasis.
Cell migration is the process in which a cell can initiate movement in response to
stimuli such as chemo-attractants or stress in the biological system.

It is a highly

orchestrated process involving many different cellular components that collectively
regulate cell motility. This process mainly encompasses the reorganization of the actin
and microtubule cytoskeletons and cellular proteins to establish cell polarity, and the
formation of a definitive leading edge. More importantly, as a cell extends its protrusions
to explore its surrounding environment in preparation for cell movement, the protrusions
are stabilized by adhesion structures used as traction points that allow cells to advance
towards or away from the stimuli (5). These adhesion structures are composed of
complexes with multiple adhesion proteins that are often characterized as focal
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complexes, focal adhesions or fibrillar adhesions depending on their sizes, morphology
and dynamics (6). Focal complexes are small nascent adhesions that are often observed
in rapidly migrating cells and most of these structures turnover within minutes, so the cell
continues to migrate (7). However, some of these nascent adhesions do mature and
evolve into focal adhesions that attach to the ends of stress fibers to maintain the structure
of the cell (8). Similarly, most of the focal adhesions disassemble, but at a slower rate, in
order for the cell to maintain its flexibility as it moves forward. The adhesions that
mature are known as fibrillar adhesions and they are involved in the remodeling of the
extracellular matrix. Therefore, a delicate balance between the disassembly and the
maturation of adhesions is a critical contributing factor towards regulating cell migration.
In fact, the reduction of adhesion turnover has been shown to increase the size of focal
adhesions and reduce cell motility (9,10).
Within these multi-protein adhesion complexes, different scaffolding and
signaling molecules are recruited to regulate the dynamics of the adhesion structures. For
instance, paxillin and FAK are important proteins that are commonly found at focal
adhesion sites and thus, are often used as focal adhesion markers. Although it possesses
no kinase activity itself, paxillin is one of the first scaffolding proteins that is recruited to
the adhesion complex during focal adhesion assembly. In addition, paxillin is important
for the recruitment of other signaling proteins, such as FAK, to the complex. In fact, mice
deficient in paxillin die during embryogenesis due to defects in cell migration (11) and
paxillin-null embryonic stem cells show defects in cell spreading (12). FAK is an
important kinase that is known as a master regulator of focal adhesion turnover. It is an
essential player in the regulation of numerous important intracellular signaling pathways
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involving the turnover of cell contacts with the extracellular matrix and the promotion of
cell migration. The loss of FAK can also lead to embryonic lethality. In addition, Fak-/fibroblasts show enlarged focal adhesions and reduced cell motility. Glycogen Synthase
Kinase 3 Beta (GSK3β), originally identified for its role in regulating glycogen
metabolism and Wnt-mediated cell proliferation, is also involved in regulating cell
migration and adhesion dynamics. GSK3β is a protein that is found constitutively active
in cells and has been reported to phosphorylate microtubule-associated proteins and
interact with microtubule motor proteins to regulate microtubule dynamics and
microtubule-dependent vesicle transport (13). In addition, GSK3β also regulates several
Rho small GTPases including Rac1, RhoA and Arf6, which in turn, control membrane
ruffling, cell spreading and lamellipodia formation. Interestingly, a small pool of inactive
GSK3β localizes at the leading edge of migrating cells and enables APC to localize to the
plus end of microtubules and stimulate microtubule growth and stability. However,
global inactivity of GSK3β can inhibit cell migration (14).
In this chapter, I studied the effects of triterpenoids on the dynamics of focal
adhesions, as they play a critical role in regulating cell migration (9,10).
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4.3

MATERIALS AND METHODS

4.3.1

Cell Culture and Antibodies
Rat2 fibroblasts were cultured using Dulbecco’s modified Eagle’s medium

(DMEM) with 10% fetal bovine serum (FBS) in a 37°C incubator with 5% CO2. AntiFAK (BD610087), anti-Rac1 (610650), and anti-paxillin (BD610051) antibodies were
purchased from BD Transductions Laboratories (Mississauga, Canada). Anti-phosphoFAK Y397 (#3283), anti-phospho-FAK Y576/577 (#3281), anti-phospho-FAK Y925
(#3284), anti-GSK3β (#9315) and anti-phospho-GSK3β serine 9 (#9336) antibodies were
purchased from Cell Signaling Technologies (Pickering, Canada). Anti-phospho-FAK
serine 722 (sc-16662-R) and anti-IQGAP1 (sc-10792) were purchased from Santa Cruz
Biotechnologies Inc. (Santa Cruz, CA). Alexa Fluor 555-conjugated phalloidin (A34055)
was purchased from Invitrogen Molecular Probes (Oregon, USA). Biotinylated CDDOMe was a generous gift from Dr. M.B. Sporn (Hanover, NH). The biotinylated form of
CDDO-Me (compound 6) has been characterized and by Honda and colleagues (15).
Collagen I (27666) used to coat the plates for cell adhesion assays was purchased from
Sigma Aldrich (Oakville, Canada).

4.3.2

Scratch Assays and Immunofluorescence Microscopy
Rat2 fibroblasts were cultured to confluency before a scratch was made with a

pipette tip. Cells were then processed for either cell migration assay studies or
immunofluorescence microscopy. For cell migration studies, cells were treated with
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media containing 0.1% DMSO or 50 mM NaCl (as vehicles), 1 µM CDDO-Im, 1 µM
CDDO-Me, 50 µM SB216763, or 50 mM lithium chloride and brightfield images were
taken over 16 hours. For immunofluorescence microscopy, cells were given 4 hours to
establish polarity and a leading edge before their 2-hour drug treatment followed by
fixation, permeabilization and incubation with anti-Rac1, anti-IQGAP1, anti-FAK, antipaxillin, anti-phalloidin, and anti-GSK3β antibodies. All immunofluorescence images
were taken using an Olympus IX81 microscope controlled by QED Invivo software or the
Olympus Fluoroview Confocal microscope controlled by Fluoroview software (Olympus,
Canada).

4.3.3

Affinity Pull-Down Assay using Biotinylated CDDO-Me
To examine the co-localization of GSK3β and CDDO-Me, Rat2 fibroblasts were

grown to confluency, scratched with a pipette tip and allowed to polarize for 6 hours.
Cells were then fixed, permeabilized and incubated with anti-Rac1 antibodies followed
by treatment with either 0.1% DMSO, 10 µM biotin, 10 µM CDDO-Me or 10 µM
biotinylated CDDO-Me. Streptavidin-Cy3 was used to visualize biotinylated CDDO-Me.
Samples were stained with DAPI to visualize the nuclei. To confirm that FAK and
GSK3β were triterpenoid-binding targets, cell lysates were incubated with 0.1% DMSO,
10 µM biotin, 10 µM CDDO-Me or 10 µM biotinylated CDDO-Me for two hours,
followed by streptavidin beads. Samples were processed by SDS-PAGE and probed with
anti-FAK and anti-GSK3β antibodies.
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4.3.4

Western Blotting
Rat2 fibroblasts were incubated with 0.1% DMSO or 50 mM NaCl (as controls),

1 µM CDDO-Im, 1 µM CDDO-Me, 50 mM Lithium Chloride or 50 µM SB216763 for
two hours before lysis. Samples were processed using SDS-PAGE and probed with antiGSK3β, anti-phospho-GSK3β, anti-paxillin, anti-phospho-paxillin, anti-FAK or antiphospho-FAK antibodies.

4.3.5

Cell Adhesion Assays
For cell adhesion stability assays, 50 000 Rat2 fibroblasts were seeded overnight

on either BSA or Collagen I-coated plates followed by incubation in 0.01% DMSO, 1
µM CDDO-Im or 1 µM CDDO-Me for two hours. For cell adhesion formation assays,
Rat2 fibroblasts were plated on 10 cm dishes overnight and treated the next day with
0.1% DMSO, 1 µM CDDO-Im or 1 µM CDDO-Me before being lifted off from the plate
using EDTA. 100 000 cells were then re-seeded into 24-well plates that were coated with
either BSA or Collagen I. After reseeding, treated cells were incubated with 0.1%
DMSO, 1 µM CDDO-Im or 1 µM CDDO-Me for additional two hours. All conditions in
both assays were done in quadruplicates. To quantify the adhesions, cells were washed
once with PBS and four images per well were taken and at least 250 cells were counted.
Cells that were still adhered to the plate were counted and graphed.
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4.3.6

Statistical Analyses

Results were provided as means ± SD. One-way ANOVA with a Tukey’s post-hoc test
was performed to assess the statistical differences between experimental groups. P<0.05
and p<0.01 were considered statistical significant.
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4.4

RESULTS
To assess whether the triterpenoids play a role in cell adhesion dynamics, I

utilized a comprehensive proteomic database that consisted of a list of triterpenoidbinding targets I created previously (1). My results showed that various structural focal
adhesion proteins were bound by the triterpenoids (Table 4.1). Therefore, I examined
whether triterpenoids affected focal adhesion morphology using immunofluorescence
microscopy. Briefly, Rat2 fibroblasts were scratched and allowed to polarized before they
were treated with DMSO, CDDO-Im or CDDO-Me for 2 hours before they were fixed,
permeabilized and stained for the focal adhesion markers, paxillin (Figure 4.1A) and
FAK (Figure 4.1B). Both paxillin and FAK were present in the cell body as well as at the
leading edge. In cells treated with DMSO as a control, these focal adhesion markers
appeared to be thin and long especially at the leading edge of migrating cells, whereas in
the cell body, the staining appeared to be fainter and with a smaller area (Figure 4.1).
However, when I treated cells with the triterpenoids, I observed that both paxillin and
FAK staining were enlarged.
Numerous studies have shown that focal adhesion enlargement can contribute to
delayed turnover and inhibition of cell migration (16,17). Therefore, I hypothesized that
the alterations observed on focal adhesions by the triterpenoids may, at least in part,
inhibit cell migration. Since the size of focal adhesions can be affected by the ability of
cells to either assemble or disassemble them, I next evaluated whether the formation or
maturation of cell adhesions was affected by triterpenoid treatment using two different
cell adhesion studies (Figure 4.2). To examine cell adhesion stability in the presence of
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Table 4-1
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Figure 4.1 Triterpenoids enlarge focal adhesions at the leading edge of migrating
cells.
A) Rat2 fibroblasts were scratched and incubated for 4 hours at 37˚C to establish cell
polarity and then treated with 0.01% DMSO (Control; top), 1 µM CDDO-Im (CDDO-Im;
middle panel) or 1 µM CDDO-Me (CDDO-Me; bottom panel) for an additional 2 hours.
The cells were then fixed, permeabilized and immunostained with anti-paxillin antibodies
(Paxillin; green) and phalloidin for actin stress fibers (Phalloidin; red). A representative
area (inset) is magnified and shown. Bar = 10 µm. Representative images from four
individual experiments are shown.
B) Rat2 fibroblasts were scratched and incubated for 4 hours at 37˚C to establish cell
polarity and then treated with 0.01% DMSO (Control; top), 1 µM CDDO-Im (CDDO-Im;
middle panel) or 1 µM CDDO-Me (CDDO-Me; bottom panel) for an additional 2 hours.
The cells were then fixed, permeabilized and immunostained with anti-FAK antibodies
(FAK; green) and phalloidin for actin stress fibers (Phalloidin; red). A representative
area (inset) is magnified and shown. Bar = 10 µm. Representative images from four
individual experiments are shown.
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Figure 4-1
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Figure 4.2 Triterpenoids do not decrease the number of adhered cells but inhibit the
association of detached cells to Collagen I.
A) Rat2 fibroblasts were plated overnight on BSA or Collagen I-coated plates followed
by incubation in 0.01% DMSO, 1 µM CDDO-Im or 1 µM CDDO-Me for 2 hours before
cells were quantitated by counting the number of adherent cells in the DMSO, CDDO-Im
or CDDO-Me (Treatment) on either BSA(-Collagen) or Collagen I-coated (+Collagen)
plates.
B) Rat2 fibroblasts were plated in 10 cm dishes overnight and treated for two hours
before being re-seeded on 24 well BSA or Collagen I-coated plates and treated with
0.01% DMSO, 1 µM CDDO-Im or 1 µM CDDO-Me for an additional 2 hours.
Quantitation was performed as described in panel A. *p<0.05.
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Figure 4-2
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the drugs after adhesions were established, Rat2 fibroblasts were plated overnight to
allow for cells to establish adhesions, followed by incubation of DMSO, CDDO-Im or
CDDO-Me for 2 hours. To test whether the triterpenoids affected the ability of cells to
establish new adhesions, cells were detached from plates and re-seeded, followed by
treatment with DMSO, CDDO-Im or CDDO-Me for two hours. My data showed that
when cell adhesions were established before drug treatments, the triterpenoids had no
effect on the number of attached cells. Interestingly, when I tested the ability of cells to
form new adhesions in the presence of the triterpenoids, the drugs appeared to inhibit the
association of detached cells to collagen I, a common extracellular matrix protein. These
results suggest that the turnover or formation kinetics of adhesions might be affected by
the triterpenoids.
Having observed the alterations that triterpenoids have on the attachment of cells
to Collagen I, I next re-examined the proteins that were on my list of proteomic proteins
that may affect focal adhesion turnover (Table 4.1) and found focal adhesion kinase
(FAK) and Glycogen Synthase Kinase Beta (GSK3β) as potential triterpenoid-binding
targets. Therefore, I proceeded to confirm the associations of triterpenoids with both FAK
and GSK3β by affinity pull-down assay using biotinylated CDDO-Me (Figure 4.3). Both
FAK and GSKβ were confirmed as triterpenoid-binding targets.

Interestingly, the

association of biotinylated triterpenoid with FAK (Figure 4.3A) appeared to be weaker
compared to that of GSK3β (Figure 4.3C). However as they are tritepenoid-binding
targets and important kinases that regulate focal adhesion dynamics, I assessed the
phosphorylation status of these proteins to examine whether their activities were affected
by the triterpenoid treatment. FAK has multiple phosphorylation sites, including tyrosines
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397, 576, 577, and 925, and serine 722, which are important in focal adhesion dynamics.
Thus, I treated cells with either DMSO, CDDO-Im or CDDO-Me, processed them for
SDS-PAGE and immunoblotted with phospho-specific FAK antibodies (Figure 4.3B).
My results showed no substantial differences in the phosphorylation statuses of all of the
sites that I examined (Figure 4.3B). Interestingly, when I performed similar analyses on
GSK3β using Western blotting and phospho-specific GSK3β antibody, I found that
triterpenoids induced the phosphorylation of GSK3β at serine 9 (Figure 4.3D). The
phosphorylation

(and likely inhibition) of GSK3β activity in the presence of the

triterpenoids led me to examine whether GSK3β localized at the leading edge with the
triterpenoids to affect cell migration. Briefly, Rat2 fibroblasts were scratched and allowed
to polarize for 4 hours before they were fixed and permeabilized. Cells were then probed
with DMSO or biotin or CDDO-Me or biotinylated CDDO-Me and anti-Rac1, as a
leading edge marker as well as GSK3β antibodies (Figure 4.4). My studies showed that
GSK3β indeed colocalized at the leading edge with Rac1 and biotinylated CDDO-Me
(Figure 4.4, bottom panel).
The confirmation of GSK3β as a triterpenoid-binding target is highly significant,
as recent studies have shown that GSK3β is involved in different aspects of cell
migration and cell adhesion dynamics (13,18-20). Previously, I also showed that the
morphology of fibroblasts was affected when cells were treated with the triterpenoids (1).
Therefore, I hypothesized that triterpenoids may modulate the sizes of focal adhesions by
affecting focal adhesion proteins via GSK3β. To examine the effects of triterpenoids on
GSK3β and focal adhesion dynamics, I first examined whether focal adhesion
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Figure 4.3 CDDO-Me binds to both FAK and GSK3β but affect only the activity of
GSK3β.
A) Rat2 cells incubated with 0.1% DMSO, 10 µM biotin, 10 µM CDDO-Me, or 10 µM
b-CDDO-Me were lysed and precipitated with neutravidin beads. Pull-down samples
were then processed for SDS-PAGE and immunoblotted for FAK. Fifty micrograms of
total protein lysates were also immunoblotted for FAK and shown.
B) Rat2 fibroblasts were incubated with 0.01% DMSO, 1 µM CDDO-Im or 1 µM
CDDO-Me for 2 hours. Cells were then lysed and processed by SDS-PAGE and
immunoblotted with anti-FAK and specific anti-phospho-FAK antibodies against tyrosine
397, tyrosines 576/577, tyrosine 925 and serine 722.
C) Rat2 cells incubated with 0.1% DMSO, 10 µM biotin, 10 µM CDDO-Me, or 10 µM
b-CDDO-Me were lysed, and precipitated with neutravidin beads. Pull down samples
were then processed for SDS-PAGE and immunoblotted for GSK3β. Fifty micrograms of
total protein lysates were also immunoblotted for GSK3β and shown.
D) Rat2 cells incubated with 0.01% DMSO (control), 1 µM CDDO-Im, or 1 µM CDDOMe were lysed and processed for SDS-PAGE and immunoblotted with anti-GSK3β and
anti-phospho-GSK3β antibodies that target serine 9 (top panel). Quantitation (bottom
panel) by densitometry was carried out using the Bio-Rad VersaDoc software and
graphed as arbitrary units versus treatments (n=3 +/-S.D.), *p<0.05.
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Figure 4-3
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Figure 4.4 GSK3β co-localizes with biotinylated CDDO-Me.
Confluent Rat2 fibroblasts were scratched and allowed to polarize for 4 hours before they
were fixed, permeabilized and incubated with monoclonal anti-Rac1 antibodies (Rac1;
green), polyclonal anti-GSK3β antibodies (GSK3β; blue), and either DMSO, 10 µM
biotin, 10 µM CDDO-Me, or 10 µM biotinylated CDDO-Me (b-CDDO-Me) followed by
Cy2-labeled anti-mouse antibody, Cy5-labeled anti-rabbit and Cy3-labeled streptavidin
respectively. Cell nuclei were stained with DAPI (DAPI; white). The co-localization of
Rac1 (green), GSK3β (blue) with b-CDDO-Me (red) at the leading edge of migrating
cells is indicated (white arrowheads). The white arrow indicates the direction of cell
movement. Representative images from three experiments are shown. Bar = 10 µm.
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morphology was altered by the GSK3 inhibitors lithium chloride (LiCl) and SB216763
by immunofluorescence microscopy. Interestingly, LiCl and SB216763 both inhibit the
activity of GSK3β, albeit via different modes of action. Specifically, LiCl inhibits
GSK3β activity by inducing the phosphorylation of GSK3β at serine 9 whereas
SB216763 elicits its inhibitory action by competitively binding to the ATP pocket of
GSK3β. However, since LiCl is a less specific inhibitor, we have utilized SB216763 in
parallel to our studies in order to assess whether the alteration of focal adhesions is a
GSK-dependent effect. Consistent with my observations in triterpenoid-treated cells
(Figure 4.1), I found that paxillin staining was also enlarged when cells were incubated
with LiCl or SB216763 (Figure 4.5). In order to assess if inhibition of GSK3β would
result in an inhibition of Rat2 cell migration, I performed migration studies using the
GSK3 inhibitors and I observed that, similar to the triterpenoid treated cells, GSK3β
inhibition led to a delay in cell migration (Figure 4.6).
Numerous studies have shown that the loss of polarity can result in the inhibition
of cell migration. I have also shown in my previous studies, that the displacement of
leading edge proteins and the loss of polarity by the triterpenoids is a major mechanism
for inhibiting cell migration (21). Therefore, I next examined whether the inhibition of
GSK3β displaces Rac1 and IQGAP1 from the leading edge of migrating cells. Cells
were scratched and allowed to polarize before they were treated in the presence or
absence of CDDO-Im, CDDO-Me, LiCl or SB216763.

Cells were then fixed,

permeabilized and immunostained with Rac1 and IQGAP1 antibodies. My results
indicated that GSK3β inhibitors did indeed displace leading edge proteins. Rac1 and
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Figure 4.5 GSK3 inhibitors enlarge focal adhesion size.
A) Rat2 fibroblasts were scratched and incubated for 4 hours at 37˚C to establish cell
polarity and then treated with control medium (Control; top panel), 50 mM Lithium
Chloride (Lithium Chloride; middle panel) or 50 µM SB216763 (SB216763; bottom
panel) for an additional 2 hours. The cells were then fixed, permeabilized and
immunostained with anti-paxillin antibody (Paxillin; green) and phalloidin (Phalloidin;
red). The scratches were made in the horizontal plane above the cells shown. A
representative area (inset) is magnified and shown. Bar = 10 µm.
B) Rat2 fibroblasts were treated with DMSO, 50 mM Sodium Chloride (NaCl), 50 mM
Lithium Chloride (LiCl) or 50 µM SB216763 (SB) for 2 hours before samples were lysed
and processed for SDS-PAGE followed by immunoblotting with phospho-FAK,
phospho-paxillin and phospho-GSK3β antibodies. Fifty micrograms of total protein
lysates were also immunoblotted for FAK, paxillin and GSK3β and shown.
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Figure 4-5
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Figure 4.6 GSK3 inhibitors attenuate cell migration.
A) Confluent Rat2 fibroblasts were scratched and treated with vehicle (control), 50 mM
LiCl or 50 µM SB216763 for 16 hours. Bright field images (magnification 10X) were
taken at the beginning of the experiment (0 h) and after 16 hours (16 h) of incubation at
37˚C. The white dotted lines indicate the edge of the leading edge of migrating cells at 0
h.
B) Cells treated with increasing concentrations of LiCl or SB216763 (0 µM - 50 µM or 0
mM - 50 mM respectively, as shown) were imaged. Cell migration was quantified and
graphed as cell migration (percentage of control) vs. inhibitors concentration (n=3±S.D.).
*p<0.01, **p<0.05.
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Figure 4-6
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IQGAP1, and promoted the loss of polarity, consistent with what I observed in
triterpenoid-treated cells (Figure 4.7). Finally, since GSK3β plays a critical role in cell
polarity and GSK3 inhibitors can effectively displace important leading edge proteins, I
assessed whether GSK3β at the leading edge were also displaced in the presence of
triterpenoids and GSK3 inhibitors. Using the same technique as described above, I
probed for GSK3β using anti-GSK3β antibodies and found that GSK3β was also
displaced from the leading edge of migrating cells in GSK3 inhibitor- and triterpenoidtreated cells (Figure 4.8).
Taken together, my results suggest that triterpenoids target GSK3β activity to
alter focal adhesion size and contribute to the inhibition of cell migration.
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Figure 4.7 Triterpenoids and GSK3 inhibitors displace leading edge proteins, Rac1
and IQGAP1, from the leading edge of migrating cells.
A) Confluent Rat2 fibroblasts were scratched and allowed to polarize for 4 hours. Cells
were then treated with DMSO, NaCl, 1 µM CDDO-Im, 1 µM CDDO-Me, 50 mM LiCl or
50 µM SB216763 for an additional 2 hours. Cells were fixed, permeabilized and
incubated with anti-Rac1 antibody (Rac1; green), phalloidin (Phalloidin; red) and antiIQGAP1 (IQGAP1; blue) antibody. The scratches were made in the horizontal plane
above the cells. The staining of Rac1, phalloidin and IQGAP1 at the leading edge of
migrating cells is indicated by green, red and blue arrows respectively. The white
arrowheads indicate the areas of colocalization of the three proteins. White arrows
indicate the direction of cellular movement. Bar = 10 µm.
B) Quantitation of cells containing Rac1 or IQGAP1 at the leading edge of migrating
cells was carried out using ImagePro software and graphed as localization at the leading
edge (% of cells) vs. treatment (n=3±SD). *,#: p<0.05 for staining of Rac1 and
IQGAP1 compared to DMSO as control. a,b: p<0.05 for staining of Rac1 and IQGAP1
compared to NaCl as control.
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Figure 4-7
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Figure 4.8 Triterpenoids displace GSK3β from the leading edge of migrating cells.
A) Confluent Rat2 fibroblasts were scratched and allowed to polarize for 4 hours. Cells
were then treated with DMSO, NaCl, 1 µM CDDO-Im, 1 µM CDDO-Me , 50 mM LiCl
or 50 µM SB216763 for an additional 2 hours before samples were fixed, permeabilized
and incubated with anti-Rac1 (Rac1; green) antibody, phalloidin (Phalloidin; red) and
anti-GSK3β (GSK3β; blue) antibody. The scratches were made in the horizontal plane
above the cells. Rac1, phalloidin and GSK3β staining at the leading edge of migrating
cells are indicated by green, red and blue arrows respectively. The white arrowheads
indicate the areas of colocalization of all three proteins. White arrows indicate the
direction of cellular movement. Bar = 10 µm.
B) Quantitations of cells containing Rac1 and GSK3β at the leading edge of migrating
cells was carried out using ImagePro software and graphed as localization at the leading
edge (% of cells) vs. treatment (n=3±SD). *,#: p<0.05 for staining of Rac1 and
GSK3β compared to DMSO as control. a,b: p<0.05 for staining of Rac1 and GSK3β
compared to NaCl as control.
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Figure 4-8
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4.5

DISCUSSION
In this study, I found that the triterpenoids altered the size of focal adhesions.

Knowing that the triterpenoids inhibit cell migration, the principal question that I sought
to answer was whether triterpenoids could alter focal adhesions to inhibit cell migration.
To address this question, I first examined whether this enlargement of focal
adhesions by triterpenoids was due to an alteration in focal adhesion turnover. Using cell
adhesion assays, I found that synthetic triterpenoids targeted cell binding to collagen I,
but did not induce the dissociation of adhered cells. This interesting alteration of focal
adhesion dynamics by the triterpenoids led us to believe that the drug compounds may
modulate kinases that regulate focal adhesion turnover to cause an alteration in the size of
the focal adhesions, which ultimately lead to delayed cell migration.

However, it is

important to note that my adhesion binding studies were performed on Collagen I and
different extracellular matrices and the variation in their concentrations can have different
effects on focal adhesion dynamics. Future studies assessing different substrates will test
whether this phenomenon is ECM-specific. Nonetheless, knowing that focal adhesion
turnover was altered by the triterpenoids, I next sought to identify triterpenoid-binding
targets that regulate focal adhesion dynamics and found FAK and GSK3β to be
triterpenoid-binding proteins.
FAK and GSK3β can modulate multiple signaling pathways relating to focal
adhesion turnover. Of the two kinases, FAK is a known master regulator of focal
adhesion turnover. Therefore, I began my assessment with FAK by studying its activity
and observed that triterpenoids did not affect the activities of FAK at various
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phosphorylation sites known for its regulation in focal adhesion dynamics.

However,

this could be due to the fact that FAK is a weak binding triterpenoid-binding target; thus,
the drugs may exert their effects via FAK. In addition, since FAK is involved in
modulating numerous cellular processes, the phosphorylation of FAK at one specific site
may lead to the activation of different signaling cascades. Therefore, it is possible that
even if one signaling pathway that is responsible for the enlargement of focal adhesions is
altered, it is concealed by another signaling pathway that acts through the same
phosphorylation site.
Interestingly, when I examined the effect of triterpenoids on GSK3β activity, I
observed an elevation in GSK3β phosphorylation on Ser 9, indicating that the GSK3β
activity was inhibited. Since the triterpenoids have previously been shown to inhibit cell
migration, I sought to examine the possible mechanism. Indeed, when I examined the
localization of GSK3β using biotinylated CDDO-Me immunofluorescence assays, I
observed that GSK3β colocalized with the biotinylated triterpenoid, b-CDDO-Me,
mainly at the leading edge and in the nucleus. This result indicated to us that the
alteration of GSK3β by the triterpenoids could play a possible role in cell migration. To
confirm this hypothesis, I assessed the effect of GSK3β inhibition in scratch assays using
GSK3 inhibitors, LiCl and SB216763. LiCl is a non-competitive inhibitor of GSK3
activity that has been used extensively to examine the functional roles of GSK3.
However, LiCl is not a selective inhibitor of GSK3 and has been reported to inhibit other
kinases such as casein kinase-2, p38 regulated/activated kinase and MAPK activated
protein kinase 2, polyphosphate 1-phosphatase and inositol monophosphatase. Therefore,
I used SB216763 in parallel with LiCl in my studies. SB216763 is a soluble, small
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molecule GSK3 inhibitor that can effectively inhibit the activities of both GSK3α and
GSK3β at concentration that is as low as 34 nM in in vitro kinase assays using purified
proteins (22). In addition, SB216763 is highly specific and elicits no effect on the activity
of at least 24 different serine/threonine and tyrosine protein kinases that were tested (22).
My data from my scratch assays indicated that cell migration was indeed delayed when
cells were treated with LiCl or SB216763. Although the concentrations of both GSK3β
inhibitors that were used in my studies were at the millimolar and micromolar ranges,
respectively, these concentrations are consistent with the ranges that other studies had
used in their in vitro cell culture studies. I also observed that SB216763 was more
effective in inhibiting cell migration than LiCl. This is not surprising as SB216763 was a
more specific GSK3β inhibitor than LiCl, which was known to affect other signaling
pathways, and hence may have potential confounding effect on cell migration. However,
I found that the concentration of GSK3β inhibitors required to reduce cell migration by
40-50% was much higher than that of the triterpenoids, indicating that the triterpenoids
were much more effective in inhibiting cell migration and that GSK3β inhibition alone
was not the main target for cell migration inhibition. These results are consistent with my
previous studies since CDDO derivatives are known to target multiple proteins in a cell
(1). Therefore, I would expect that even though GSK3β is an important target, the
treatment of GSK3β inhibitors alone would not be sufficient in abolishing cell migration
to the same extent as the triterpenoids.
Numerous studies have shown that cell migration is inhibited when the total
cellular GSK3β level is inhibited by common GSK3 inhibitors such as LiCl and
SB216763 (14,23-27). However, it is important to note that other studies have found that
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local inhibition of GSK3β at the leading edge can actually regulate the stability of
microtubules and promote cell migration (14). , Interestingly, my data seems to support
both of these existing models. Specifically, through Western blotting studies, which
measures the amount of total phosphorylated GSK3β level in the cells, triterpenoids may
inhibit cell migration by inactivating the overall GSK3β activity. Although SB216763
does not induce the phosphorylation of GSK3 to elicit its inhibitory effect, its subsequent
effect on cell migration is still consistent to the model that inhibiting overall GSK3β can
impair cell migration. In our immunofluorescence studies, we also found that GSK3β was
effectively displaced in triterpenoid-treated cells. Taken together, it seems that the
synthetic triterpenoids can delay overall cell migration in part by inactivating total
GSK3β activity and displacing the local pool of inactive GSK3β at the leading edge.
Evidently, the extent and the location in which phosphorylated GSK3β resides both play
critical roles in cell migration; therefore, to further understand and confirm our results, it
would be imperative to examine the extent of GSK3β phosphorylation in the cell and
where this phosphorylation takes place by immunofluorescence microscopy using
phospho-specific GSK3β antibodies.
With the understanding that triterpenoids can affect GSK3β activity and at least
partially inhibit cell migration, I then sought to understand whether the alteration of focal
adhesions plays a role in GSK3β-dependent cell migration inhibition. I propose that the
inhibition of GSK3β contributes to the enlargement of focal adhesion which delays cell
migration.

Indeed, when I treated the cells with GSK3 inhibitors and studied the

morphology of focal adhesions using paxillin as my adhesion marker, I found that cells
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treated with LiCl and SB216763 possessed focal adhesions that differ from cells treated
with vehicle, similar and consistent with what I observed in triterpenoid-treated cells.
Finally, previous studies have shown that the local inhibition of GSK3β at the
leading edge can play a critical role in regulating cell polarity by stabilizing microtubules
via leading edge proteins such as APC and CLASP2. With the novel understanding that
global inhibition of GSK3β by triterpenoids could inhibit cell migration, I wanted to
investigate whether the effect of global GSK3β inactivity on cell polarity was also similar
to what I observed in triterpenoid-treated cells. My previous studies have implicated that
the displacement of polarity proteins such as Par6, PKC and leading edge proteins such
as Rac1 and IQGAP1 by the triterpenoids can severely reduce the rate of cell migration
(21). Since Rac1 plays a critical role in membrane ruffling and the formation of leading
edge whereas IQGAP1 is an important scaffolding protein that acts to coordinate multiple
cytoskeletal proteins for cell migration, I examined whether global GSK3β inhibition
could affect these proteins from localizing to the leading edge. My data showed that the
inactivation of total GSK3β using GSK3β inhibitors could indeed cause the displacement
of these important proteins, similar to my observations with triterpenoid-treated cells.
Cell motility is critical in regulating many physiological processes including
growth, development and tissue homeostasis. While cell migration is a precursor event
for tumor metastasis, to effectively inhibit cell migration is challenging, as it involves the
convergence of different signaling pathways. Triterpenoids are promising candidates for
targeting multiple signaling pathways including the cytoskeletal network and the polarity
complex (Chapters 2 and 3). In the present study, I found that triterpenoids targeted
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GSK3β and altered its activity, its localization as well as the localization of other leading
edge proteins. As a correlate, an apparent enlargement of focal adhesions and delayed
cell migration were observed. This mechanism represents yet another pathway where
triterpenoids may be effective in targeting cell migration.

I expect that the results

obtained from these studies will provide better insight that would ultimately improve the
design of future triterpenoid analogues so that they could target more specific aspects of
cell migration.
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4.6
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CHAPTER 5

5.1

SUMMARY OF MAJOR FINDINGS
Synthetic triterpenoids are promising candidates that have received notable

attention as anti-cancer agents in recent years for their favorable effects on specific
targeted areas of cancer, including apoptosis, anti-inflammation, and anti-proliferation.
However, very little work had been done on their effect on cancer metastasis.
Specifically, there were virtual no data assessing how triterpenoids might affect the
underlying cell motility. Therefore, the overall goal of my thesis was to characterize the
effect of triterpenoids on cell migration.
The first part of this thesis asked whether one of the most potent triterpenoid
derivatives, CDDO-Im, played a role in TGFβ-mediated signaling and cell migration and
if so, through which molecular mechanisms. My initial studies on the triterpenoids were
TGFβ−focused because aberrant TGFβ signaling pathway is an important player in
tumorigenesis (1-6). In addition, Ji et. al had shown that the activation of the canonical
Smad signaling pathway by CDDO-Im led to the monocytic differentiation of HL60
leukemia cells (7). Therefore, since CDDO-Im is shown to play a role in affecting an
important aspect of cancer through delaying the activation of the Smad pathway, I
predicted that the triterpenoids may also have an effect on cell migration via the
regulation of the TGFβ signaling pathway. Understanding the underlying mechanism of
action in which triterpenoids affect cell migration via TGFβ can provide useful insights in
how to better utilize the drugs to target metastasis. In Chapter 2 of this thesis, I showed
that the synthetic triterpenoid, CDDO-Im, played a role in delaying TGFβ-mediated
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signaling by affecting the trafficking and turnover of TGFβ receptors, which explained
the prolonged Smad2 activation that was observed in triterpenoid-treated cells.

In

addition, my findings demonstrated for the first time that CDDO-Im could impair
TGFβ mediated cell migration by disrupting the microtubule network and displacing the
important proteins at the leading edge that establish cell polarity (Figure 5.1).
In Chapter 3, I provided evidence that the inhibitory effects of the triterpenoids
on cell migration inhibition were not limited to TGFβ. In fact, the phenomenon that we
observed in TGFβ-dependent cell migration could actually be extended to general cell
migration. To understand how triterpenoids inhibit cell migration, I utilized a twopronged proteomic approach that led to the discovery of several novel triterpenoidbinding proteins involved in cell migration. Having established that microtubules were
affected by the triterpenoids through my previous studies, I decided to examine whether
these drugs had an effect on the actin cytoskeleton. I predicted that the triterpenoids
would affect cell migration by disrupting actin cytoskeleton dynamics, since I observed
the loss of the leading edge and polarity in triterpenoid-treated cells, and these processes
are heavily regulated by actin polymerization. Interestingly, I found that triterpenoids
affected only branched actin polymerization by targeting the Arp3 nucleation site of the
novel triterpenoid-binding target, the Arp2/3 complex, while leaving stress fibers intact
(Figure 5.1).
While I was conducting studies to confirm that stress fibers were indeed not
triterpenoid-binding targets, I noticed that triterpenoids appear to enlarge focal adhesions,
suggesting that these drugs may affect cell adhesions and consequently, inhibit cell
migration.

Therefore, I began to investigate the underlying mechanism in which
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triterpenoids regulate cell adhesion dynamics and ultimately cell migration. Indeed,
Chapter 4 shows that triterpenoids can inhibit cell migration in part by changing adhesion
sizes via the alteration of GSK3β activity and displacing GSK3β as well as other proteins
from the leading edge of migrating cells (Figure 5.1).

5.2

LIMITATIONS AND FUTURE STUDIES
It is important to note that all of the work presented in this thesis was done using

purified proteins and cultured cell models. Since the nature of my work was heavily
mechanism-based, these models offered great advantages as I attempted to characterize
signaling pathways targeted by triterpenoids. Using cell culture models, I was able to
understand the effects of synthetic triterpenoids on cell migration in a much simpler
system with less confounding factors and where the physiochemical and physiological
environments were tightly controlled.

To ensure that the triterpenoid-induced

phenomena that I observed were not cell type specific, I carried out parallel studies in
different cell lines. Using purified proteins, I was also able to test the direct interactions
of the triterpenoids with specific proteins of interest. However, one of the limitations of
using non-tumorigenic cells was that they might be less relevant in the context of a cancer
cell model or in vivo. Therefore, now that we have a better basic understanding of how
the triterpenoids act on non-transformed cell lines, future studies using tumor cells where
more variables exist and animal tumor models will be useful and imperative in allowing
us to extend our understanding on how triterpenoids function as potential anti-cancer
agents. Normal embryonic development requires that cells migrate to specific regions
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Figure 5.1 Molecular mechanisms whereby the synthetic triterpenoids inhibit cell
migration.
In response to a stimulus, a cell establishes polarity, redistributes its proteins to the
leading edge and rearranges the cytoskeletal network in order to prepare for movement.
However, our studies have shown that the triterpenoids can disrupt the microtubule
network, target proteins at the leading edge by displacing them from the leading edge,
prevent branched actin polymerization by binding to Arp3 in the Arp2/3 complex and
affect GSK3β activity. As a result, a migrating cell (left cell) loses its polarity; in
addition, important proteins at the leading edge are displaced and focal adhesion sizes are
altered. These changes collectively lead to the inhibition of cell migration (right cell).
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Figure 5-1
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of the organism. Both cancer cells and cells involved in embryonic development are
often highly migratory and express proteins that are important for cell motility. Since
Rat2 fibroblasts are highly migratory, it makes them not only good models for our studies
but the results that were attained from them are also likely to be translatable to future
tumor cell and in vivo studies using rodents. Therefore, I predict that the results attained
using tumor cell lines and in vivo models will be similar to my own observations with the
Rat2 fibroblast culture model. In addition, it would be interesting to examine whether
triterpenoids can affect EMT, a process which many cells undergo prior to acquiring
migratory and invasive phenotypes. To conduct these studies, we can utilize cell lines
such as A549 (non-small cell lung cancer cells) that are of epithelial origin and can be
induced by TGFβ to undergo mesenchymal transition. Specifically, we can examine
whether the treatment of triterpenoids can delay or even prevent A549 cells from
becoming more invasive and migratory by immunofluorescence microscopy and invasion
assays. This type of studies should provide insights on how triterpenoids may play a role
in cancer metastasis.
In Chapters 2 and 3, I provided evidence that cell migration was inhibited by the
triterpenoids.

I also identified three different and novel underlying mechanisms of

actions whereby triterpenoids inhibited cell migration. Specifically, I showed that the
triterpenoids target the TGFβ signaling pathway by delaying TGFβ receptor endocytosis
and trafficking. However, the importance of receptor trafficking and endocytosis is not
limited to the TGFβ pathway. In fact, signaling associated with different growth factors
and chemokines relies on endocytosis and trafficking of their receptors, and
manipulations that compromise these processes can severely affect cell polarity and
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migration. As such, studies have shown that the disruption of endocytosis impairs cell
polarization and affects the distribution of important membrane proteins such as integrins,
which are involved in cell adhesion (8). In addition, Arp2/3 and WASP, both of which
are affected by the triterpenoids, also play an important role in these processes (9). In my
previous studies, I have shown that microtubules were affected by the triterpenoids and
that the network no longer spanned from the microtubule organizing center and stabilize
to the edge of migrating cells. The microtubule network serves as an important function
for vesicle transport. Therefore, it is possible that motor proteins along the microtubule
cytoskeleton which play a critical role in endosomal movement may be affected and
represents a potential mechanism of action that explains why trafficking was altered in
triterpenoid-treated cells. This could also explain why some proteins are displaced from
the leading edge of migrating cells, as some of these proteins may rely on vesicle
transport to localize to the leading edge. Hence, it will be essential to examine how
triterpenoids regulate receptor trafficking and endocytosis, and whether the drugs exert
their effects through the proteins that regulate membrane trafficking and endocytosis.
Particularly, dynamin as well as Rab and Arf GTPases play critical roles in controlling
receptor recycling, which in turn regulate different aspects of cell migration, adhesion and
cytoskeletal dynamics (8,10-16). Aside from trafficking, the loss of polarity induced by
triterpenoids that we observed could be due to the possibility that triterpenoids may target
the components that make up the cell migration process, which includes leading edge
proteins.

Leading edge proteins are important in regulating cytoskeletal dynamics,

adhesions and consequently, cell motility. Therefore, it will be imperative to understand
the roles that triterpenoids play on them in order to gain more insights on how
triterpenoids affect cell migration. For instance, IQGAP1 would be a prime candidate for
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further investigation. As mentioned before, IQGAP1 is a key scaffolding protein that
serves as a hub for a large array of proteins involved in cell migration; in addition, it acts
as a bridge to link and coordinate the microtubule and actin cytoskeletal network during
forward cell movement. Since we saw the displacement of the leading edge proteins,
Par6, PKC and Rac1, as well as IQGAP1 in the presence of the synthetic triterpenoids, it
will be important to investigate whether the displacement of these leading edge proteins is
a consequence of an initial displacement of IQGAP1,
In Chapter 4 of this thesis, I have offered some insights on how focal adhesions
may be altered by the triterpenoids, which in turn would affect cell migration. However,
some future studies must be performed in order to fully decipher the effect of the drugs on
focal adhesions. For instance, I found that the re-establishment of focal adhesions on
Collagen I was affected by the triterpenoids. Although the purpose of these experiments
was to examine whether triterpenoids affected the general turnover of focal adhesions, the
different results that we observed in the presence and absence of collagen suggested to me
that cells could react differently depending on different substrates beneath them. In fact,
while the extracellular matrix proteins play a key role in providing structural integrity of
normal tissues, they are also important components that tumor cells can exploit to create a
microenvironment that is favorable for tumorigenesis (17,18). Therefore, it would be
important to understand how triterpenoids affect focal adhesions when cells are plated on
different ECM proteins.

In Chapter 4, I also showed that triterpenoids targeted

GSK3β activity to inhibit cell adhesion, which was consistent with what was observed
when cells were treated with GSK3 inhibitors, suggesting that the effect of triterpenoids
on focal adhesions likely involves GSK3β. However, these inhibitors target both the
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alpha and beta isoforms of GSK3. Thus, these studies did not fully address whether
GSK3α, GSK3β or both isoforms are the targets of triterpenoids.

GSK3α and GSK3β

have overlapping as well as unique functions in different cellular processes although this
has not been thoroughly examined vis-à-vis cell migration. Therefore, it will be of major
significance to confirm that triterpenoids are indeed targeting specifically GSK3β to elicit
their effects. In order to test this, siRNA studies targeting only GSK3α, GSK3β or both
GSK3 isoforms followed by the examination of their activities, focal adhesion sizes and
rate of cell migration should be done.
Although two novel triterpenoid binding targets that are important for cell
migration have been identified in my studies, the exact binding site(s) bound by the
triterpenoids are unknown. So far, reactive cysteines seem to be a favorable binding site
for triterpenoids and the hydrophobic site of both β-tubulin and Arp3 of the Arp2/3
complex have been identified (19,20). But comparative analysis between proteins and
biochemical studies should be performed to see whether there is a consensus amino acid
sequence that triterpenoids preferably bind. Having this knowledge will be important in
designing more effective derivatives of synthetic triterpenoids to specifically target cell
migration and possibly other cellular processes.

5.3

SIGNIFICANCE OF RESEARCH AND CONCLUSION
Cancer is one of the leading causes of deaths in Canada. It not only affects the

well being of many Canadians fighting against this disease, but it is also a tremendous
financial burden on the Canadian health care system. Therefore, the development of
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drugs that can treat or control cancer is one of the foremost priorities of the
pharmaceutical industry. As such, a vast number of compounds are constantly developed,
and some have even shown remarkable success. However, the two major caveats of all
chemotherapeutic compounds are their toxic side effects and the development of
resistance after chronic treatment. These issues stem from the fact that effective cancer
compounds target specific signaling pathways in cancer that are also important for the
regulation of normal cellular functions. Thus, the inhibition or augmentation of aberrant
pathways by various compounds may slow the progression of cancer, but also cause
detrimental effects in normal cellular functions. In addition, as tumors develop, they have
been shown to acquire mutations that allow them to be more tolerant to anti-cancer
compounds and eventually resistant to previous treatment. As a result, despite all the
drugs that are on the market, there is still a constant need for drugs that can effectively
treat cancer with minimal side effects.
Although triterpenoids were known to target tumor cells by inducing apoptosis,
my work has determined that they may also target cell migration.

Indeed, I have

provided evidence that the triterpenoids can act via different signaling pathways that are
often affected in cancer to elicit their inhibitory effects on cell migration. In fact, in the
past three years, research studies have begun to examine the effects of synthetic
triterpenoids on cancer metastasis and metastatic burden in in vivo models (21,22). In
addition, I have identified two novel protein targets, Arp2/3 and GSK3β and provided the
underlying molecular mechanism in which triterpenoids may govern cell migration
through these proteins.

Furthermore, I have presented a list of other potential
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triterpenoid-binding targets that form the basis for future work towards deciphering
pathways that may be important in targeting cell migration.
Collectively, the information in this thesis offers novel insights into not only how
cell migration is regulated as a whole, but also how the triterpenoid compounds may be
modified to specifically target tumor metastasis (Figure 5.2).
Triterpenoids are unique because they have minimal side effects and can
selectively target cancer cells while generally sparing normal cells. This property renders
them favorable candidates for biochemical modifications and they have a great potential
to become highly effective anti-cancer agents. Although cancer may not be curable, a
novel way of creating a bottleneck for invasive tumor cells by inhibiting cell migration
and consequently, preventing metastasis will undoubtedly increase the survival rates and
well being of cancer patients.
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Figure 5.2 Triterpenoids affect different aspects of carcinogenesis.
Cancer occurs when a single cell becomes mutated due to multiple insults stemming from
different genetic and/or environmental factors. As a result, the cancer cell proliferates
abnormally and forms a tumor mass that can bypass the fate of terminal cell
differentiation, an important regulator of cell growth. These cancer cells eventually
acquire the ability to escape apoptosis and form new blood vessels, a process known as
angiogenesis, in order to support the growing tumor mass. Eventually, these cells undergo
epithelial-to-mesenchymal transition (EMT), in which they become more migratory and
invasive. They then degrade and move through the extracellular matrix of the
surrounding tissues, which allows them to enter the blood vessels and migrate (or
metastasize) to other parts of the body. Upon arrival at a new site, the tumor cell begins to
invade, divide, and form a new tumor. Note that cancer cells can also metastasize to
other parts of the body through the lymphatic system. In early stages of cancer, cell
division, differentiation, apoptosis and angiogenesis are all important aspects of
tumorigenesis. Many studies have shown that triterpenoids can effectively target all of
these events. In addition, triterpenoids have also displayed cytoprotective effect, which is
important since inflammation is heavily associated to cancer progression. In recent years,
a few studies have shown the effects of synthetic triterpenoids on cancer metastasis. Our
laboratory (To et al.) was the first to show that the triterpenoids can effectively inhibit
cell migration, which is an important precursor event to cancer metastasis.
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Figure 5-2

241

5.4

REFERENCES

1.

Lampropoulos, P., Zizi-Sermpetzoglou, A., Rizos, S., Kostakis, A., Nikiteas, N.,
and Papavassiliou, A. G. (2012) Cancer Lett 314, 1-7

2.

Javelaud, D., Alexaki, V. I., Dennler, S., Mohammad, K. S., Guise, T. A., and
Mauviel, A. (2011) Cancer Res 71, 5606-5610

3.

Achyut, B. R., and Yang, L. (2011) Gastroenterology 141, 1167-1178

4.

Santibanez, J. F., Quintanilla, M., and Bernabeu, (2011) C. Clin Sci (Lond) 121,
233-251

5.

Drabsch, Y., and ten Dijke, P. (2011) J Mammary Gland Biol Neoplasia 16, 97108

6.

Su, E., Han, X., and Jiang, G. (2010) Tumori 96, 659-666

7.

Ji, Y., Lee, H. J., Goodman, C., Uskokovic, M., Liby, K., Sporn, M., and Suh, N.
(2006) Mol Cancer Ther 5, 1452-1458

8.

Jones, M. C., Caswell, P. T., and Norman, J. C. (2006) Curr Opin Cell Biol 18,
549-557

9.

Anitei, M., and Hoflack, B. (2011) Nat Cell Biol 14, 11-19

10.

Farooqui, R., Zhu, S., and Fenteany, G. (2006) Exp Cell Res 312, 1514-1525

11.

Randazzo, P. A., and Hirsch, D. S. (2004) Cell Signal 16, 401-413

12.

Sabe, H. (2003) J Biochem 134, 485-489

13.

Turner, C. E., West, K. A., and Brown, M. C. (2001) Curr Opin Cell Biol 13, 593599

14.

Hutagalung, A. H., and Novick, P. J. (2011) Physiol Rev 91, 119-149

15.

Mohrmann, K., and van der Sluijs, P. (1999) Mol Membr Biol 16, 81-87

16.

Ezratty, E. J., Partridge, M. A., and Gundersen, G. G. (2005) Nat Cell Biol 7, 581590

17.

Campbell, N. E., Kellenberger, L., Greenaway, J., Moorehead, R. A., LinnerthPetrik, N. M., and Petrik, J. (2010) J Oncol 2010, 586905

242

18.

Friedl, P., and Alexander, S. (2011) Cell 147, 992-1009

19.

Couch, R. D., Ganem, N. J., Zhou, M., Popov, V. M., Honda, T., Veenstra, T. D.,
Sporn, M. B., and Anderson, A. C. (2006) Mol Pharmacol 69, 1158-1165

20.

To, C., Shilton, B. H., and Di Guglielmo, G. M. (2010) J Biol Chem 285, 2794427957

21.

Townson, J. L., Macdonald, I. C., Liby, K. T., Mackenzie, L., Dales, D. W.,
Hedley, B. D., Foster, P. J., Sporn, M. B., and Chambers, A. F. (2011) Clin Exp
Metastasis 28, 309-317

22.

Deeb, D., Gao, X., Liu, Y., Jiang, D., Divine, G. W., Arbab, A. S., Dulchavsky, S.
A., and Gautam, S. C. (2011) Carcinogenesis 32, 757-764

243

CURRICULUM VITAE
Name:

Ciric Chi Wing To

Post-secondary
Education and
Degrees:

University of Toronto
Toronto, Ontario, Canada
2002-2006, B.Sc.
Western University
London, Ontario, Canada
2007-2012, Ph.D.

Honors and
Awards:

Western University
Charles W. Gowdey Research Day – Best Poster Award
2007
Schulich Graduate Scholarship
2007-2008
Hari and Gudrun Sharma Award
2009
Canadian Cancer Society Research Institute
Senior Ph.D. Student Travel Award
2009
Western University
Western Graduate Research Scholarship
2007-2011
Graduate Programs in Physiology and Pharmacology/Toxicology
Graduate Student Travel Award
2011
Graduate Thesis Research Award
2007, 2009-2012
Ontario Ministry of Training, Colleges and Universities
Ontario Graduate Scholarship
2010-2012

Related Work
Experience:

Research Assistant
University of Toronto
2005-2006
Research Assistant
Western University

244

2006-2007
Teaching Assistant
Western University
2008-2011

Publications:
To C, Shilton BH, Di Guglielmo GM. Synthetic triterpenoids target the Arp2/3 complex
and inhibit branched actin polymerization. (2010) J. Biol. Chem. 285 (36): 27944-57.
To C, Kulkarni S, Pawson T, Honda T, Gribble GW, Sporn MB, Wrana JL, Di Guglielmo
GM. The synthetic triterpenoid CDDO-Imidazolide alters TGFβ-dependent signaling and
cell migration by affecting the cytoskeleton and the polarity complex. (2008) J. Biol.
Chem. 283 (17):11700-11713.

Poster Presentations:
To C and Di Guglielmo GM. The effects of synthetic triterpenoids on Glycogen Synthase
Kinase 3 Beta (GSKβ) and cell adhesions. A.C. Camargo Global Meeting of
Translational Science, Sao Paulo, Brazil (2011)
To C and Di Guglielmo GM. The effects of synthetic triterpenoids on Glycogen Synthase
Kinase 3 Beta (GSKβ) and cell adhesions. American Association for Cancer Research
(AACR) Annual Meeting, Florida, CA. (2011)
To C, Shilton, BH, Di Guglielmo GM. Synthetic triterpenoids target Actin-related
protein 3 (Arp-3) and inhibit cell migration. American Society of Cell Biology (ASCB)
Annual Meeting, San Diego, CA. (2009)
To C and Di Guglielmo GM. Synthetic triterpenoids target members of the polarity
complex and inhibit cell migration. American Society of Cell Biology (ASCB) Annual
Meeting, San Francisco, CA. (2008)
To C, Kulkarni S, Pawson T, Honda T, Gribble GW, Sporn MB, Wrana JL, Di Guglielmo
GM. The synthetic triterpenoid CDDO-Imidazolide alters TGFβ-dependent signaling and
cell migration by affecting the cytoskeleton and the polarity complex. American Society
of Cell Biology (ASCB) Annual Meeting, Washington, DC. (2007)
To C and Di Guglielmo GM. The synthetic triterpenoid CDDO-Imidazolide alters TGFβdependent signaling and cell migration by affecting the cytoskeleton and the polarity
complex. Charles W. Gowdey Research Day, London, ON. (2007).

